Note: Descriptions are shown in the official language in which they were submitted.
CA 02724198 2010-11-12
WO 2009/138236 PCT/EP2009/003447
Novel and powerful MHC-class II peptides derived from survivin
The present invention relates to peptides, nucleic acids, and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the
immunotherapy
of cancer. The present invention furthermore relates to survivin-derived tumor-
associated
cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other
tumor-associated
peptides that serve as active pharmaceutical ingredients of vaccine
compositions that
stimulate anti-tumor immune responses. The present invention specifically
relates to three
novel peptide sequences and variants thereof derived from HLA class I and
class II molecules
of human tumor cells that can be used in vaccine compositions for eliciting
anti-tumor
immune responses.
Background of the inventioJ
n
Gliomas are brain tumors originating from glial cells in the nervous system.
Glial cells,
commonly called neuroglia or simply glia, are non-neuronal cells that provide
support and
nutrition, maintain homeostasis, form myelin, and participate in signal
transmission in the
nervous system. The two most important subgroups of gliomas are astrocytomas
and
oligodendrogliomas, named according to the normal glial cell type from which
they originate
(astrocytes or oligodendrocytes, respectively). Belonging to the subgroup of
astrocytomas,
glioblastoma multiforme (referred to as glioblastoma hereinafter) is the most
common
malignant brain tumor in adults and accounts for approx. 40% of all malignant
brain tumors
and approx. 50% of gliomas (CBTRUS, 2006). It aggressively invades the central
nervous
system and is ranked at the highest malignancy level (grade IV) among all
gliomas. Although
there has been steady progress in their treatment due to improvements in
neuroimaging,
microsurgery, diverse treatment options, such as temozolomide or radiation,
glioblastomas
remain incurable (Macdonald, 2001; Burton and Prados, 2000; Prados and Levin,
2000). The
lethality rate of this brain tumor is very high: the average life expectancy
is 9 to 12 months
after first diagnosis. The 5-year survival rate during the observation period
from 1986 to 1990
was 8.0%. To date, the five-year survival rate following aggressive therapy
including gross
tumor resection is still less than 10% (Burton and Prados, 2000; Nieder et
al., 2000;
Napolitano et al., 1999; Dazzi et al., 2000). Accordingly, there is a strong
medical need for an
alternative and effective therapeutic method.
CA 02724198 2010-11-12
WO 2009/138236- 2 - PCT/EP2009/003447
Tumor cells of glioblastomas are the most undifferentiated ones among brain
tumors, so the
tumor cells have high potential of migration and proliferation and are highly
invasive, leading
to very poor prognosis. Glioblastomas lead to death due to rapid, aggressive,
and infiltrative
growth in the brain. The infiltrative growth pattern is responsible for the
unresectable nature
of these tumors. Glioblastomas are also relatively resistant to radiation and
chemotherapy,
and, therefore, post-treatment recurrence rates are high. In addition, the
immune response to
the neoplastic cells is rather ineffective in completely eradicating all
neoplastic cells
following resection and radiation therapy (Roth and Weller, 1999; Dix et al.,
1999; Sablotzki
et al., 2000).
Glioblastoma is classified into primary glioblastoma (de novo) and secondary
glioblastoma,
depending on differences in the gene mechanism during malignant transformation
of
undifferentiated astrocytes or glial precursor cells. Secondary glioblastoma
occurs in a
younger population of up to 45 years of age. During 4 to 5 years, on average,
secondary
glioblastoma develops from lower-grade astrocytoma through undifferentiated
astrocytoma.
In contrast, primary glioblastoma predominantly occurs in an older population
with a mean
age of 55 years. Generally, primary glioblastoma occurs as fulminant
glioblastoma
characterized by tumor progression within 3 months from the state with no
clinical or
pathological abnormalities (Pathology and Genetics of the Nervous Systems. 29-
39 (IARC
Press, Lyon, France, 2000)).
Glioblastoma migrates along myelinated nerves and spreads widely in the
central nervous
system. In most cases surgical treatment shows only limited sustainable
therapeutic effect
(Neurol. Med. Chir. (Tokyo) 34, 91-94, 1994; Neurol. Med. Chir. (Tokyo) 33,
425-458, 1993;
Neuropathology 17, 186-188, 1997) (Macdonald, 2001; Prados and Levin, 2000).
Malignant glioma cells evade detection by the host's immune system by
producing
immunosuppressive agents that impair T cell proliferation and production of
the immune-
stimulating cytokine IL-2 (Dix et al., 1999).
Intracranial neoplasms can arise from any of the structures or cell types
present in the CNS,
including the brain, meninges, pituitary gland, skull, and even residual
embryonic tissue. The
overall annual incidence of primary brain tumors in the United States is 14
cases per 100,000.
CA 02724198 2010-11-12
WO 2009/138236- 3 - PCT/EP2009/003447
The most common primary brain tumors are meningiomas, representing 27% of all
primary
brain tumors, and glioblastomas, representing 23% of all primary brain tumors
(whereas
glioblastomas account for 40% of malignant brain tumor in adults). Many of
these tumors are
aggressive and of high grade. Primary brain tumors are the most common solid
tumors in
children and the second most frequent cause of cancer death after leukemia in
children.
The search for effective treatment of glioblastomas in patients is still
ongoing today.
Immunotherapy, or treatment via recruitment of the immune system, to fight
these neoplastic
cells has been investigated. First encouraging results were obtained by
Northwest
Therapeutics using "DCVax Brain" for the treatment of glioblastoma in immuno-
therapeutic
studies in humans, in which antigen-specific CTL responses could be induced
leading to
prolonged median survival times compared to that obtained applying standard
treatment
accompanied by minimal toxicity (Heimberger et al., 2006).
Colorectal Carcinoma
According to the American Cancer Society, colorectal cancer (CRC) is the third
most
common cancer in the US, afflicting more than 175,000 new patients each year.
In the US,
Japan, France, Germany, Italy, Spain and the UK, it affects more than 480,000
patients. It is
one of the most common causes of cancer mortality in developed countries. The
1- and 5-year
relative survival for persons with colorectal cancer is 84% and 64%,
respectively. Survival
continues to decline beyond 5 years to 57% at 10 years after diagnosis. When
colorectal
cancers are detected at an early, localized stage, the 5-year survival is 90%;
however, only
39% of colorectal cancers are diagnosed at this stage, mostly due to low rates
of screening.
After the cancer has spread regionally to involve adjacent organs or lymph
nodes, the 5-year
survival drops to 68%. For persons with distant metastases, 5-year survival is
10%.
Research suggests that the onset of colorectal cancer is the result of
interactions between
inherited and environmental factors. In most cases adenomatous polyps appear
to be
precursors to colorectal tumors; however the transition may take many years.
The primary
risk factor for colorectal cancer is age, with 90% of cases diagnosed over the
age of 50 years.
Other risk factors for colorectal cancer according to the American Cancer
Society include
alcohol consumption, a diet high in fat and/or red meat and an inadequate
intake of fruits and
vegetables. Incidence continues to rise, especially in areas such as Japan,
where the adoption
of westernized diets with excess fat and meat intake and a decrease in fiber
intake may be to
CA 02724198 2010-11-12
WO 2009/138236- 4 - PCT/EP2009/003447
blame. However, incidence rates are rising not as fast as previously which may
be due to
increasing screening and polyp removal, thus preventing progression of polyps
to cancer.
As in most solid tumors, first line treatment is surgery, however, its
benefits remain confined
to early-stage patients, yet a significant proportion of patients is diagnosed
in advanced stages
of the disease. For advanced colorectal cancer chemotherapy regimens based on
fluorouracil-
based regimens are standard of care. The majority of these regimens are the so-
called
FOLFOX (infusional 5-FU/leucovorin plus oxaliplatin) and FOLFIRI (irinotecan,
leucovorin,
bolus and continuous-infusion 5-FU) protocols.
The introduction of third-generation cytotoxics such as irinotecan and
oxaliplatin has raised
the hope of significantly improving efficacy, but prognosis is still
relatively poor, and the
survival rate generally remains at approximately 20 months in metastatic
disease and, as a
result, the unmet needs in the disease remain high.
Recently a novel generation of drugs, molecular-targeted agents, such as
Avastin
(bevacizumab) and Erbitux (cetuximab), became available, and about 40
compounds are in
late-stage clinical development for different stages of colorectal cancer.
Combinations of
several of these compounds increase the number of potential treatment options
to be expected
for the future. The vast majority of substances is in phase II, with the EGFR
being addressed
by these compounds more often than any other target in colorectal cancer
trials, which is due
to the fact that in ¨80% of patients with colorectal cancer EGFR expression is
upregulated.
Clinical trials with stage II patients combining chemotherapy with the
recently approved
monoclonal antibodies (rnAbs) (cetuximab + irinotecan or FOLFOX4; bevacizumab
as a
single-agent or together with FOLFOX4) are currently being conducted. Three to
four year
observation periods are expected for statistically significant results from
these trials.
Monoclonal antibodies (mAbs) presently used in oncology in general have an
excellent
chance of not interfering with active immunotherapy. In fact, there is
preclinical
(GABRILOVICH 1999) and clinical evidence suggesting that depletion of VEGF (by
bevacizumab) contributes positively to DC-mediated activation of T-cells
(Osada T, Chong
G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly
HK, Clay
CA 02724198 2010-11-12
WO 2009/138236- 5 - PCT/EP2009/003447
T, Morse MA. The effect of anti-VEGF therapy on immature myeloid cell and
dendritic cells
in cancer patients. Cancer Immunol Immunother. 2008 Jan 10.).
Prostate carcinoma and other tumors
With an estimated 27,050 deaths in 2007, prostate cancer is a leading cause of
cancer death in
men. Although death rates have been declining among white and African American
men since
the early 1990s, rates in African American men remain more than twice as high
as those in
white men. Prostate cancer is the most frequently diagnosed cancer in men. For
reasons that
remain unclear, incidence rates are significantly higher in African American
men than in
white men. Incidence rates of prostate cancer have changed substantially over
the last 20
years: rapidly increasing from 1988-1992, declining sharply from 1992-1995,
and increasing
modestly since 1995. These trends in large part reflect increased prostate
cancer screening
with the prostate-specific antigen (PSA) blood test. Moderate incidence
increases in the last
decade are most likely attributable to widespread PSA screening among men
younger than 65.
Prostate cancer incidence rates have leveled off in men aged 65 years and
older. Rates peaked
in white men in 1992 (237.6 per 100,000 men) and in African American men in
1993 (342.8
per 100,000 men).
Treatment for prostate cancer may involve watchful waiting, surgery, radiation
therapy, High
Intensity Focused Ultrasound (HIFU), chemotherapy, cryosurgery, hormonal
therapy, or some
combination. Which option is best depends on the stage of the disease, the
Gleason score, and
the PSA level. Other important factors are the man's age, his general health,
and his feelings
about potential treatments and their possible side effects. Because all
treatments can have
significant side effects, such as erectile dysfunction and urinary
incontinence, treatment
discussions often focus on balancing the goals of therapy with the risks of
lifestyle alterations.
If the cancer has spread beyond the prostate, treatment options significantly
change, so most
doctors who treat prostate cancer use a variety of nomograms to predict the
probability of
spread. Treatment by watchful waiting, HIFU, radiation therapy, cryosurgery,
and surgery are
generally offered to men whose cancer remains within the prostate. Hormonal
therapy and
chemotherapy are often reserved for disease which has spread beyond the
prostate. However,
there are exceptions: radiation therapy may be used for some advanced tumors,
and hormonal
therapy is used for some early stage tumors. Cryotherapy, hormonal therapy,
and
chemotherapy may also be offered if initial treatment fails and the cancer
progresses.
CA 02724198 2010-11-12
WO 2009/138236- 6 - PCT/EP2009/003447
In a significant number of patients with prostate carcinoma who undergo
radical
prostatectomy because of clinically suspected organ-limited growth, a
definitive histological
workup of the surgical preparation shows a locally extensive tumor extending
beyond the
borders of the organ. These patients have a high risk for early local
recurrence, usually
detectable as an increasing PSA level in terms of a biochemical relapse.
Therapeutic options
in this situation include external radiotherapy and hormone ablation; however,
the value of
these therapeutic approaches, especially with respect to prolonging the
patient's long-term
survival, must not be regarded as proven. In addition, possible treatment-
associated
complications such as the development of urethral strictures (radiotherapy),
loss of libido and
impotence, the risk of a reduction in skeletal calcium salts in terms of
osteoporosis, and a
markedly increased risk of pathologic bone fractures (hormone ablation) must
be considered.
More than 90% of all prostate cancers are discovered in the local and regional
stages; the 5-
year relative survival rate for patients whose tumors are diagnosed at these
stages approaches
100%. Over the past 25 years, the 5-year survival rate for all stages combined
has increased
from 69% to nearly 90%. According to the most recent data, relative 10-year
survival is 93%
and 15-year survival is 77%. The dramatic improvements in survival,
particularly at 5 years,
are partly attributable to earlier diagnosis and improvements in treatment.
Nevertheless, the
survival rate drops significantly after the spreading to other tissues and
organs.
Lung Cancer
Estimated 210,000 new cases are expected in 2007 in the USA, accounting for
about 15% of
cancer diagnoses. The incidence rate is declining significantly in men, from a
high of 102
cases per 100,000 in 1984 to 78.5 in 2003. In women, the rate is approaching a
plateau after a
long period of increase. Lung cancer is classified clinically as small cell
(13%) or non-small
cell (87%) for the purposes of treatment.
Lung cancer accounts for the most cancer-related deaths in both men and women.
An
estimated 160,390 deaths, accounting for about 29% of all cancer deaths, are
expected to
occur in 2007. Since 1987, more women have died each year from lung cancer
than from
breast cancer. Death rates have continued to decline significantly in men from
1991-2003 by
about 1.9% per year. Female lung cancer death rates are approaching a plateau
after
CA 02724198 2010-11-12
WO 2009/138236- 7 - PCT/EP2009/003447
continuously increasing for several decades. These trends in lung cancer
mortality reflect the
decrease in smoking rates over the past 30 years.
Treatment options are determined by the type (small cell or non-small cell)
and stage of
cancer and include surgery, radiation therapy, chemotherapy, and targeted
biological therapies
such as bevacizumab (Avastine) and erlotinib (Tarceva8). For localized
cancers, surgery is
usually the treatment of choice. Recent studies indicate that survival with
early-stage, non-
small cell lung cancer is improved by chemotherapy following surgery. Because
the disease
has usually spread by the time it is discovered, radiation therapy and
chemotherapy are often
used, sometimes in combination with surgery. Chemotherapy alone or combined
with
radiation is the usual treatment of choice for small cell lung cancer; on this
regimen, a large
percentage of patients experience remission, which is long lasting in some
cases.
The 1-year relative survival for lung cancer has slightly increased from 37%
in 1975-1979 to
42% in 2002, largely due to improvements in surgical techniques and combined
therapies.
However, the 5-year survival rate for all stages combined is only 16%. The
survival rate is
49% for cases detected when the disease is still localized; however, only 16%
of lung cancers
are diagnosed at this early stage.
Table 1: Estimated new cancer cases and deaths by sex for the US in 2007
(American Cancer
Society. Cancer Facts & Figures 2007. Atlanta: American Cancer Society; 2007.)
Sites Estimated New Cases Estimated Deaths
Both Sexes Male Female Both Sexes Male Female
Glioma and Brain 20,500 11,170 9,330 12,740 7,150
5,590
Breast 180,510 2,030 178,480 40,910 450 40,460
Prostate 218,890 218,890 27,050 27,050
Esophagus 15,560 12,130 3,430 13,940 10,900 3,040
Colon 112,340 55,290 57,050 52,180 26,000 26,180
Renal 51,190 31,590 19,600 12,890 8,080 4,810
Pancreas 37,170 18,830 18,340 33,370 16,840 16,530
Squamous cell 1,000,000 n. d. n. d. n. d. n. d. n. d.
carcinomas;
Keratinocytic
neoplasms of the
skin
Leukemia 44,240 24,800 19,440 21,790 12,320 9,470
CA 02724198 2010-11-12
WO 2009/138236- PCT/EP2009/003447
- 8
Lung 213,380 114,760 98,620 160,390 89,510
70,880
Non-Hodgkins 63,190 34,210 28,990 18,660 9,600 9,060
Lymphoma
Ovarian 22,430 22,430 15,280 15,280
Melanoma 59,940 33,910 26,030 8,110 5,220 2,890
There thus remains a need for new efficacious and safe treatment option for
glioblastoma,
prostate tumor, breast cancer, esophageal cancer, colorectal cancer, clear
cell renal cell
carcinoma, lung cancer, CNS, ovarian, melanoma (Tamm et al. 1998) pancreatic
cancer,
squamous cell carcinoma, leukemia and medulloblastoma and other tumors which
show an
overexpression of survivin, enhancing the well-being of the patients without
using
chemotherapeutic agents or other agents which may lead to severe side effects.
Summary of the invention
In a first aspect thereof, the present invention relates to a peptide
comprising a sequence
selected from the group of SEQ ID No. 1 to SEQ ID No. 3, or a variant thereof
that is at least
85% homologous to SEQ ID No. 1 to SEQ ID No. 3, or a variant thereof that
induces T cells
cross-reacting with said variant peptide; wherein said peptide is not the full-
length
polypeptide of human survivin. Preferably, said peptide is selected from a
peptide having a
specific HLA-subtype, such as HLA-A*02 or HLA-DR.
In a second aspect thereof, the present invention relates to a nucleic acid,
encoding a peptide
according to the present invention or an expression vector capable of
expressing said nucleic
acid.
In a third aspect thereof, the present invention relates to a host cell
comprising the nucleic
acid or the expression vector according to the present invention, wherein said
host cell
preferably is an antigen presenting cell, in particular a dendritic cell or
antigen presenting cell.
In a fourth aspect thereof, the present invention relates to an in vitro
method for producing
activated cytotoxic T lymphocytes (CTL), comprising contacting in vitro CTL
with antigen
loaded human class I MHC molecules expressed on the surface of a suitable
antigen-
presenting cell or an artificial construct mimicking an antigen-presenting
cell for a period of
time sufficient to activate said CTL in an antigen specific manner, wherein
said antigen is a
peptide according to the present invention.
CA 02724198 2010-11-12
WO 2009/138236- 9 - PCT/EP2009/003447
Use of a peptide according to the present invention, the nucleic acid or the
expression vector
according to the present invention, the cell according to the present
invention, or an activated
cytotoxic T lymphocyte produced according to the present invention for the
treatment of
cancer or for the manufacture of a medicament against cancer, wherein said
medicament
preferably is a vaccine. Preferably, said cancer is selected from astrocytoma,
pilocytic
astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas,
ependymoma,
glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma,
retinoblastoma, neuroblastoma, germinoma, teratoma, gangliogliomas,
gangliocytoma, central
gangliocytoma, primitive neuroectodermal tumors (PNET, e.g. medulloblastoma,
medulloepithelioma, neuroblastoma, retinoblastoma, ependymoblastoma), tumors
of the
pineal parenchyma (e.g. pineocytoma, pineoblastoma), ependymal cell tumors,
choroid plexus
tumors, neuroepithelial tumors of uncertain origin (e.g. gliomatosis cerebri,
astroblastoma),
glioblastoma prostate tumor, breast cancer, esophageal cancer, colon cancer,
colorectal
cancer, renal cell carcinoma, clear cell renal cell carcinoma, lung cancer,
CNS, ovarian,
melanoma pancreatic cancer, squamous cell carcinoma, leukemia and
medulloblastoma, and
other tumors or cancers showing an overexpression of Survivin.
A kit, comprising: (a) a container that contains a pharmaceutical composition
containing a
peptide according to the present invention, the nucleic acid or the expression
vector according
to the present invention, a cell according to the present invention, or an
activated cytotoxic T
lymphocyte according to the present invention, in solution or in lyophilized
form; (b)
optionally, a second container containing a diluent or reconstituting solution
for the
lyophilized formulation; (c) optionally, at least one peptide selected from
the group consisting
of the peptides according to SEQ ID NOs 4 to 24, and (d) optionally,
instructions for the use
of the solution and/or the reconstitution and/or use of the lyophilized
formulation.
A method for producing a recombinant antibody specifically binding to a human
major
histocompatibility complex (MHC) class I or II being complexed with a HLA-
restricted
antigen, the method comprising: immunizing a genetically engineered non-human
mammal
comprising cells expressing said human major histocompatibility complex (MHC)
class I or II
with a soluble form of a MHC class I or II molecule being complexed with said
HLA-
restricted antigen; isolating mRNA molecules from antibody producing cells of
said non-
human mammal; producing a phage display library displaying protein molecules
encoded by
CA 02724198 2010-11-12
WO 2009/138236- 10 - PCT/EP2009/003447
said mRNA molecules; and isolating at least one phage from said phage display
library, said
at least one phage displaying said antibody specifically bindable to said
human major
histocompatibility complex (MHC) class I or II being complexed with said HLA-
restricted
antigen.
An antibody that specifically binds to a human major histocompatibility
complex (MHC)
class I or II being complexed with a HLA-restricted antigen, wherein the
antibody preferably
is a polyclonal antibody, monoclonal antibody and/or a chimeric antibody.
Detailed description of the invention
The term "peptide" is used herein to designate a series of amino acid
residues, connected one
to the other typically by peptide bonds between the alpha-amino and carbonyl
groups of the
adjacent amino acids. The peptides are typically 9 amino acids in length, but
can be as short
as 8 amino acids in length, and as long as 16 amino acids in length.
The term "oligopeptide" is used herein to designate a series of amino acid
residues, connected
one to the other typically by peptide bonds between the alpha-amino and
carbonyl groups of
the adjacent amino acids. The length of the oligopeptide is not critical to
the invention, as
long as the correct epitope or epitopes are maintained therein. The
oligopeptides are typically
less than about 30 amino acid residues in length, and greater than about 14
amino acids in
length.
The term "polypeptide" designates a series of amino acid residues, connected
one to the other
typically by peptide bonds between the alpha-amino and carbonyl groups of the
adjacent
amino acids. The length of the polypeptide is not critical to the invention as
long as the
correct epitopes are maintained. In contrast to the terms peptide or
oligopeptide, the term
polypeptide is meant to refer to molecules containing more than about 30 amino
acid residues.
A peptide, oligopeptide, protein, or polynucleotide coding for such a molecule
is
"immunogenic" (and thus an "immunogen" within the present invention), if it is
capable of
inducing an immune response. In the case of the present invention,
immunogenicity is more
specifically defined as the ability to induce a T-cell response. Thus, an
"immunogen" would
be a molecule that is capable of inducing an immune response, and in the case
of the present
invention, a molecule capable of inducing a T-cell response.
CA 02724198 2010-11-12
WO 2009/138236- 11 - PCT/EP2009/003447
A T cell "epitope" requires a short peptide that is bound to a class I or II
MHC receptor,
forming a ternary complex (MHC class I alpha chain, beta-2-microglobulin, and
peptide) that
can be recognized by a T cell bearing a matching T-cell receptor binding to
the MHC/peptide
complex with appropriate affinity. Peptides binding to MHC class I molecules
are typically 8
to 14 amino acids in length, and most typically 9 amino acids in length. T
cell epitopes that
bind to MHC class II molecules are typically 12 to 30 amino acids in length.
In the case of
peptides that bind to MHC class II molecules, the same peptide and the
corresponding T cell
epitope may share a common core segment, but differ in the overall length due
to flanking
sequences of differing lengths upstream of the amino-terminus of the core
sequence and
downstream of its carboxy-terminus, respectively. MHC class II receptors have
a more open
conformation, peptides bound to MHC class II receptors are correspondingly not
completely
buried in the structure of the MHC class II molecule peptide-binding cleft as
they are in the
MHC class I molecule peptide-binding cleft. Surprisingly, this is not the case
for the peptide
according to SEQ ID NO: 1, as small variations in the length of the peptide
lead to an extreme
decrease of activity (see below).
In humans there are three different genetic loci that encode MHC class I
molecules (the
MHC-molecules of the human are also designated human leukocyte antigens
(HLA)): HLA-
A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02, and HLA-A*11 are examples of
different
MHC class I alleles that can be expressed from these loci.
Table 2: Top 30 expressed alleles in different populations
% chance of allele expressed in an individual
Top 30 expressed alleles
Allele Caucasian Allele African-American Allele
Hispanic Allele Oriental
A*0201 45.6% C*0401 29.0% A*0201 37.1% A*1101
38.4%
C*0701 27.7% C*0701 25.4% C*0401 25.4% A*2402
33.7%
A*0101 27.4% C*0602 23.0% A*2402 24.9% C*0702
33.3%
A*0301 23.8% A*0201 22.3% C*0702 24.2% C*0102
27.7%
C*0702 21.5% A*2301 20.7% C*0701 20.8% A*3303
23.3%
C*0401 21.2% C*0202 19.0% C*0304 14.4% C*0801
21.6%
B*4402 20.2% A*0301 18.7% A*0301 14.3% C*0304
19.9%
B*0702 18.1% C*0702 18.1% B*0702 13.2% A*0201
18.1%
B*0801 18.1% B*5301 18.1% B*3501 12.8% B*4001
15.2%
CA 02724198 2010-11-12
WO 2009/138236 PCT/EP2009/003447
C*0501 17.2% B*0702 15.8% C*0602 12.3% C*0401
14.0%
C*0304 16.8% C*1601 15.7% C*0501 11.9% B*5801
13.3%
C*0602 15.7% B*1503 13.9% A*0101 11.4% B*4601
12.7%
A*1101 15.3% B*5801 13.5% A*1101 11.0% B*5101
12.4%
B*4001 13.6% A*6802 12.7% B*5101 10.8% C*0302
12.0%
A*2402 12.1% C*1701 11.7% C*1601 10.6% B*3802
11.4%
B*3501 10.7% B*4501 10.8% B*4403 9.9% A*0207
11.0%
C*0303 10.6% B*4201 10.5% C*0102 9.7% B*1501 9.4%
B*5101 10.4% A*3001 10.4% A*2902 9.7% A*0206 9.3%
C*1203 9.9% B*3501 10.1% C*0802 9.3% C*0303 9.2%
B*1501 9.6% A*0101 10.0% B*1801 9.1% B*1502 9.1%
A*2902 8.9% C*0304 9.3% A*3101 8.9% A*0203 8.8%
A*2601 8.2% A*3002 9.2% B*5201 8.6% B*4403 8.6%
A*3201 8.2% B*0801 8.5% B*1402 8.6% C*1402 8.4%
C*0802 7.7% A*3402 8.4% C*0202 7.6% B*3501 7.2%
A*2501 7.5% A*7401 8.4% C*1203 7.6% C*0602 7.0%
B*5701 7.1% A*3303 8.0% A*2601 7.6% B*5401 6.9%
B*1402 6.7% C*1801 7.3% A*6801 7.1% B*1301 6.6%
C*0202 6.6% A*2902 7.2% B*0801 7.0% B*4002 6.3%
B*1801 6.4% B*4403 6.9% A*3002 - 6.8% B*5502 6.3%
B*4403 6.4% B*4901 6.9% B*4402 6.5% A*2601 6.0%
There are 3 different loci in the human genome for MHC class II genes: HLA-DR,
HLA-DQ,
and HLA-DP. MHC class II receptors are heterodimers consisting of an alpha and
a beta
chain, both anchoring in the cell membrane via a transmembrane region. HLA-
DRB1*04, and
HLA-DRB1*07 are two examples of different MHC class II beta alleles that are
known to be
encoded in these loci. Class II alleles are very polymorphic, e.g. several
hundred different
HLA-DRB1 alleles have been described. Therefore, for therapeutic and
diagnostic purposes a
peptide that binds with appropriate affinity to several different HLA class II
receptors is
highly desirable. A peptide binding to several different HLA class II
molecules is called a
promiscuous binder.
As used herein, reference to a DNA sequence includes both single stranded and
double
stranded DNA. Thus, the specific sequence, unless the context indicates
otherwise, refers to
the single strand DNA of such sequence, the duplex of such sequence with its
complement
(double stranded DNA) and the complement of such sequence. The term "coding
region"
refers to that portion of a gene which either naturally or normally codes for
the expression
CA 02724198 2010-11-12
WO 2009/138236- 13 - PCT/EP2009/003447
product of that gene in its natural genomic environment, i.e., the region
coding in vivo for the
native expression product of the gene.
The coding region can be from a normal, mutated or altered gene, or can even
be from a DNA
sequence, or gene, wholly synthesized in the laboratory using methods well
known to those of
skill in the art of DNA synthesis.
The term "nucleotide sequence" refers to a heteropolymer of
deoxyribonucleotides.
The nucleotide sequence coding for a particular peptide, oligopeptide, or
polypeptide may be
naturally occurring or they may be synthetically constructed. Generally, DNA
segments
encoding the peptides, polypeptides, and proteins of this invention are
assembled from cDNA
fragments and short oligonucleotide linkers, or from a series of
oligonucleotides, to provide a
synthetic gene that is capable of being expressed in a recombinant
transcriptional unit
comprising regulatory elements derived from a microbial or viral operon.
The term "expression product" means the polypeptide or protein that is the
natural translation
product of the gene and any nucleic acid sequence coding equivalents resulting
from genetic
code degeneracy and thus coding for the same amino acid(s).
The term "fragment", when referring to a coding sequence, means a portion of
DNA
comprising less than the complete coding region, whose expression product
retains essentially
the same biological function or activity as the expression product of the
complete coding
region.
The term "DNA segment" refers to a DNA polymer, in the form of a separate
fragment or as a
component of a larger DNA construct, which has been derived from DNA isolated
at least
once in substantially pure form, i.e., free of contaminating endogenous
materials and in a
quantity or concentration enabling identification, manipulation, and recovery
of the segment
and its component nucleotide sequences by standard biochemical methods, for
example, by
using a cloning vector. Such segments are provided in the form of an open
reading frame
uninterrupted by internal nontranslated sequences, or introns, which are
typically present in
eukaryotic genes. Sequences of non-translated DNA may be present downstream
from the
CA 02724198 2010-11-12
WO 2009/138236- 14 - PCT/EP2009/003447
open reading frame, where the same do not interfere with manipulation or
expression of the
coding regions.
The term "primer" means a short nucleic acid sequence that can be paired with
one strand of
DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis
of a
deoxyribonucleotide chain.
The term "promoter" means a region of DNA involved in binding of RNA
polymerase to
initiate transcription.
The term "open reading frame (ORF)" means a series of triplets coding for
amino acids
without any termination codons and is a sequence (potentially) translatable
into protein.
The term "isolated" means that the material is removed from its original
environment (e.g.,
the natural environment if it is naturally occurring). For example, a
naturally-occurring
polynucleotide or polypeptide present in a living animal is not isolated, but
the same
polynucleotide or polypeptide, separated from some or all of the coexisting
materials in the
natural system, is isolated. Such polynucleotides could be part of a vector
and/or such
polynucleotides or polypeptides could be part of a composition, and still be
isolated in that
such vector or composition is not part of its natural environment.
The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in
accordance
with the present invention may also be in "purified" form. The term "purified2
does not
require absolute purity; rather, it is intended as a relative definition, and
can include
preparations that are highly purified or preparations that are only partially
purified, as those
terms are understood by those of skill in the relevant art. For example,
individual clones
isolated from a cDNA library have been conventionally purified to
electrophoretic
homogeneity. Purification of starting material or natural material to at least
one order of
magnitude, preferably two or three orders, and more preferably four or five
orders of
magnitude is expressly contemplated. Furthermore, the claimed polypeptide
which has a
purity of preferably 99.999%, or at least 99.99% or 99.9%; and even desirably
99% by weight
or greater is expressly contemplated.
CA 02724198 2010-11-12
WO 2009/138236- 15 - PCT/EP2009/003447
The nucleic acids and polypeptide expression products disclosed according to
the present
invention, as well as expression vectors containing such nucleic acids and/or
such
polypeptides, may be in "enriched form". As used herein, the term "enriched"
means that the
concentration of the material is at least about 2, 5, 10, 100, or 1000 times
its natural
concentration (for example), advantageously 0.01 %, by weight, preferably at
least about
0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by
weight are
also contemplated. The sequences, constructs, vectors, clones, and other
materials comprising
the present invention can advantageously be in enriched or isolated form.
The term "active fragment" means a fragment that generates an immune response
(i.e., has
immunogenic activity) when administered, alone or optionally with a suitable
adjuvant, to an
animal, such as a mammal, for example, a rabbit or a mouse, and also including
a human,
such immune response taking the form of stimulating a T-cell response within
the recipient
animal, such as a human. Alternatively, the "active fragment" may also be used
to induce a T-
cell response in vitro.
As used herein, the terms "portion", "segment", and "fragment", when used in
relation to
polypeptides, refer to a continuous sequence of residues, such as amino acid
residues, which
sequence forms a subset of a larger sequence. For example, if a polypeptide
were subjected to
treatment with any of the common endopeptidases, such as trypsin or
chymotrypsin, the
oligopeptides resulting from such treatment would represent portions, segments
or fragments
of the starting polypeptide. This means that any such fragment will
necessarily contain as part
of its amino acid sequence a segment, fragment or portion, that is
substantially identical, if not
exactly identical, to a sequence of SEQ ID NO: 1 to SEQ ID NO: 3, which
correspond to the
naturally occurring, or "parent" protein of the SEQ ID NO: 1 to SEQ ID NO: 3,
namely
survivin. When used in relation to polynucleotides, such terms refer to the
products produced
by treatment of said polynucleotides with any of the common endonucleases.
In accordance with the present invention, the term "percent identity" or
"percent identical",
when referring to a sequence, means that a sequence is compared to a claimed
or described
sequence after alignment of the sequence to be compared (the "Compared
Sequence") with
the described or claimed sequence (the "Reference Sequence"). The Percent
Identity is then
determined according to the following formula:
Percent Identity= 100 [I -(C/R)]
CA 02724198 2010-11-12
WO 2009/138236- 16 - PCT/EP2009/003447
wherein C is the number of differences between the Reference Sequence and the
Compared
Sequence over the length of alignment between the Reference Sequence and the
Compared
Sequence, wherein
(i) each base or amino acid in the Reference Sequence that does not have a
corresponding
aligned base or amino acid in the Compared Sequence and
(ii) each gap in the Reference Sequence and
(iii) each aligned base or amino acid in the Reference Sequence that is
different from an
aligned base or amino acid in the Compared Sequence, constitutes a difference;
and R is the number of bases or amino acids in the Reference Sequence over the
length of the
alignment with the Compared Sequence with any gap created in the Reference
Sequence also
being counted as a base or amino acid.
If an alignment exists between the Compared Sequence and the Reference
Sequence for
which the percent identity as calculated above is about equal to or greater
than a specified
minimum Percent Identity then the Compared Sequence has the specified minimum
percent
identity to the Reference Sequence even though alignments may exist in which
the herein
above calculated Percent Identity is less than the specified Percent Identity.
The original peptides disclosed herein can be modified by the substitution of
one or more
residues at different, possibly selective, sites within the peptide chain, if
not otherwise stated.
Such substitutions may be of a conservative nature, for example, where one
amino acid is
replaced by an amino acid of similar structure and characteristics, such as
where a
hydrophobic amino acid is replaced by another hydrophobic amino acid. Even
more
conservative would be replacement of amino acids of the same or similar size
and chemical
nature, such as where leucine is replaced by isoleucine. In studies of
sequence variations in
families of naturally occurring homologous proteins, certain amino acid
substitutions are
more often tolerated than others, and these are often show correlation with
similarities in size,
charge, polarity, and hydrophobicity between the original amino acid and its
replacement, and
such is the basis for defining "conservative substitutions".
Conservative substitutions are herein defined as exchanges within one of the
following five
groups: Group 1-small aliphatic, nonpolar or slightly polar residues (Ala,
Ser, Thr, Pro, Gly);
Group 2-polar, negatively charged residues and their amides (Asp, Asn, Glu,
Gin); Group 3-
CA 02724198 2010-11-12
WO 2009/138236- 17 - PCT/EP2009/003447
polar, positively charged residues (His, Arg, Lys); Group 4-large, aliphatic,
nonpolar residues
(Met, Leu, Ile, Val, Cys); and Group 5-large, aromatic residues (Phe, Tyr,
Trp).
Less conservative substitutions might involve the replacement of one amino
acid by another
that has similar characteristics but is somewhat different in size, such as
replacement of an
alanine by an isoleucine residue. Highly non-conservative replacements might
involve
substituting an acidic amino acid for one that is polar, or even for one that
is basic in
character. Such "radical" substitutions cannot, however, be dismissed as
potentially
ineffective since chemical effects are not totally predictable and radical
substitutions might
well give rise to serendipitous effects not otherwise predictable from simple
chemical
principles.
Of course, such substitutions may involve structures other than the common L-
amino acids.
Thus, D-amino acids might be substituted for the L-amino acids commonly found
in the
antigenic peptides of the invention and yet still be encompassed by the
disclosure herein. In
addition, amino acids possessing non-standard R groups (i.e., R groups other
than those found
in the common 20 amino acids of natural proteins) may also be used for
substitution purposes
to produce immunogens and immunogenic polypeptides according to the present
invention.
If substitutions at more than one position are found to result in a peptide
with substantially
equivalent or greater antigenic activity as defined below, then combinations
of those
substitutions will be tested to determine if the combined substitutions result
in additive or
synergistic effects on the antigenicity of the peptide. At most, no more than
four positions
within the peptide would simultaneously be substituted.
The term "T-cell response" means the specific proliferation and activation of
effector
functions induced by a peptide in vitro or in vivo. For MHC class I restricted
CTLs, effector
functions may be lysis of peptide-pulsed, peptide-precursor pulsed or
naturally peptide-
presenting target cells, secretion of cytokines, preferably Interferon-gamma,
TNF-alpha, or
IL-2 induced by peptide, secretion of effector molecules, preferably granzymes
or perforins
induced by peptide, or degranulation. For MHC class II-restricted T helper
cells, effector
functions may be peptide induced secretion of cytokines, preferably, IFN-
gamma, TNF-alpha,
IL-4, IL5, IL-10, or IL-2, or peptide-induced degranulation. Possible effector
functions for
CTLs and T helper cells are not limited to this list.
CA 02724198 2010-11-12
WO 2009/138236- 18 - PCT/EP2009/003447
Preferably, when the CTLs specific for a peptide derived from any of SEQ ID
NO: 1 to 3 are
tested against the substituted peptides, the peptide concentration at which
the substituted
peptides achieve half the maximal increase in lysis relative to background is
no more than
about 1 mM, preferably no more than about 1 M, more preferably no more than
about 1 nM,
and still more preferably no more than about 100 pM, and most preferably no
more than about
pM. It is also preferred that the substituted peptide be recognized by CTLs
from more than
one individual, at least two, and more preferably three individuals.
Thus, the epitopes of the present invention may be identical to naturally
occurring tumor-
associated or tumor-specific epitopes or may include epitopes that differ by
no more than four
residues from the reference peptide, as long as they have substantially
identical antigenic
activity.
Stimulation of an immune response is dependent upon the presence of antigens
recognized as
foreign by the host immune system. The discovery of the existence of tumor
associated
antigens has now raised the possibility of using a host's immune system to
foster an immune
response that is specific for target antigens expressed on the surface of
tumor cells and which
through this mechanism of action is capable of inducing regression, stasis or
slowed-down
growth of the tumor. Various mechanisms of harnessing both the humoral and
cellular arms
of the immune system are currently being explored for cancer immunotherapy.
Specific elements of the cellular immune response are capable of specifically
recognizing and
destroying tumor cells. The isolation of cytotoxic T cells (CTL) from tumor-
infiltrating cell
populations or from peripheral blood suggests that such cells play an
important role in natural
immune defenses against cancer (Cheever et al., 1993; Zeh, III et al., 1999).
Based on the
analysis of 415 specimens from patients suffering from colorectal cancer,
Galon et al. were
able to demonstrate that type, density and location of immune cells in tumor
tissue are
actually a better predictor for survival of patients than the widely employed
TNM-staging of
tumors (Galon et al., 2006).
MHC class I present peptides that result from proteolytic cleavage of
predominantly
endogenous proteins, DRIPs and larger peptides. MHC class II molecules can be
found
predominantly on professional antigen presenting cells (APCs), and primarily
present
CA 02724198 2010-11-12
WO 2009/138236- 19 - PCT/EP2009/003447
peptides of exogenous or transmembrane proteins that are taken up by APCs
during the
course of endocytosis, and are subsequently processed (Cresswell, 1994).
Complexes of
peptide and MHC class I molecules are recognized by CD8-positive cytotoxic T-
lymphocytes
bearing the appropriate TCR (T-cell receptor), and complexes of peptide and
MHC class II
molecules are recognized by CD4-positive-helper-T cells bearing the
appropriate TCR. It is
well known that the TCR, the peptide and the MHC are thereby present in a
stoichiometric
amount of 1:1:1.
CD4-positive helper T cells play an important role in inducing and sustaining
effective
responses by CD8-positive cytotoxic T cells (Wang and Livingstone, 2003; Sun
and Bevan,
2003; Shedlock and Shen, 2003). Initially, the priming and expansion of CTLs
in lymph
nodes is supported by CD4+ T-cells (Schoenberger et al., 1998). One mechanism
therefore
might be the guidance of naive CD8+ cells to the place of functional CD4+ T-
cell ¨ APC
interaction (Castellino et al., 2006). Finally, the generation of functional
CD8+ memory cells
is in most cases dependent on CD4+ T-cell assistance (Sun and Bevan, 2003;
Janssen et al.,
2003). For these reasons, the identification of CD4-positive T-cell epitopes
derived from
tumor associated antigens (TAA) is of great importance for the development of
pharmaceutical products for triggering anti-tumor immune responses (Kobayashi
et al., 2002;
Qin et al., 2003; Gnjatic et al., 2003). At the tumor site, T helper cells,
support a CTL friendly
cytokine milieu (Qin and Blankenstein, 2000; Mortara et al., 2006) and attract
effector cells,
e.g. CTLS, NK cells, macrophages, granulocytes (Marzo et al., 2000; Hwang et
al., 2007).
In the absence of inflammation, expression of MHC class II molecules is mainly
restricted to
cells of the immune system, especially professional antigen-presenting cells
(APC), e.g.,
monocytes, monocyte-derived cells, macrophages, dendritic cells. In cancer
patients, cells of
the tumor have surprisingly been found to express MHC class II molecules
(Dengjel et al.,
2006).
It was shown in mammalian animal models, e.g., mice, that even in the absence
of CTL
effector cells (i.e., CD8-positive T lymphocytes), CD4-positive T cells are
sufficient for
inhibiting manifestation of tumors via inhibition of angiogenesis by secretion
of interferon-
gamma (IFNy) (Qin and Blankenstein, 2000). Also the direct killing of tumor
cells by
cytotoxic CD4+ T cells via lymphotoxins and granzyme B has been proposed
(Penna et al.,
1992; Littaua et al., 1992).
CA 02724198 2010-11-12
WO 2009/138236- 20 - PCT/EP2009/003447
Additionally, it was shown that CD4-positive T cells recognizing peptides from
tumor-
associated antigens presented by HLA class II molecules can counteract tumor
progression
via the induction of antibody (Ab) responses (Kennedy et al., 2003).
In contrast to tumor-associated peptides binding to HLA class I molecules,
only a small
number of class II ligands of tumor associated antigens (TAA) have been
described to date.
Since the constitutive expression of HLA class II molecules is usually limited
to cells of the
immune system (Mach et al., 1996), the possibility of isolating class II
peptides directly from
primary tumors was not considered possible. However, Dengjel et al. were
recently successful
in identifying a number of MHC Class II epitopes directly from tumors (WO
2007/028574,
EP 1 760 088 Bl; (Dengjel et al., 2006).
The antigens that are recognized by the tumor specific cytotoxic T
lymphocytes, that is, their
epitopes, can be molecules derived from all protein classes, such as enzymes,
receptors,
transcription factors, etc. which are expressed and, as compared to unaltered
cells of the same
origin, up-regulated in cells of the respective tumor.
The current classification of tumor associated antigens (TAAs) comprises the
following major
groups (Novellino et al., 2005):
1. Cancer-testis antigens: The first TAAs ever identified that can be
recognized by T cells
(van der Bruggen et al., 1991) belong to this class, which was originally
called cancer-testis
(CT) antigens because of the expression of its members in histologically
different human
tumors and, among normal tissues, only in spermatocytes/spermatogonia of
testis and,
occasionally, in placenta. Since the cells of testis do not express class I
and II HLA
molecules, these antigens cannot be recognized by T cells in normal tissues
and can therefore
be considered as immunologically tumor-specific. Well-known examples for CT
antigens are
the MAGE family members or NY-ESO-1.
2. Differentiation antigens: These TAAs are shared between tumors and the
normal tissue
from which the tumor arose; most are found in melanomas and normal
melanocytes. Many of
these melanocyte lineage-related proteins are involved in the biosynthesis of
melanin and are
therefore not tumor specific but nevertheless are widely used for cancer
immunotherapy.
CA 02724198 2010-11-12
WO 2009/138236- 21 - PCT/EP2009/003447
Examples include, but are not limited to, tyrosinase and Melan-A/MART-1 for
melanoma or
PSA for prostate cancer.
3. Overexpressed TAAs: Genes encoding widely expressed TAAs have been detected
in
histologically different types of tumors as well as in many normal tissues,
generally with
lower expression levels. It is possible that many of the epitopes processed
and potentially
presented by normal tissues are below the threshold level for T-cell
recognition, while their
overexpression in tumor cells can trigger an anticancer response by breaking
previously
established tolerance. Prominent examples for this class of TAAs are Her-
2/neu, Survivin,
Telomerase or WT1.
4. Tumor specific antigens: These unique TAAs arise from mutations of normal
genes (such
as p-catenin, CDK4, etc.). Some of these molecular changes are associated with
neoplastic
transformation and/or progression. Tumor specific antigens are generally able
to induce
strong immune responses without bearing the risk for autoimmune reactions
against normal
tissues. On the other hand, these TAAs are in most cases only relevant to the
exact tumor on
which they were identified and are usually not shared between many individual
tumors.
5. TAAs arising from abnormal post-translational modifications: Such TAAs may
arise from
proteins that are neither specific nor overexpressed in tumors but
nevertheless become tumor
associated by posttranslational processes primarily active in tumors. Examples
for this class
arise from altered glycosylation patterns leading to novel epitopes in tumors
as for MUC1 or
events like protein splicing during degradation, which may or may not be tumor
specific
(Hanada et al., 2004; Vigneron et al., 2004).
6. Oncoviral proteins: These TAAs are viral proteins that may play a critical
role in the
oncogenic process and, because they are foreign (not of human origin), they
can evoke a T-
cell response. Examples of such proteins are the human papilloma type 16 virus
proteins, E6
and E7, which are expressed in cervical carcinoma.
For proteins to be recognized by cytotoxic T-lymphocytes as tumor-specific or -
associated
antigens, and in order to be used in a therapy, particular prerequisites must
be fulfilled. The
antigen should be expressed mainly by tumor cells and not or in comparably
small amounts
by normal healthy tissues. It is furthermore desirable, that the respective
antigen is not only
present in a type of tumor, but also in high concentrations (i.e. copy numbers
of the respective
peptide per cell). Tumor-specific and tumor-associated antigens are often
derived from
proteins directly involved in transformation of a normal cell to a tumor cell
due to a function
e.g. in cell cycle control or suppression of apoptosis. Additionally, also
downstream targets of
CA 02724198 2010-11-12
WO 2009/138236- 22 - PCT/EP2009/003447
the proteins directly causative for a transformation may be upregulated and
thus may be
indirectly tumor-associated. Such indirectly tumor-associated antigens may
also be targets of
a vaccination approach (Singh-Jasuja et al., 2004). In both cases it is
essential that epitopes
are present in the amino acid sequence of the antigen, since such a peptide
("immunogenic
peptide") that is derived from a tumor associated antigen should lead to an in
vitro or in vivo
T-cell-response.
Basically, any peptide able to bind a MHC molecule may function as a T-cell
epitope. A
prerequisite for the induction of an in vitro or in vivo T-cell-response is
the presence of a T
cell with a corresponding TCR and the absence of immunological tolerance for
this particular
epitope.
Therefore, TAAs are a starting point for the development of a tumor vaccine.
The methods for
identifying and characterizing the TAAs are based on the use of CTL that can
be isolated
from patients or healthy subjects, or they are based on the generation of
differential
transcription profiles or differential peptide expression patterns between
tumors and normal
tissues (Lemmel et al., 2004; Weinschenk et al., 2002).
However, the identification of genes over-expressed in tumor tissues or human
tumor cell
lines, or selectively expressed in such tissues or cell lines, does not
provide precise
information as to the use of the antigens being transcribed from these genes
in an immune
therapy. This is because only an individual subpopulation of epitopes of these
antigens are
suitable for such an application since a T cell with a corresponding TCR has
to be present and
immunological tolerance for this particular epitope needs to be absent or
minimal. It is
therefore important to select only those peptides from over-expressed or
selectively expressed
proteins that are presented in connection with MHC molecules against which a
functional T
cell can be found. Such a functional T cell is defined as a T cell that upon
stimulation with a
specific antigen can be clonally expanded and is able to execute effector
functions ("effector
T cell").
T-helper cells play an important role in orchestrating the effector function
of CTLs in anti-
tumor immunity. T-helper cell epitopes that trigger a T-helper cell response
of the TH1 type
support effector functions of CD8-positive killer T cells, which include
cytotoxic functions
directed against tumor cells displaying tumor-associated peptide/MHC complexes
on their
CA 02724198 2010-11-12
WO 2009/138236- 23 - PCT/EP2009/003447
cell surfaces. In this way tumor-associated T-helper cell peptide epitopes,
alone or in
combination with other tumor-associated peptides, can serve as active
pharmaceutical
ingredients of vaccine compositions that stimulate anti-tumor immune
responses.
Since both types of response, CD8 and CD4 dependent, contribute jointly and
synergistically
to the anti-tumor effect, the identification and characterization of tumor-
associated antigens
recognized by either CD8+ CTLs (ligand: MHC class I molecule + peptide
epitope) or by
CD4-positive T-helper cells (ligand: MHC class II molecule + peptide epitope)
is important in
the development of tumor vaccines.
Considering the severe side-effects and expense associated with treating
cancer better
prognosis and diagnostic methods are desperately needed. Therefore, there is a
need to
identify other factors representing biomarkers for cancer in general and
glioblastoma in
particular. Furthermore, there is a need to identify factors that can be used
in the treatment of
cancer in general and glioblastoma in particular,
Furthermore there is no established therapeutic design for prostate cancer
patients with
biochemical relapse after radical prostatectomy, usually caused by residual
tumor left in situ
in the presence of locally advanced tumor growth. New therapeutic approaches
that confer
lower morbidity with comparable therapeutic efficacy relative to the currently
available
therapeutic approaches would be desirable.
The present invention provides peptides that are useful in treating
glioblastoma, prostate
cancer and other tumors that overexpress survivin. These peptides were partly
directly shown
by mass spectrometry to be naturally presented by HLA molecules on primary
human
glioblastoma samples (see Example 1 and Figure 1), or in the case of SEQ ID
NO: 1 and 2
predicted according to the SYFPEITHI prediction algorithm (Rammensee et al.,
1995) to be
promiscuous binders to the HLA-DR alleles HLA-DRB1*01, DRB1*03, DRB1*04,
DRB1*11, and DRB1*15 (see attachment). Based on this data and the frequencies
of these
frequent DRB1 alleles (Mori et al., 1995; Chanock et al., 2004), it can be
assumed that 92 %
of A*02-positive Caucasians express at least one DRB1 allele that binds these
peptides (SEQ
ID NO: 1 to SEQ ID NO: 3). SEQ ID NO: 2 contains the same core sequence as SEQ
ID NO:
1, elongated by two N-terminal amino acids from the natural survivin sequence
to contain a
described class I T-cell epitope from survivin (Schmitz et al., 2000). SEQ ID
NO: 3 contains
CA 02724198 2010-11-12
WO 2009/138236- 24 - PCT/EP2009/003447
the same sequence as SEQ ID NO: 1, wherein the last C-terminal amino acid is
modified from
an asparagine (N) to aspartic acid (D).
The source gene from which SEQ ID NO: 1 to SEQ ID NO: 3 are derived ¨ survivin
¨ was
shown to be highly overexpressed in glioblastoma, prostate tumor, breast
cancer, esophageal
cancer, colorectal cancer, clear cell renal cell carcinoma, lung cancer, CNS,
ovarian,
melanoma (Tamm et al. 1998) pancreatic cancer, squamous cell carcinoma,
leukemia and
medulloblastoma compared with normal tissues (see Example 2 and Figure 2)
demonstrating
a high degree of tumor association of the peptide, i.e. these peptides are
strongly presented on
tumor tissue but not on normal tissues.
HLA-bound peptides can be recognized by the immune system, specifically T
lymphocytes/T
cells. T cells can destroy the cells presenting the recognized HLA/peptide
complex, e.g.
glioblastoma tumor cells presenting the survivin-derived (SEQ ID NO: 1 to SEQ
ID NO: 3). T
helper cells activated by the survivin-derived peptides can inhibit tumor
vascularization, can
attract effector cells of the immune system and facilitate CTL priming,
proliferation, and a
sustained CD8+ T-cell response.
All peptides of the present invention have been shown to be capable of
stimulating T cell
responses (see Example 3 and Figure 3). Thus, the peptides are useful for
generating an
immune response in a patient by which tumor cells can be destroyed. An immune
response in
a patient can be induced by direct administration of the described peptides or
suitable
precursor substances (e.g. elongated peptides, proteins, or nucleic acids
encoding these
peptides) to the patient, ideally in combination with an agent enhancing the
immunogenicity
(i.e. an adjuvant). The immune response originating from such a therapeutic
vaccination can
be expected to be highly specific against tumor cells because the target
peptides of the present
invention are not presented on normal tissues in comparable copy numbers,
preventing the
risk of undesired autoimmune reactions against normal cells in the patient.
The pharmaceutical compositions comprise the peptides either in the free form
or in the form
of a pharmaceutically acceptable salt.
As used herein, "a pharmaceutically acceptable salt" refers to a derivative of
the disclosed
peptides wherein the peptide is modified by making acid or base salts of the
agent. For
CA 02724198 2010-11-12
WO 2009/138236- 25 - PCT/EP2009/003447
example, acid salts are prepared from the free base (typically wherein the
neutral form of the
drug has a neutral ¨NH2 group) involving reaction with a suitable acid.
Suitable acids for
preparing acid salts include both organic acids, e.g., acetic acid, propionic
acid, glycolic acid,
pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic
acid, fumaric acid,
tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid,
ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as
well as inorganic
acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid
phosphoric acid and
the like. Conversely, preparation of basic salts of acid moieties which may be
present on a
peptide are prepared using a pharmaceutically acceptable base such as sodium
hydroxide,
potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine or
the like.
In an especially preferred embodiment the pharmaceutical compositions comprise
the
peptides as salts of acetic acid (acetates) or hydrochloric acid (chlorides).
In addition to being useful for treating cancer, the peptides of the present
invention are also
useful as diagnostics. Since the peptides were generated from glioblastoma and
since it was
determined that these peptides are not present in normal tissues, these
peptides can be used to
diagnose the presence of a cancer.
The presence of claimed peptides on tissue biopsies can assist a pathologist
in diagnosis of
cancer. Detection of certain peptides by means of antibodies, mass
spectrometry or other
methods known in the art can tell the pathologist that the tissue is malignant
or inflamed or
generally diseased. Presence of groups of peptides can enable classification
or
subclassification of diseased tissues.
The detection of peptides on diseased tissue specimen can enable the decision
about the
benefit of therapies involving the immune system, especially if T lymphocytes
are known or
expected to be involved in the mechanism of action. Loss of MHC expression is
a well
described mechanism by which infected of malignant cells escape
immunosurveillance. Thus,
presence of peptides shows that this mechanism is not exploited by the
analyzed cells.
The peptides might be used to analyze lymphocyte responses against those
peptides such as T
cell responses or antibody responses against the peptide or the peptide
complexed to MHC
molecules. These lymphocyte responses can be used as prognostic markers for
decision on
CA 02724198 2010-11-12
WO 2009/138236- 26 - PCT/EP2009/003447
further therapy steps. These responses can also be used as surrogate markers
in
immunotherapy approaches aiming to induce lymphocyte responses by different
means, e.g.
vaccination of protein, nucleic acids, autologous materials, adoptive transfer
of lymphocytes.
In gene therapy settings, lymphocyte responses against peptides can be
considered in the
assessment of side effects. Monitoring of lymphocyte responses might also be a
valuable tool
for follow-up examinations of transplantation therapies, e.g. for the
detection of graft versus
host and host versus graft diseases.
The peptides can be used to generate and develop specific antibodies against
MHC/peptide
complexes. These can be used for therapy, targeting toxins or radioactive
substances to the
diseased tissue. Another use of these antibodies can be targeting
radionuclides to the diseased
tissue for imaging purposes such as PET. This use can help to detect small
metastases or to
determine the size and precise localization of diseased tissues.
In addition, they can be used to verify a pathologist's diagnosis of a cancer
based on a
biopsied sample.
Table 3 shows the peptides according to the present invention, their
respective SEQ ID NO:,
the HLA alleles to which the respective peptides bind, and the source proteins
from which
these peptides may arise. Of special interest is the fact that the peptide
according to SEQ ID
NO: 2 binds to HLA-DR as well as HLA-A*02 thus eliciting two different
responses.
Table 3: Peptides of the present invention
Source
SEQ ID NO: Peptide Code Sequence HLA Alleles Protein(s)
1 BIR-002 TLGEFLKLDRERAKN HLA-DR Survivin
HLA-DR and Survivin
2 BIR-004 ELTLGEFLKLDRERAKN HLA-A*02
3 BIR-002a TLGEFLKLDRERAKD HLA-DR Survivin
Expression of BIRC5 (survivin), a member of the inhibitor of apoptosis protein
(IAP) family,
is elevated in fetal tissues and in various human cancers, with greatly
reduced expression in
adult normal differentiated tissues, particularly if their proliferation index
is low. Survivin
seems to be capable of regulating both cellular proliferation and apoptotic
cell death.
CA 02724198 2010-11-12
WO 2009/138236- 27 - PCT/EP2009/003447
Although survivin is usually located in the cell cytoplasmic region and
associated with poor
prognosis in cancer, nuclear localization, indicative of favorable prognosis,
has also been
reported (O'Driscoll et al., 2003). Regulation of and through survivin has
been described by
several mechanisms. Survivin seems to be associated with the molecular
chaperone Hsp60. In
vivo, Hsp60 is abundantly expressed in primary human tumors as compared with
matched
normal tissues. Acute ablation of Hsp60 by small interfering RNA destabilizes
the
mitochondrial pool of survivin, induces mitochondrial dysfunction, and
activates caspase-
dependent apoptosis (Ghosh et al., 2008). Furthermore, Ras inhibition results
in release of the
survivin "brake" on apoptosis and in activation of the mitochondrial apoptotic
pathway.
Especially in glioblastoma, resistance to apoptosis can be abolished by a Ras
inhibitor that
targets survivin (Blum et al., 2006). There also seems to be a correlation
between NF-kappaB
hyperactivity in gliomas and hyperexpression of survivin, one of NF-kappaB
target genes.
Thus, NF-kappaB-activated anti-apoptotic genes are hyperexpressed in tumor
samples.
Especially in glioblastoma, very high levels of survivin expression are
detectable (Angileri et
al., 2008). It is suggested that survivin overexpression in brain gliomas
might play an
important role in malignant proliferation, anti-apoptosis and angiogenesis
(Zhen et al., 2005;
Liu et al., 2006). Several analyses were performed to study survivin
expression and its impact
on survival in glioblastoma. To summarize, survivin expression, especially the
simultaneous
expression in nucleus and cytoplasm in astrocytic tumors was significantly
associated with
malignancy grade (with highest survivin expression in glioblastoma) and
shorter overall
survival times compared with patients who had survivin-negative tumors
(Kajiwara et al.,
2003; Saito et al., 2007; Uematsu et al., 2005; Mellai et al., 2008; Grunda et
al., 2006; Xie et
al., 2006; Sasaki et al., 2002; Chakravarti et al., 2002).
Survivin-overexpression has also been described for other tumor entities. In
breast cancer,
survivin expression is associated with higher grade and shorter disease-free
survival
(Yamashita et al., 2007; Al-Joudi et al., 2007; Span et al., 2004). In
esophageal cancer cell
lines, the promoter activity of survivin was shown to be 28.5 fold higher than
in normal
tissues (Sato et al., 2006). In colorectal cancer, survivin expression is also
associated with
pathological grade and lymph node metastasis (Tan et al., 2005). The
aggressiveness of clear
cell renal cell carcinoma was shown to be associated with survivin expression.
Furthermore,
expression of survivin is inversely associated with cancer-specific survival
(Kosari et al.,
2005). Survivin expression can be detected in a panel of keratinocytic
neoplasms and
hyperproliferative skin lesions but not in normal skin (Bowen et al., 2004).
In pancreatic
CA 02724198 2010-11-12
WO 2009/138236- 28 - PCT/EP2009/003447
cancer cell lines, survivin was amplified in 58% of the tested cell lines
(Mahlamaki et al.,
2002). In squamous cell carcinoma, survivin expression can help to identify
cases with more
aggressive and invasive clinical phenotype (Lo et al., 2001).
As survivin is such a promising target for cancer therapy, studies using
survivin-derived
peptides showed that survivin is immunogenic in tumor patients by eliciting
CD8+ T cell-
mediated responses. In addition, survivin specifically stimulated CD4+ T-cell
reactivity in
peripheral blood lymphocytes from the same patients (Casati et al., 2003;
Piesche et al.,
2007).
Survivin (SVN, BIRC) is overexpressed in a multitude of cancer entities. Thus,
in general,
overexpression of survivin is thought to be associated with shorter overall-
survival and higher
malignancy grades.
Piesche (2006) disclosed as part of his study (see also (Piesche et al.,
2007)), MHC class II
and HLA class II-restricted candidate epitopes in survivin (SVN) and in
proteinase-3 (PR3),
which were determined using the computer program TEPITOPE (Bian and Hammer,
2004).
The TEPITOPE analysis yielded 6 candidate epitopes for SVN and 11 candidate
epitopes for
PR3 with high binding probability for various HLA-DR alleles. These 17
peptides were used
in T cell immunologic experiments after synthesis and chromatographic
purification. The
variable lengths of the peptides resulted from overlapping epitopes that were
considered
together in one peptide (Table 4).
Table 4: Names, AA position, and AA sequences of the synthetic SVN peptides
disclosed
by Piesche 2006.
Peptide Position Amino acid sequence T cell frequency
Sup 10-24 (SEQ ID NO: 28) WQPFLKDHRISTFKN 8.64*10-7
S22 22-36 (SEQ ID NO: 29) FKNWPFLEGAAATPE 7.2*1 0-7
S40 40-54 (SEQ ID NO: 30) EAGFIHAPTENEPDL 8.64*10-7
S58 58-72 (SEQ ID NO: 31) FFCFKELEGWEPDDD 4.32*10-7
S88 88-103 (SEQ ID NO: LGEFLKLDRERAKNKI 1.73*10-7
32)
Silo 110-124 (SEQ ID NO: KNKIAKETNNKKKEF 8.64*10-7
33)
CA 02724198 2010-11-12
WO 2009/138236- 29 - PCT/EP2009/003447
(Note: S88 actually is S98, thus, Piesche et al may have made an error in
determining the
position of this epitope).
Titration experiments with the corresponding peptides were performed by
Piesche to estimate
the peptide HLA affinity or the peptide HLA/TCR avidity. The lower the peptide
concentration, the higher the binding affinity of the peptide epitopes to the
MHC molecules,
an important prerequisite for the natural presentation of "genuine" T cell
epitopes from an
intracellular processing of the protein antigen. The measured half-maximal
proliferative
activity of the peptide-specific T cell clones were <50 nM for S10, 400 ¨ 700
nM for 540, 2000
¨ 3000 nM for S88 and 100 ¨ 300 nM for P58. Piesche further disclosed that
only the SVN
peptide S10 elicted a specific T cell proliferation during exposure with
recombinant SVN
protein. This was shown in three S io-specific T cell clones from different
donors. Piesche et
al. investigated the processing and presentation of SVN peptide epitopes from
natural antigen
by co-culturing of peptide-specific T cell clones with SVN protein-pulsed DCs.
Only the SVN
peptide S10 was able to cause specific T cell proliferation during exposure
with recombinant
SVN protein. This was shown in three S10-specific T cell clones from different
donors. No
specific proliferation in response to the natural antigen was detected for the
PR3-specific T
cell clones.
Further, tumor antigens from apoptotic or necrotic tumor cells were
internalized by APCs in
vivo, processed independently of MHC II, and presented to CD4+ T cells. For T
cell recognition
of the genuine S 10 epitope, DCs with tumor cell lysates from various SVN-
positive tumor cell
lines were pulsed. For the S 10 epitope, direct in vitro recognition of lysate-
pulsed DCs from the
tumor cell lines Karpas-422, Jurkat, and HL-60 was detected. This was shown in
at least three
Sio-specific T cell clones from different donors.
To show that the epitope S10 can induce an immune response in cancer patients
the presence of
the corresponding CD4+ T lymphocytes in the blood of tumor patients had to be
confirmed.
PBMCs from various patients were isolated and stimulated with the S10 peptide.
For this
purpose PBMC samples were drawn from patients before beginning of treatment
and after the
start of cytotoxicstatic therapy, Monocytes and B cells contained in the PBMC
fraction were
used as antigen-/peptide-presenting cells. After one week of culturing, the
cells were analyzed
with respect to their peptide-specific proliferation using a [31-1]-thymidine
incorporation assay.
Of 13 tested patients, three had a detectable proliferative response in vitro.
CA 02724198 2010-11-12
WO 2009/138236- 30 - PCT/EP2009/003447
The potential use of peptide epitopes in immunotherapy essentially depends on
whether the
peptide-specific CD4+ T lymphocytes respond to the corresponding antigen.
Recognition of
the naturally processed protein antigen in the form of "genuine" or "true"
epitopes is
influenced by various factors in principle.
Piesche showed that protein recognition was only detectable for the SVN
epitope S10. For the
other identified peptides (SVN: S40, S88; PR3: P583 P2165 P2355 and P239) no
protein recognition was
detectable. Piesche et al. stated that it is important, during endosomal
proteolysis, for the
present sequence motifs not to be degraded, as in the case of "cryptic"
epitopes. In contrast to
MHC class I-restricted epitopes, MHC class II molecules can take up peptides
of variable
length (12-28); therefore, proteolytic cleavage of the peptide epitopes into
defined lengths is
not required.
Surprisingly, the inventors show in the present invention that another
epitope, SEQ ID NO: 1,
derived from survivin which is shorter than S88, but also overlapping,
elicited a strong
immuno-response in 16 out of 19 patients in vivo. (See Example 4). Due to the
high
polymorphism of the HLA-DR locus, this is also a proof of the highly
promiscuous binding of
peptide SEQ ID NO: 1 as predicted, as an immune response can only be evoked by
a peptide
bound to an HLA molecule.
The importance of the cancer entities for which an overexpression of survivin
was described
in the literature is illustrated by Table 2. Cancer indications for which
overexpression of
survivin are a commonly described feature were accountable for over 415,000
deaths in 2007
(see Table 1).
Piesche et al. (2006) showed in vitro the presence of appropriate precursors
for peptide S88 in
three out of four donors with overlapping HLA-DR alleles. Here the body of
evidence is too
small to deduce a promiscuous binding of S88 to HLA-DR, as the obtained
results may be
explained by binding to two different HLA-DR alleles (e.g. DR3 and DR11 5 or
DR1 and
DR3, or DR11 and DR4). In addition, the stimulation indices obtained by a
quite unspecific
proliferation assay ([311]-thymidine incorporation) from whole PBMC cultures
are quite low
and a positive control is missing (e.g. a mix of well-characterized, strongly
immunogenic viral
peptides) and appropriate negative controls (stimulation during proliferation
assay with an
CA 02724198 2010-11-12
WO 2009/138236- 31 - PCT/EP2009/003447
irrelevant control peptide) are missing. The data on precursor frequencies
were not confirmed
by a second type of assay.
WO 2007/036638 (õWang et al"), amongst others, discloses survivin peptides of
the amino
acid sequences
96-110 (LTLGEFLKLDRERAK; SEQ ID No 25);
99-113 (GEFLKLDRERAKNKI; SEQ ID No 26); and
102-116 (LKLDRERAKNKIAKE; SEQ ID No 27).
As a region binding HLA-molecules of MI-IC class II with "good" affinity (IC50
< 1000 nM),
the region 84 to 113 is described. Nevertheless, the peptides as examined in
Wang et al. show
a very broad spectrum of binding towards the different HLA-molecules, and said
binding
even differs drastically within said region as described, if the peptides are
shifted in their
sequence by one or two amino acids.
The peptide of the present invention of SEQ ID NO: 3 (TLGEFLKLDRERAKD; "BIR-
002a"
peptide) comprises a sequence of the BIR-002 peptide of the present invention
of SEQ ID
NO: 1, except that C-terminally, said peptide ends with the amino acid
aspartic acid (D)
instead of asparagine (N). The peptide overlaps with the peptide S88 of
Piesche, which
contains the last three amino acids NKI. As mentioned above, the S88 peptide
was inactive in
a specific T cell proliferation assay during exposure with recombinant SVN
protein. In
contrast, the BIR-002a peptide showed a strong MHC II-related immuno-response.
Without
wanting to be bound by theory, it is assumed that an enzymatic conversion of
the asparagine
into aspartic acid through an asparaginase takes place in vivo, and thus the C-
terminal amino
acid is modified (and the peptide becomes activated and/or further activated).
Since the C-
terminal asparagine of the Piesche-peptide S88 is blocked by two amino acids,
said peptide is
inactive (further showing the importance of a single amino acid change in the
activity of this
peptide).
Furthermore, it was noted that the immuno-responses and activities of other
peptides
comprising a C-terminal asparagine (such as, for example, SEQ ID NO: 1) maybe
also depend
from a C-terminal conversion into an acid amino acid, in particular aspartic
acid. Thus, in one
aspect of the present invention, the peptide according to SEQ ID NO: 1 may be
seen as a
"prodrug" for SEQ ID NO: 3, which provides the active peptide according to SEQ
ID NO: 3
after enzymatic conversion. It should be understood that the present invention
also
CA 02724198 2010-11-12
WO 2009/138236- 32 - PCT/EP2009/003447
encompasses chemical conversion of the amino acid, particularly asparagine,
and the
spontaneous deamidation by the loss of one molecule of water.
Furthermore, the examples showing an activity for the peptide according to SEQ
ID NO: 1
support also an activity for the modified peptide according to SEQ ID NO: 3.
It could furthermore be found in the context of the present invention that the
solubilities of
peptides in the area of the BIR-002 peptide (region 84 to 113) differ
drastically for very
similar peptides. It has to be notes that in Wang et al. peptides in the
region close to the BIR-
002 peptide were actually insoluble, and binding studies could not be
performed.
The solubilities were determined as follows:
BIR-002 (SEQ ID No: 1): <32,9 mg/mL (acetate)
BIR-002a (SEQ ID No: 3) (D instead of N at the C-terminal end): <23,5 mg/mL
BIR-014 (comparative peptide of Wang, SEQ ID No. 25): <99,5 mg/mL
Yet another aspect of the present invention relates to an antibody that
specifically binds to a
human major histocompatibility complex (MHC) class I or II being complexed
with a HLA-
restricted antigen (in the following also designate as "complex-specific
antibody"). Yet
another aspect of the present invention then relates to a method of producing
said antibody
specifically binding to a human major histocompatibility complex (MHC) class I
or II being
complexed with a HLA-restricted antigen, the method comprising: immunizing a
genetically
engineered non-human mammal comprising cells expressing said human major
histocompatibility complex (MHC) class I or II with a soluble form of a MHC
class I or II
molecule being complexed with said HLA-restricted antigen; isolating mRNA
molecules
from antibody producing cells of said non-human mammal; producing a phage
display library
displaying protein molecules encoded by said mRNA molecules; and isolating at
least one
phage from said phage display library, said at least one phage displaying said
antibody
specifically bindable to said human major histocompatibility complex (MHC)
class I or II
being complexed with said HLA-restricted antigen. Respective methods for
producing such
antibodies and single chain class I major histocompatibility complexes, as
well as other tools
for the production of these antibodies are disclosed in WO 03/068201, WO
2004/084798, WO
01/72768, WO 03/070752, and Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y.
Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-
like
CA 02724198 2013-12-23
WO 2009/138236 - 33 - PCT/EP2009/003447
specificity: new tools to study antigen presentation and TCR-peptide-MHC
interactions. J
Mol Recog,nit. 2003 Sep-Oct;16(5):324-32.; Denkberg G, Lev A, Eisenbach L,
Benhar I,
Reiter Y. Selective targeting of melanoma and APCs using a recombinant
antibody with
TCR-like specificity directed toward a melanoma differentiation antigen. J
Immunol. 2003
Sep 1;171(5):2197-207; and Cohen CJ, Sang 0, Yamano Y, Tomaru U, Jacobson S,
Reiter Y.
Direct phenotypic analysis of human MHC class I antigen presentation:
visualization,
quantitation, and in situ detection of human viral epitopes using peptide-
specific, MHC-
restricted human recombinant antibodies. J Immunol. 2003 Apr 15;170(8):4349-
61, which for
the purposes of the present invention are all explicitly incorporated by
reference in their
entireties.
Preferably, the antibody is binding with a binding affinity of below 20
nanomolar, preferably
of below 10 nanomolar, to the complex, which is regarded as õspecific" in the
context of the
present invention.
The term "antibody" is used herein in a broad sense and includes both
polyclonal and
monoclonal antibodies. In addition to intact immunoglobulin molecules, also
included in the
term "antibodies" are fragments or polymers of those immunoglobulin molecules
and
humanized versions of immunoglobulin molecules, so long as they exhibit any of
the desired
properties (e.g., being a complex-specific antibody as above, delivery of a
toxin to a cancer
cell expressing an cancer marker gene at an increased level, and/or inhibiting
the activity of
an cancer marker polypeptide, such as survivin) described herein.
Whenever possible, the antibodies of the invention may be purchased from
commercial
sources. The antibodies of the invention may also be generated using well-
known methods.
The skilled artisan will understand that either full length cancer marker
polypeptides or
fragments thereof may be used to generate the antibodies of the invention. A
polypeptide to
be used for generating an antibody of the invention may be partially or fully
purified from a
natural source, or may be produced using recombinant DNA techniques. For
example, a
cDNA encoding a survivin polypeptide, or a fragment thereof, can be expressed
in
prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect,
or mammalian cells),
after which the recombinant protein can be purified and used to generate a
monoclonal or
polyclonal antibody preparation that specifically bind the cancer marker
polypeptide used to
generate the antibody. Complex-specific antibodies will usually be generated
as above.
CA 02724198 2010-11-12
WO 2009/138236- 34 - PCT/EP2009/003447
One of skill in the art will know that the generation of two or more different
sets of
monoclonal or polyclonal antibodies maximizes the likelihood of obtaining an
antibody with
the specificity and affinity required for its intended use (e.g., ELISA,
immunohistochemistry,
in vivo imaging, immunotoxin therapy). The antibodies are tested for their
desired activity by
known methods, in accordance with the purpose for which the antibodies are to
be used (e.g.,
ELISA, immunohistochemistry, immunotherapy, etc.; for further guidance on the
generation
and testing of antibodies, see, e.g., Harlow and Lane, Antibodies: A
Laboratory Manual, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988). For example,
the
antibodies may be tested in ELISA assays, Western blots, immunohistochemical
staining of
formalin-fixed cancer samples or frozen tissue sections. After their initial
in vitro
characterization, antibodies intended for therapeutic or in vivo diagnostic
use are tested
according to known clinical testing methods.
The term "monoclonal antibody" as used herein refers to an antibody obtained
from a
substantially homogeneous population of antibodies, i.e.; the individual
antibodies comprising
the population are identical except for possible naturally occurring mutations
that may be
present in minor amounts. The monoclonal antibodies herein specifically
include "chimeric"
antibodies in which a portion of the heavy and/or light chain is identical
with or homologous
to corresponding sequences in antibodies derived from a particular species or
belonging to a
particular antibody class or subclass, while the remainder of the chain(s) is
identical with or
homologous to corresponding sequences in antibodies derived from another
species or
belonging to another antibody class or subclass, as well as fragments of such
antibodies, so
long as they exhibit the desired antagonistic activity (U.S. Pat.
No.4,816,567).
Monoclonal antibodies of the invention may be prepared using hybridoma
methods. In a
hybridoma method, a mouse or other appropriate host animal, is typically
immunized with an
immunizing agent to elicit lymphocytes that produce or are capable of
producing antibodies
that will specifically bind to the immunizing agent. Alternatively, the
lymphocytes may be
immunized in vitro.
The monoclonal antibodies may also be made by recombinant DNA methods, such as
those
described in U.S. Pat. No.4,816,567. DNA encoding the monoclonal antibodies of
the
invention can be readily isolated and sequenced using conventional procedures
(e.g., by using
CA 02724198 2010-11-12
WO 2009/138236- 35 - PCT/EP2009/003447
oligonucleotide probes that are capable of binding specifically to genes
encoding the heavy
and light chains of murine antibodies).
In vitro methods are also suitable for preparing monovalent antibodies.
Digestion of
antibodies to produce fragments thereof, particularly, Fab fragments, can be
accomplished
using routine techniques known in the art. For instance, digestion can be
performed using
papain. Examples of papain digestion are described in WO 94/29348 published
December 22,
1994 and U.S. Pat. No.4,342,566. Papain digestion of antibodies typically
produces two
identical antigen binding fragments, called Fab fragments, each with a single
antigen binding
site, and a residual Fe fragment. Pepsin treatment yields a fragment that has
two antigen
combining sites and is still capable of cross-linking antigen.
The antibody fragments, whether attached to other sequences or not, can also
include
insertions, deletions, substitutions, or other selected modifications of
particular regions or
specific amino acids residues, provided the activity of the fragment is not
significantly altered
or impaired compared to the non-modified antibody or antibody fragment. These
modifications can provide for some additional property, such as to remove/add
amino acids
capable of disulfide bonding, to increase its bio-longevity, to alter its
secretory characteristics,
etc. In any case, the antibody fragment must possess a bioactive property,
such as binding
activity, regulation of binding at the binding domain, etc. Functional or
active regions of the
antibody may be identified by mutagenesis of a specific region of the protein,
followed by
expression and testing of the expressed polypeptide. Such methods are readily
apparent to a
skilled practitioner in the art and can include site-specific mutagenesis of
the nucleic acid
encoding the antibody fragment.
The antibodies of the invention may further comprise humanized antibodies or
human
antibodies. Humanized forms of non-human (e.g., murine) antibodies are
chimeric
immunoglobulins, irnmunoglobulin chains or fragments thereof (such as Fv, Fab,
Fab' or
other antigen-binding subsequences of antibodies) which contain minimal
sequence derived
from non-human inununoglobulin. Humanized antibodies include human
immunoglobulins
(recipient antibody) in which residues from a complementary determining region
(CDR) of
the recipient are replaced by residues from a CDR of a non-human species
(donor antibody)
such as mouse, rat or rabbit having the desired specificity, affinity and
capacity. In some
instances, Fv framework (FR) residues of the human immunoglobulin are replaced
by
CA 02724198 2010-11-12
WO 2009/138236- 36 - PCT/EP2009/003447
corresponding non-human residues. Humanized antibodies may also comprise
residues which
are found neither in the recipient antibody nor in the imported CDR or
framework sequences.
In general, the humanized antibody will comprise substantially all of at least
one, and
typically two, variable domains, in which all or substantially all of the CDR
regions
correspond to those of a non-human immunoglobulin and all or substantially all
of the FR
regions are those of a human immunoglobulin consensus sequence. The humanized
antibody
optimally also will comprise at least a portion of an immunoglobulin constant
region (Fc),
typically that of a human immunoglobulin.
Methods for humanizing non-human antibodies are well known in the art.
Generally, a
humanized antibody has one or more amino acid residues introduced into it from
a source
which is non-human. These non-human amino acid residues are often referred to
as "import"
residues, which are typically taken from an "import" variable domain.
Humanization can be
essentially performed by substituting rodent CDRs or CDR sequences for the
corresponding
sequences of a human antibody. Accordingly, such "humanized" antibodies are
chimeric
antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an
intact human variable
domain has been substituted by the corresponding sequence from a non-human
species. In
practice, humanized antibodies are typically human antibodies in which some
CDR residues
and possibly some FR residues are substituted by residues from analogous sites
in rodent
antibodies.
Transgenic animals (e.g., mice) that are capable, upon immunization, of
producing a full
repertoire of human antibodies in the absence of endogenous immunoglobulin
production can
be employed. For example, it has been described that the homozygous deletion
of the
antibody heavy chain joining region gene in chimeric and germ-line mutant mice
results in
complete inhibition of endogenous antibody production. Transfer of the human
germ-line
immunoglobulin gene array in such germ-line mutant mice will result in the
production of
human antibodies upon antigen challenge. Human antibodies can also be produced
in phage
display libraries as, for example, described above for the complex-specific
antibodies.
Antibodies of the invention are preferably administered to a subject in a
pharmaceutically
acceptable carrier. Typically, an appropriate amount of a pharmaceutically-
acceptable salt is
used in the formulation to render the formulation isotonic. Examples of the
pharmaceutically-
acceptable carrier include saline, Ringer's solution and dextrose solution.
The pH of the
CA 02724198 2010-11-12
WO 2009/138236- 37 - PCT/EP2009/003447
solution is preferably from about 5 to about 8, and more preferably from about
7 to about 7.5.
Further carriers include sustained release preparations such as semipermeable
matrices of
solid hydrophobic polymers containing the antibody, which matrices are in the
form of shaped
articles, e.g., films, liposomes or microparticles. It will be apparent to
those persons skilled in
the art that certain carriers may be more preferable depending upon, for
instance, the route of
administration and concentration of antibody being administered.
The antibodies can be administered to the subject, patient, or cell by
injection (e.g.,
intravenous, intraperitoneal, subcutaneous, intramuscular), or by other
methods such as
infusion that ensure its delivery to the bloodstream in an effective form. The
antibodies may
also be administered by intratumoral or peritumoral routes, to exert local as
well as systemic
therapeutic effects. Local or intravenous injection is preferred.
Effective dosages and schedules for administering the antibodies may be
determined
empirically, and making such determinations is within the skill in the art.
Those skilled in the
art will understand that the dosage of antibodies that must be administered
will vary
depending on, for example, the subject that will receive the antibody, the
route of
administration, the particular type of antibody used and other drugs being
administered.
Antibodies in Human Diagnosis and Therapy, Haber et al, eds. Raven Press, New
York
(1977) pp. 365-389. A typical daily dosage of the antibody used alone might
range from about
1 ( g/kg to up to 100 mg/kg of body weight or more per day, depending on the
factors
mentioned above. Following administration of an antibody for treating cancer,
the efficacy of
the therapeutic antibody can be assessed in various ways well known to the
skilled
practitioner. For instance, the size, number, and/or distribution of cancer in
a subject receiving
treatment may be monitored using standard tumor imaging techniques. A
therapeutically-
administered antibody that arrests tumor growth, results in tumor shrinkage,
and/or prevents
the development of new tumors, compared to the disease course that would
occurs in the
absence of antibody administration, is an efficacious antibody for treatment
of cancers.
The antibodies may also be used for in vivo diagnostic assays. Generally, the
antibody is
, 131/ , 3H, 32 p 0 35
labeled with a radionucleotide (such as "In, 99Tc, 14C r
S) so that the tumor
can be localized using immunoscintiography. In one embodiment, antibodies or
fragments
thereof bind to the extracellular domains of two or more cancer targets and
the affinity value
(Kd) is less than 1 x10 M.
CA 02724198 2010-11-12
WO 2009/138236- 38 - PCT/EP2009/003447
Antibodies for diagnostic use may be labeled with probes suitable for
detection by various
imaging methods. Methods for detection of probes include, but are not limited
to,
fluorescence, light, confocal and electron microscopy; magnetic resonance
imaging and
spectroscopy; fluoroscopy, computed tomography and positron emission
tomography.
Suitable probes include, but are not limited to, fluorescein, rhodamine, eosin
and other
fluorophores, radioisotopes, gold, gadolinium and other lanthanides,
paramagnetic iron,
fluorine-18 and other positron-emitting radionuclides. Additionally, probes
may be bi- or
multi-functional and be detectable by more than one of the methods listed.
These antibodies
may be directly or indirectly labeled with said probes. Attachment of probes
to the antibodies
includes covalent attachment of the probe, incorporation of the probe into the
antibody, and
the covalent attachment of a chelating compound for binding of probe, amongst
others well
recognized in the art. For immunohistochemistry, the disease tissue sample may
be fresh or
frozen or may be embedded in paraffin and fixed with a preservative such as
formalin. The
fixed or embedded section contains the sample are contacted with a labeled
primary antibody
and secondary antibody, wherein the antibody is used to detect the NCAN
protein express in
situ.
The present invention thus provides a peptide comprising a sequence that is
selected from the
group of SEQ ID NO: 1 to SEQ ID NO: 3 or a variant thereof which is at least
85%,
preferably at least 95% homologous to SEQ ID NO: 1 to SEQ ID NO: 3 or a
variant thereof
that will induce T cells cross-reacting with said peptide.
In a preferred embodiment for the treatment of renal cell carcinoma the
peptide of the SEQ ID
NO: 1 and/or SEQ ID NO: 2 and/or SEQ ID NO: 3 is used in combination with at
least two of
the peptides with SEQ ID NO: 4 to SEQ ID NO: 13 and SEQ ID NO: 24. The peptide
of the
SEQ ID NO: 1 to SEQ ID NO: 3 may thereby be administered separately or
together with the
other peptides in one formulation.
Internal Antigen Sequence SEQ ID No.
Sequence ID
IMA-MMP-001 Matrix metalloproteinase 7 SQDDIKGIQKLYGKRS 4
IMA-ADF-002 Adipophilin VMAGDIYSV 5
IMA-ADF-001 Adipophilin SVASTITGV 6
IMA-APO-001 Apolipoprotein Li ALADGVQKV 7
CA 02724198 2010-11-12
WO 2009/138236- 39 - PCT/EP2009/003447
IMA-CCN-001 Cyclin DI LLGATCMFV 8
IMA-GUC-001 G= UCY1A3 SVFAGVVGV 9
IMA-K67-001 K= IAA0367 ALFDGDPHL 10
IMA-MET-001 c-met proto-oncogene YVDPVITSI 11
IMA-MUC-001 M= UC1 STAPPVHNV 12
IMA-RGS-001 RGS-5 LAALPHSCL 13
IMA-HBV-001 H= BV FLPSDFFPSV 14
IMA-NCAN-001 Neurocan VLCGPPPAV 24
A detailed description of the peptides and the antigens provided above is
disclosed in WO
2007/028573.
In a preferred embodiment for the treatment of colon cancer, the peptide of
the SEQ ID NO: 1
to SEQ ID NO: 3 is used in combination with at least two of the peptides with
SEQ ID NO:
15 to 24,4, 8, 11 or 12. The peptide of the SEQ ID NO: 1 to SEQ ID NO: 3 may
thereby be
administered separately or together with the other peptides in one
formulation.
SEQ ID binds to
NO: Peptide ID Sequence Gene Symbol Function MHC
implicated in linking actin
15 C20-001 ALSNLEVTL C20orf42 cytoskeleton to ECM HLA-A*02
16 NOX-001 ILAPVILYI -NOX1 NADPH oxidase HLA-A*02
17 ODC-001 ILDQKINEV -0DC1 Ornithine decarboxylase HLA-
A*02
DNA polymerase delta
18 PCN-001 KLMDLDVEQL PCNA auxiliary protein HLA-A*02
transforming growth factor,
19 TGFBI-001 ALFVRLLALA TGFBI beta-induced HLA-A*02
20 TOP-001 KIFDEILVNA TOP2A/TOP2B Topoisomerase HLA-A*02
_
transforming growth factor,
21 TGFBI-004 TPPIDAHTRNLLRNH TGFBI beta-induced HLA-DR
22 CEA-006 SPQYSWRINGIPQQHT -CEACAM5 ¨C¨arcinoembryonic antigen HLA-DR
CCN-001 LLGATCMFV CCND1 Cycl in Dl HLA-A*02
12 MUC-001 STAPPVHNV MUC1 Mucin 1 HLA-A*02
4 -MMP-0O1 SQDDIKGIQKLYGKRS MMP7 Metalloproteinase 7 HLA-DR
23 CEA-004 YLSGANLNL .CEACAM5 variant of CEA peptide HLA-
A*02
11 MET-001 YVDPVITSI MET met proto-oncogene HLA-A*02
CA 02724198 2010-11-12
WO 2009/138236- 40 - PCT/EP2009/003447
A detailed description of the peptides and the antigens provided above is
disclosed in
EP07014796.2 and US 60/953,161.
The peptides of the invention have the ability to bind to a molecule of the
human major
histocompatibility complex (MHC) class-I or -II.
In the present invention, the term "homologous" refers to the degree of
identity between
sequences of two amino acid sequences, i.e. peptide or polypeptide sequences.
The
aforementioned "homology" is determined by comparing two sequences aligned
under
optimal conditions over the sequences to be compared. The sequences to be
compared herein
may have an addition or deletion (for example, gap and the like) in the
optimum alignment of
the two sequences. Such a sequence homology can be calculated by creating an
alignment
using, for example, the ClustalW algorithm (Nucleic Acid Res., 22(22): 4673
4680 (1994).
Commonly available sequence analysis software, more specifically, Vector NT!,
GENETYX
or analysis tools provided by public databases.
A person skilled in the art will be able to assess, whether T cells induced by
a variant of a
specific peptide will be able to cross-react with the peptide itself (Fong et
al., 2001);
(Zaremba et al., 1997; Colombetti et al., 2006; Appay et al., 2006).
By a "variant" of the given amino acid sequence the inventors mean that the
side chains of,
for example, one or two of the amino acid residues are altered (for example by
replacing them
with the side chain of another naturally occurring amino acid residue or some
other side
chain) such that the peptide is still able to bind to an HLA molecule in
substantially the same
way as a peptide consisting of the given amino acid sequence in SEQ ID NO:1 to
24. For
example, a peptide may be modified so that it at least maintains, if not
improves, the ability to
interact with and bind to the binding groove of a suitable MHC molecule, such
as HLA-A*02
or -DR, and in that way it at least maintains, if not improves, the ability to
bind to the TCR of
activated CTL. These CTL can subsequently cross-react with cells and kill
cells that express a
polypeptide which contains the natural amino acid sequence of the cognate
peptide as defined
in the aspects of the invention. As can be derived from the scientific
literature (Rammensee et
al., 1997) and databases (Rammensee et al., 1999), certain positions of HLA
binding peptides
are typically anchor residues forming a core sequence fitting to the binding
motif of the HLA
receptor, which is defined by polar, electrophysical, hydrophobic and spatial
properties of the
CA 02724198 2010-11-12
WO 2009/138236- 41 - PCT/EP2009/003447
polypeptide chains constituting the binding groove. Thus one skilled in the
art would be able
to modify the amino acid sequences set forth in SEQ ID NO:1 to 24, by
maintaining the
known anchor residues, and would be able to determine whether such variants
maintain the
ability to bind MHC class I or II molecules. The variants of the present
invention retain the
ability to bind to the TCR of activated CTL, which can subsequently cross-
react with- and kill
cells that express a polypeptide containing the natural amino acid sequence of
the cognate
peptide as defined in the aspects of the invention.
Those amino acid residues that do not substantially contribute to interactions
with the T-cell
receptor can be modified by replacement with another amino acid whose
incorporation does
not substantially affect T-cell reactivity and does not eliminate binding to
the relevant MHC.
Thus, apart from the proviso given, the peptide of the invention may be any
peptide (by which
term the inventors include oligopeptide or polypeptide), which includes the
amino acid
sequences or a portion or variant thereof as given.
Table 5: Variants and motif of the peptide according to SEQ ID NO: 24
NCAN Position 1 2 3 4
5 6 7 8 9
Peptide Code VL C GP P P AV
Variants
E K
A GI I AE
YP KL Y
F T YTH
V
V
It is furthermore known for MHC-class II-presented peptides that these
peptides are
composed of a "core sequence" having an amino acid sequence fitting to a
certain HLA-
allele-specific motif and, optionally, N- and/or C-terminal extensions that do
not interfere
with the function of the core sequence (i.e. are deemed as irrelevant for the
interaction of the
CA 02724198 2010-11-12
WO 2009/138236- 42 - PCT/EP2009/003447
peptide and all or a subset of T cell clones recognizing the natural
counterpart). The N- and/or
C-terminal extensions can, for example, be between 1 to 10 amino acids in
length,
respectively. These peptides can be used either directly in order to load MHC
class II
molecules or the sequence can be cloned into the vectors according to the
description herein
below. As these peptides constitute the final product of the processing of
larger peptides
within the cell, longer peptides can be used as well. The peptides of the
invention may be of
any size, but typically they may be less than 100,000 in molecular weight,
preferably less than
50,000, more preferably less than 10,000 and typically about 5,000. In terms
of the number of
amino acid residues, the peptides of the invention may have fewer than 1,000
residues,
preferably fewer than 500 residues, more preferably fewer than 100, more
preferably fewer
than 100 and most preferably between 30 and 8 residues. Accordingly, the
present invention
also provides peptides and variants thereof wherein said peptide or variant
has an overall
length of between 8 and 100, preferably between 8 and 30, and most preferred
between 8 and
16, namely 8, 9, 10, 11, 12, 13, 14, 15, 16 amino acids.
For MHC class II restricted peptides, several different peptides with the same
core sequence
may be presented in the MHC molecule. As the interaction with the recognizing
T (helper)
cell is defined by a core sequence of 9 to 11 amino acids, several length
variants may be
recognized by the same T (helper) cell clone. Thus, several different lengths
variants of a core
binding sequence may be used for direct loading of MHC class II molecules
without the nee
for further processing and trimming at the N- or C-terminal ends.
Correspondingly, naturally
- -
occurring or artificial variants that induce T cells cross-reacting with a
peptide of the
invention are often length variants.
If a peptide that is longer than around 12 amino acid residues is used
directly to bind to a
MHC class II molecule, it is preferred that the residues that flank the core
HLA binding
region are residues that do not substantially affect the ability of the
peptide to bind
specifically to the binding groove of the MHC class II molecule or to present
the peptide to
the T (-helper) cell. However, as already indicated above, it will be
appreciated that larger
peptides may be used, e.g. when encoded by a polynucleotide, since these
larger peptides may
be fragmented by suitable antigen-presenting cells. However, in same cases it
has been shown
that the core sequence flanking regions can influence the peptide binding to
MHC class II
molecule or the interaction of the dimeric MHC:peptide complex with the TCR in
both
directions compared to a reference peptide with the same core sequence.
Intramolecular
CA 02724198 2010-11-12
WO 2009/138236- 43 - PCT/EP2009/003447
tertiary structures within the peptide (e.g. loop formation) normally decrease
the affinities to
the MHC or TCR. Intermolecular interactions of the flanking regions with parts
of the MHC
or TCR beside the peptide binding grooves may stabilize the interaction. These
changes in
affinity can have a dramatic influence on the potential of a MHC class II
peptide to induce T
(helper) cell responses.
It is also possible, that MHC class I epitopes, although usually between 8-10
amino acids
long, are generated by peptide processing from longer peptides or proteins
that include the
actual epitope. It is preferred that the residues that flank the actual
epitope are residues that do
not substantially affect proteolytic cleavage necessary to expose the actual
epitope during
processing.
Accordingly, the present invention also provides peptides and variants of MHC
class I
epitopes wherein the peptide or variant has an overall length of between 8 and
100, preferably
between 8 and 30, and most preferred between 8 and 16, namely 8, 9, 10, 11,
12, 13, 14, 15,
16 amino acids.
Of course, the peptide or variant according to the present invention will have
the ability to
bind to a molecule of the human major histocompatibility complex (MHC) class I
or II.
Binding of a peptide or a variant to a MHC complex may be tested by methods
known in the
art, for example those described in the literature for different MHC class II
alleles (e.g. Vogt
et al., 1994; Malcherek et al., 1994; Manici et al., 1999; Hammer et al.,
1995; Tompkins et al.,
1993; Boyton et al., 1998).
In a particularly preferred embodiment of the invention the peptide consists
or consists
essentially of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO:
3.
The peptides according to the present invention can also consist of a
continuous stretch of
amino acids as depicted in SEQ ID NO: 1 to 3, wherein said stretch is a part
of said sequence
having a length of at least 8 amino acids (e.g. 8, 9, 10, 11, 12, 13, 14, 15,
or 16), as long as a
core sequence is present in said peptide, rendering it functional in eliciting
an immuno-
response as described herein.
CA 02724198 2013-12-23
WO 2009/138236- 44 - PCT/EP2009/003447
"Consisting essentially of' shall mean that a peptide according to the present
invention, in
addition to the sequence according to any of SEQ ID No. 1 to SEQ ID No. 3 or a
variant
thereof contains additional N- and/or C-terminally located stretches of amino
acids that are
not necessarily forming part of the peptide that functions as an epitope for
MI-IC molecules
epitope.
Nevertheless, these stretches can be important to provide an efficient
introduction of the
peptide according to the present invention into the cells. In one embodiment
of the present
invention, the peptide is a fusion protein which comprises, for example, the
80 N-terminal
amino acids of the HLA-DR antigen-associated invariant chain (p33, in the
following "Ii") as
derived from the NCBI, GenBank Accession-number X00497 (Strubin, M. et al
1984).
Examples for further preferred peptides include peptides having a specific HLA-
subtype and
is capable of stimulating CD8 cells, and wherein said peptide comprises the
specific anchor
amino acid-motif as depicted in the following Table 6.
Table 6: HLA-subtypes and anchor motifs of preferred peptide according to SEQ
ID
NO:24
HLA-
Peptide subtype Position 1 2 3 4 5 6 7 8 9
24 A*02 Peptide Code V L CGPPPAV
Anchor
motif x L x x x x xx V
In addition, the peptide or variant may be modified further to improve
stability and/or binding
to MHC molecules in order to elicit a stronger immune response. Methods for
such an
optimization of a peptide sequence are well known in the art and include, for
example, the
introduction of reverse peptide bonds or non-peptide bonds.
In a reverse peptide bond amino acid residues are not joined by peptide (-CO-
NH-) linkages
but the peptide bond is reversed. Such retro-inverso peptidomimetics may be
made using
methods known in the art, for example such as those described in Meziere et al
(1997) J.
lmmunol. 159, 3230-3237, incorporated herein by reference. This approach
involves making
pseudopeptides containing changes involving the backbone, and not the
orientation of side
CA 02724198 2013-12-23
WO 2009/138236- 45 - PCT/EP2009/003447
chains. Meziere et al (1997) show that for MHC binding and T helper cell
responses, these
pseudopeptides are useful. Retro-inverse peptides, which contain NH-CO bonds
instead of
CO-NH peptide bonds, are much more resistant to proteolysis.
A non-peptide bond is, for example, -C1-12-NH, -CH2S-, -CH2CH2-, -CH=CH-, -
COCH2-, -
CH(OH)CH2-, and -CH2S0-. United States Patent 4,897,445 provides a method for
the solid
phase synthesis of non-peptide bonds (-CH2-NH) in polypeptide chains which
involves
polypeptides synthesized by standard procedures and the non-peptide bond
synthesized by
reacting an amino aldehyde and an amino acid in the presence of NaCNBH3.
Peptides comprising the sequences described above may be synthesized with
additional
chemical groups present at their amino and/or carboxy termini, to enhance the
stability,
bioavailability, and/or affinity of the peptides. For example, hydrophobic
groups such as
carbobenzoxyl, dansyl, or t-butyloxycarbonyl groups may be added to the
peptides' amino
termini. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonyl group may
be placed at
the peptides' amino termini. Additionally, the hydrophobic group, t-
butyloxycarbonyl, or an
amido group may be added to the peptides' carboxy termini.
Further, the peptides of the invention may be synthesized to alter their
steric configuration.
For example, the D-isomer of one or more of the amino acid residues of the
peptide may be
used, rather than the usual L-isomer. Still further, at least one of the amino
acid residues of
the peptides of the invention may be substituted by one of the well known non-
naturally
occurring amino acid residues. Alterations such as these may serve to increase
the stability,
bioavailability and/or binding action of the peptides of the invention.
Similarly, a peptide or variant of the invention may be modified chemically by
reacting
specific amino acids either before or after synthesis of the peptide. Examples
for such
modifications are well known in the art and are summarized e.g. in R.
Lundblad, Chemical
Reagents for Protein Modification, 3rd ed. CRC Press, 2005, which is
incorporated herein by
reference. Chemical modification of amino acids includes but is not limited
to, modification
by acylation, amidination, pyridoxylation of lysine, reductive alkylation,
trinitrobenzylation
of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS), amide
modification of
carboxyl groups and sulphydryl modification by perfonnic acid oxidation of
cysteine to
cysteic acid, formation of mercurial derivatives, formation of mixed
disulphides with other
CA 02724198 2013-12-23
WO 2009/138236- 46 - PCT/EP2009/003447
thiol compounds, reaction with maleimide, carboxymethylation with iodoacetic
acid or
iodoacetarnide and carbamoylation with cyanate at alkaline pH, although
without limitation
thereto. In this regard, the skilled person is referred to Chapter 15 of
Current Protocols In
Protein Science, Eds. Coligan et al. (John Wiley & Sons NY 1995-2000) for more
extensive
methodology relating to chemical modification of proteins.
Briefly, modification of e.g. arginyl residues in proteins is often based on
the reaction of
vicinal dicarbonyl compounds such as phenylglyoxal, 2,3-butanedione, and 1,2-
cyclohexanedione to form an adduct. Another example is the reaction of
methylglyoxal with
arginine residues. Cysteine can be modified without concomitant modification
of other
nucleophilic sites such as lysine and histidine. As a result, a large number
of reagents are
available for the modification of cysteine. The websites of companies such as
Sigma-Aldrich
(http://www.sigma-aldrich.com) provide information on specific reagents.
Selective reduction of disulfide bonds in proteins is also common. Disulfide
bonds can be
formed and oxidized during the heat treatment of biopharmaceuticals.
Woodward's Reagent K may be used to modify specific glutamic acid residues. N-
(3-
(dimethylamino)propy1)-N'-ethylcarbodiimide can be used to form intra-
molecular crosslinks
between a lysine residue and a glutamic acid residue.
For example, diethylpyrocarbonate is a reagent for the modification of
histidyl residues in
proteins. Histidine can also be modified using 4-hydroxy-2-nonenal.
The reaction of lysine residues and other a-amino groups is, for example,
useful in binding of
peptides to surfaces or the cross-linking of proteins/peptides. Lysine is the
site of attachment
of poly(ethylene)glycol and the major site of modification in the glycation of
proteins.
Methionine residues in proteins can be modified with e.g. iodoacetamide,
bromoethylamine,
and chloramine T. Tetranitromethane and N-acetylimidazole can be used for the
modification
of tyrosyl residues. Cross-linking via the formation of dityrosine can be
accomplished with
hydrogen peroxide/copper ions.
CA 02724198 2010-11-12
WO 2009/138236- 47 - PCT/EP2009/003447
Recent studies on the modification of tryptophan have used N-bromosuccinimide,
2-hydroxy-
5-nitrobenzyl bromide or 3-bromo-3-methy1-2-(2-nitrophenylmercapto)-3H-indole
(BPNS-
skatole).
Successful modification of therapeutic proteins and peptides with PEG is often
associated
with an extension of circulatory half-life while cross-linking of proteins
with glutaraldehyde,
polyethyleneglycol diacrylate and formaldehyde is used for the preparation of
hydrogels.
Chemical modification of allergens for immunotherapy is often achieved by
carbamylation
with potassium cyanate.
A peptide or variant, wherein the peptide is modified or includes non-peptide
bonds is a
preferred embodiment of the invention. Generally, peptides and variants (at
least those
containing peptide linkages between amino acid residues) may be synthesized by
the Fmoc-
polyamide mode of solid-phase peptide synthesis as disclosed by Lu et al
(1981) and
references therein. Temporary N-amino group protection is afforded by the 9-
fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly
base-labile
protecting group is done using 20% piperidine in N, N-dimethylformamide. Side-
chain
functionalities may be protected as their butyl ethers (in the case of serine
threonine and
tyrosine), butyl esters (in the case of glutamic acid and aspartic acid),
butyloxycarbonyl
derivative (in the case of lysine and histidine), trityl derivative (in the
case of cysteine) and 4-
methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine).
Where
glutamine or asparagine are C-terminal residues, use is made of the 4,4'-
dimethoxybenzhydryl
group for protection of the side chain amido functionalities. The solid-phase
support is based
on a polydimethyl-acrylamide polymer constituted from the three monomers
dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross
linker) and
acryloylsarcosine methyl ester (functionalizing agent). The peptide-to-resin
cleavable linked
agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative.
All amino acid
derivatives are added as their preformed symmetrical anhydride derivatives
with the exception
of asparagine and glutamine, which are added using a reversed N, N-
dicyclohexyl-
carbodiimide/1 hydroxybenzotriazole mediated coupling procedure. All coupling
and
deprotection reactions are monitored using ninhydrin, trinitrobenzene
sulphonic acid or isotin
test procedures. Upon completion of synthesis, peptides are cleaved from the
resin support
with concomitant removal of side-chain protecting groups by treatment with 95%
trifluoroacetic acid containing a 50 % scavenger mix. Scavengers commonly used
include
CA 02724198 2010-11-12
WO 2009/138236- 48 - PCT/EP2009/003447
ethandithiol, phenol, anisole and water, the exact choice depending on the
constituent amino
acids of the peptide being synthesized. Also a combination of solid phase and
solution phase
methodologies for the synthesis of peptides is possible (see, for example,
Bruckdorfer et al.
2004, and the references as cited therein).
Trifluoroacetic acid is removed by evaporation in vacuo, with subsequent
trituration with
diethyl ether affording the crude peptide. Any scavengers present are removed
by a simple
extraction procedure which on lyophilisation of the aqueous phase affords the
crude peptide
free of scavengers. Reagents for peptide synthesis are generally available
from e.g.
Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK.
Purification may be performed by any one, or a combination of, techniques such
as re-
crystallization, size exclusion chromatography, ion-exchange chromatography,
hydrophobic
interaction chromatography and (usually) reverse-phase high performance liquid
chromatography using e.g. acetonitril/water gradient separation.
Analysis of peptides may be carried out using thin layer chromatography,
electrophoresis, in
particular capillary electrophoresis, solid phase extraction (CSPE), reverse-
phase high
performance liquid chromatography, amino-acid analysis after acid hydrolysis
and by fast
atom bombardment (FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-
TOF
mass spectrometric analysis.
A further aspect of the invention provides a nucleic acid (for example a
polynucleotide)
encoding a peptide or peptide variant of the invention. The polynucleotide may
be, for
example, DNA, cDNA, PNA, CNA, RNA or combinations thereof, either single-
and/or
double-stranded, or native or stabilized forms of polynucleotides, such as,
for example,
polynucleotides with a phosphorothioate backbone and it may or may not contain
introns so
long as it codes for the peptide. Of course, only peptides that contain
naturally occurring
amino acid residues joined by naturally occurring peptide bonds are encodable
by a
polynucleotide. A still further aspect of the invention provides an expression
vector capable of
expressing a polypeptide according to the invention.
A variety of methods have been developed to link polynucleotides, especially
DNA, to
vectors for example via complementary cohesive termini. For instance,
complementary
CA 02724198 2010-11-12
WO 2009/138236- 49 - PCT/EP2009/003447
homopolymer tracts can be added to the DNA segment to be inserted to the
vector DNA. The
vector and DNA segment are then joined by hydrogen bonding between the
complementary
homopolymeric tails to form recombinant DNA molecules.
Synthetic linkers containing one or more restriction sites provide an
alternative method of
joining the DNA segment to vectors. Synthetic linkers containing a variety of
restriction
endonuclease sites are commercially available from a number of sources
including
International Biotechnologies Inc, New Haven, CN, USA.
A desirable method of modifying the DNA encoding the polypeptide of the
invention uses the
polymerase chain reaction as disclosed by (Saiki et al (1988)). This method
may be used for
introducing the DNA into a suitable vector, for example by engineering in
suitable restriction
sites, or it may be used to modify the DNA in other useful ways as is known in
the art. If viral
vectors are used, pox- or adenovirus vectors are preferred.
The DNA (or in the case of retroviral vectors, RNA) may then be expressed in a
suitable host
to produce a polypeptide comprising the peptide or variant of the invention.
Thus, the DNA
encoding the peptide or variant of the invention may be used in accordance
with known
techniques, appropriately modified in view of the teachings contained herein,
to construct an
expression vector, which is then used to transform an appropriate host cell
for the expression
and production of the polypeptide of the invention. Such techniques include
those disclosed in
US Patent Nos. 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751,
4,704,362, 4,710,463,
4,757,006, 4,766,075, and 4,810,648.
The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide
constituting
the compound of the invention may be joined to a wide variety of other DNA
sequences for
introduction into an appropriate host. The companion DNA will depend upon the
nature of the
host, the manner of the introduction of the DNA into the host, and whether
episomal
maintenance or integration is desired.
Generally, the DNA is inserted into an expression vector, such as a plasmid,
in proper
orientation and correct reading frame for expression. If necessary, the DNA
may be linked to
the appropriate transcriptional and translational regulatory control
nucleotide sequences
recognized by the desired host, although such controls are generally available
in the
CA 02724198 2010-11-12
WO 2009/138236- 50 - PCT/EP2009/003447
expression vector. The vector is then introduced into the host through
standard techniques.
Generally, not all of the hosts will be transformed by the vector. Therefore,
it will be
necessary to select for transformed host cells. One selection technique
involves incorporating
into the expression vector a DNA sequence, with any necessary control
elements, that codes
for a selectable trait in the transformed cell, such as antibiotic resistance.
Alternatively, the gene for such selectable trait can be on another vector,
which is used to co-
transform the desired host cell. Host cells that have been transformed by the
recombinant
DNA of the invention are then cultured for a sufficient time and under
appropriate conditions
known to those skilled in the art in view of the teachings disclosed herein to
permit the
expression of the polypeptide, which can then be recovered.
Many expression systems are known, including bacteria (for example E. coli and
Bacillus
subtilis), yeasts (for example Saccharomyces cerevisiae), filamentous fungi
(for example
Aspergillus spec.), plant cells, animal cells and insect cells. Preferably,
the system can be
mammalian cells such as CHO cells available from the ATCC Cell Biology
Collection.
A typical mammalian cell vector plasmid for constitutive expression comprises
the CMV or
SV40 promoter with a suitable poly A tail and a resistance marker, such as
neomycin. One
example is pSVL available from Pharmacia, Piscataway, NJ, USA. An example of
an
inducible mammalian expression vector is pMSG, also available from Pharmacia.
Useful
yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally
available from
Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404,
pRS405
and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast
selectable
markers HIS3, TRP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere
plasmids (Ycps). CMV promoter-based vectors (for example from from Sigma-
Aldrich)
provide transient or stable expression, cytoplasmic expression or secretion,
and N-terminal or
C-terminal tagging in various combinations of FLAG, 3xFLAG, c-myc or MAT.
These fusion
proteins allow for detection, purification and analysis of recombinant
protein. Dual-tagged
fusions provide flexibility in detection.
The strong human cytomegalovirus (CMV) promoter regulatory region drives
constitutive
protein expression levels as high as 1 mg/L in COS cells. For less potent cell
lines, protein
levels are typically ¨0.1 mg/L. The presence of the SV40 replication origin
will result in high
CA 02724198 2010-11-12
WO 2009/138236- 51 - PCT/EP2009/003447
levels of DNA replication in SV40 replication permissive COS cells. CMV
vectors, for
example, can contain the pMB1 (derivative of pBR322) origin for replication in
bacterial
cells, the b-lactamase gene for ampicillin resistance selection in bacteria,
hGH polyA, and the
fl origin. Vectors containing the preprotrypsin leader (PPT) sequence can
direct the secretion
of FLAG fusion proteins into the culture medium for purification using ANTI-
FLAG
antibodies, resins, and plates. Other vectors and expression systems are well
known in the art
for use with a variety of host cells.
The present invention also relates to a host cell transformed with a
polynucleotide vector
construct of the present invention. The host cell can be either prokaryotic or
eukaryotic.
Bacterial cells may be preferred prokaryotic host cells in some circumstances
and typically
are a strain of E. coli such as, for example, the E. coli strains DH5
available from Bethesda
Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the
American Type
Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred
eukaryotic
host cells include yeast, insect and mammalian cells, preferably vertebrate
cells such as those
from a mouse, rat, monkey or human fibroblastic and colon cell lines. Yeast
host cells include
YPH499, YPH500 and YPH501, which are generally available from Stratagene
Cloning
Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include
Chinese hamster
ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo
cells
NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells
available from the ATCC as CRL 1650 and 293 cells which are human embryonic
kidney
cells. Preferred insect cells are Sf9 cells which can be transfected with
baculovirus expression
vectors. An overview regarding the choice of suitable host cells for
expression can be found
in, for example, the textbook of Paulina Balbas and Argelia Lorence "Methods
in Molecular
Biology Recombinant Gene Expression, Reviews and Protocols," Part One, Second
Edition,
ISBN 978-1-58829-262-9, and other literature known to the person of skill.
Transformation of appropriate cell hosts with a DNA construct of the present
invention is
accomplished by well known methods that typically depend on the type of vector
used. With
regard to transformation of prokaryotic host cells, see, for example, Cohen et
al (1972) Proc.
Natl. Acad. Sci. USA 69, 2110, and Sambrook et al (1989) Molecular Cloning, A
Laboratory
Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation
of yeast
cells is described in Sherman et al (1986) Methods In Yeast Genetics, A
Laboratory Manual,
Cold Spring Harbor, NY. The method of Beggs (1978) Nature 275,104-109 is also
useful.
CA 02724198 2010-11-12
WO 2009/138236- 52 - PCT/EP2009/003447
With regard to vertebrate cells, reagents useful in transfecting such cells,
for example calcium
phosphate and DEAE-dextran or liposome formulations, are available from
Stratagene
Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA.
Electroporation
is also useful for transforming and/or transfecting cells and is well known in
the art for
transforming yeast cell, bacterial cells, insect cells and vertebrate cells.
Successfully transformed cells, i.e. cells that contain a DNA construct of the
present
invention, can be identified by well known techniques such as PCR.
Alternatively, the
presence of the protein in the supernatant can be detected using antibodies.
It will be appreciated that certain host cells of the invention are useful in
the preparation of the
peptides of the invention, for example bacterial, yeast and insect cells.
However, other host
cells may be useful in certain therapeutic methods. For example, antigen-
presenting cells,
such as dendritic cells, may usefully be used to express the peptides of the
invention such that
they may be loaded into appropriate MHC molecules. Thus, the current invention
provides a
host cell comprising a nucleic acid or an expression vector according to the
invention.
In a preferred embodiment, the host cell is an antigen presenting cell, in
particular a dendritic
cell or antigen presenting cell. APCs loaded with a recombinant fusion protein
containing
prostatic acid phosphatase (PAP) are currently under investigation for the
treatment of
prostate cancer (Sipuleucel¨T) (Small EJ et al 2006; Rini et al 2006).
A further aspect of the invention provides a method of producing a peptide or
its variant, the
method comprising culturing a host cell and isolating the peptide from the
host cell or its
culture medium.
In another embodiment the peptide, the nucleic acid or the expression vector
of the invention
are used in medicine. For example, the peptide or its variant may be prepared
for intravenous
(i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.)
injection, intraperitoneal (i.p.)
injection, intramuscular (i.m.) injection. Preferred methods of peptide
injection include s.c.,
i.d., i.p., i.m., and i.v. Preferred methods of DNA injection include i.d.,
i.m., s.c., i.p. and i.v.
Doses of e.g. between 50 g and 1.5 mg, preferably 125 g to 500 g, of
peptide or DNA
may be given and will depend on the respective peptide or DNA. Doses of this
range were
successfully used in previous trials (Brunsvig et al 2006; Staehler et al
2007).
CA 02724198 2010-11-12
WO 2009/138236- 53 - PCT/EP2009/003447
Another aspect of the present invention includes an in vitro method for
producing activated T
cells, the method comprising contacting T-cells in vitro with antigen loaded
human class I or
II MHC molecules expressed on the surface of a suitable antigen-presenting
cell for a period
of time sufficient to activate the T-cell in an antigen specific manner,
wherein the antigen is a
peptide according to the invention. Preferably, a sufficient amount of the
antigen is used with
an antigen-presenting cell.
In the case of a MHC class II epitope being used as an antigen, the T-cells
are CD4-positive
helper cells, preferably of THI-type. The MHC class II molecules may be
expressed on the
surface of any suitable cell. Preferably the cell does not naturally express
MHC class II
molecules (in which case the cell has been transfected in order to express
such a molecule).
Alternatively, if the cell naturally expresses MHC class II molecules, it is
preferred that it is
defective in the antigen-processing or antigen-presenting pathways. In this
way, it is possible
for the cell expressing the MHC class II molecule to be completely loaded with
a chosen
peptide antigen before activating the T-cell.
The antigen-presenting cell (or stimulator cell) typically has MHC class II
molecules on its
surface and preferably is itself substantially incapable of loading said MHC
class II molecule
with the selected antigen. The MHC class II molecule may readily be loaded
with the selected
antigen in vitro.
Preferably, the mammalian cell lacks or has a reduced level or function of the
TAP peptide
transporter. Suitable cells that lack the TAP peptide transporter include T2,
RMA-S and
Drosophila cells. TAP is the Transporter associated with Antigen Processing.
The human peptide loading deficient cell line T2 is available from the
American Type Culture
Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA under
Catalogue No
CRL 1992; the Drosophila cell line Schneider line 2 is available from the ATCC
under
Catalogue No CRL 19863; the mouse RMA-S cell line is described in Karre et al
1985.
Preferably, the host cell before transfection expresses substantially no MHC
class I molecules.
It is also preferred that the stimulator cell expresses a molecule important
for providing a co-
stimulatory signal for T-cells such as any of B7.1, B7.2, ICAM-1 and LFA 3.
The nucleic
CA 02724198 2013-12-23
WO 2009/138236- 54 - PCT/EP2009/003447
acid sequences of numerous MHC class II molecules and of the costimulator
molecules are
publicly available from the GenBank and EMBL databases.
Similarly, in case of a MHC class I epitope being used as an antigen, the T
cells are CD8-
positive CTLs.
If an antigen-presenting cell is transfected to express such an epitope,
preferably the cell
comprises an expression vector capable of expressing a peptide containing SEQ
ID NO: 1 to
SEQ ID NO: 3 or a variant amino acid sequence thereof.
A number of other methods may be used for generating CTL in vitro. For
example, the
methods described in Peoples et al (1995) and Kawakami et al (1992) use
autologous tumor-
infiltrating lymphocytes in the generation of CTL. Plebanski et al (1995)
makes use of
autologous peripheral blood lymphocytes (PLBs) in the preparation of CTL.
Jochmus et al
(1997) describes the production of autologous CTL by pulsing dendritic cells
with peptide or
polypeptide, or via infection with recombinant virus. Hill et al (1995) and
Jerome et al (1993)
make use of B cells in the production of autologous CTL. In addition,
macrophages pulsed
with peptide or polypeptide, or infected with recombinant virus, may be used
in the
preparation of autologous CTL. S. Walter et al. 2003 describe the in vitro
priming of T cells
by using artificial antigen presenting cells (aAPCs), which is also a suitable
way for
generating T cells against the peptide of choice. In this study, aAPCs were
generated by the
coupling of preformed MHC:peptide complexes to the surface of polystyrene
particles
(microbeads) by biotin:streptavidin biochemistry. This system permits the
exact control of the
MHC density on aAPCs, which allows to selectively elicit high- or low-avidity
antigen-
specific T cell responses with high efficiency from blood samples. Apart from
MHC:peptide
complexes, aAPCs should carry other proteins with co-stimulatory activity like
anti-CD28
antibodies coupled to their surface. Furthermore such aAPC-based systems often
require the
addition of appropriate soluble factors, e. g. cytokines like interleuldn-12.
Allogeneic cells may also be used in the preparation of T cells and a method
is described in
detail in WO 97/26328, incorporated herein by reference. For example, in
addition to
Drosophila cells and T2 cells, other cells may be used to present antigens
such as CHO cells,
baculovirus-infected insect cells, bacteria, yeast, vaccinia-infected target
cells. In addition
plant viruses may be used (see, for example, Porta et al (1994)) which
describes the
CA 02724198 2010-11-12
WO 2009/138236- 55 - PCT/EP2009/003447
development of cowpea mosaic virus as a high-yielding system for the
presentation of foreign
peptides.
The activated T-cells that are directed against the peptides of the invention
are useful in
therapy. Thus, a further aspect of the invention provides activated T cells
obtainable by the
foregoing methods of the invention. Activated T cells, which are produced by
the above
method, will selectively recognize a cell that aberrantly expresses a
polypeptide that
comprises an amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 3.
Preferably, the T-cell recognizes the cell by interacting through its TCR with
the
HLA/peptide-complex (for example, binding). The 1-cells are useful in a method
of killing
target cells in a patient whose target cells aberrantly express a polypeptide
comprising an
amino acid sequence of the invention wherein the patient is administered an
effective number
of the activated 1-cells. The T-cells that are administered to the patient may
be derived from
the patient and activated as described above (i.e. they are autologous 1-
cells). Alternatively,
the T-cells are not from the patient but are from another individual. Of
course, it is preferred if
the individual is a healthy individual. By "healthy individual" the inventors
mean that the
individual is generally in good health, preferably has a competent immune
system and, more
preferably, is not suffering from any disease which can be readily tested for,
and detected.
In vivo, the target cells for the CD4-positive T-cells according to the
present invention can be
cells of the tumor (which sometimes express MHC class II) and/or stromal cells
surrounding
the tumor (tumor cells) (which sometimes also express MHC class II (Dengjel et
al., 2006)).
The T- cells of the present invention may be used as active ingredients of a
therapeutic
composition. Thus, the invention also provides a method of killing target
cells in a patient
whose target cells aberrantly express a polypeptide comprising an amino acid
sequence of the
invention, the method comprising administering to the patient an effective
number of T-cells
as defined above.
By "aberrantly expressed" the inventors also mean that the polypeptide is over-
expressed
compared to normal levels of expression or that the gene is silent in the
tissue from which the
tumor is derived but in the tumor it is expressed. By "over-expressed" the
inventors mean that
the polypeptide is present at a level at least 1.2-fold of that present in
normal tissue;
CA 02724198 2010-11-12
WO 2009/138236- 56 - PCT/EP2009/003447
preferably at least 2-fold, and more preferably at least 5-fold or 10-fold the
level present in
normal tissue.
T-cells may be obtained by methods known in the art, e.g. those described
above. Protocols
for this so-called adoptive transfer of T-cells are well known in the art and
can be found, e.g.
in (Rosenberg et al., 1987; Rosenberg et al., 1988; Dudley et al., 2002; Yee
et al., 2002;
Dudley et al., 2005); reviewed in (Gattinoni et al., 2006) and (Morgan et al.,
2006).
Any molecule of the invention, i.e. the peptide, nucleic acid, expression
vector, cell, activated
CTL, T-cell receptor or the nucleic acid encoding it is useful for the
treatment of disorders,
characterized by cells escaping an immune response. Therefore any molecule of
the present
invention may be used as medicament or in the manufacture of a medicament. The
molecule
may be used by itself or combined with other molecule(s) of the invention or
(a) known
molecule(s).
Preferably, the medicament of the present invention is a vaccine. It may be
administered
directly into the patient, into the affected organ or systemically i.d., i.m.,
s.c., i.p. and i.v., or
applied ex vivo to cells derived from the patient or a human cell line which
are subsequently
administered to the patient, or used in vitro to select a subpopulation of
immune cells derived
from the patient, which are then re-administered to the patient. If the
nucleic acid is
administered to cells in vitro, it may be useful for the cells to be
transfected so as to co-
express immune-stimulating cytokines, such as interleukin-2. The peptide may
be
substantially pure, or combined with an immune-stimulating adjuvant (see
below) or used in
combination with immune-stimulatory cytokines, or be administered with a
suitable delivery
system, for example liposomes. The peptide may also be conjugated to a
suitable carrier such
as keyhole limpet haemocyanin (KLH) or mannan (see WO 95/18145 and Longenecker
et al
(1993)). The peptide may also be tagged, may be a fusion protein, or may be a
hybrid
molecule. The peptides whose sequence is given in the present invention are
expected to
stimulate CD4 or CD8 T-cells. However, stimulation of CD8 CTLs is more
efficient in the
presence of help provided by CD4 T-helper cells. Thus, for MHC Class I
epitopes that
stimulate CD8 CTL the fusion partner or sections of a hybrid molecule suitably
provide
epitopes which stimulate CD4-positive T cells. CD4- and CD8-stimulating
epitopes are well
known in the art and include those identified in the present invention.
CA 02724198 2010-11-12
WO 2009/138236- 57 - PCT/EP2009/003447
In one aspect, the vaccine comprises at least one peptide having the amino
acid sequence set
forth in SEQ ID NO:1, 2 or 3 and at least one additional peptide, preferably
two to 50, more
preferably two to 25, even more preferably two to 15 and most preferably two,
three, four,
five, six, seven, eight, nine, ten, eleven, twelve or thirteen peptides. The
peptide(s) may be
derived from one or more specific TAAs and may bind to MHC class I and/or
class II
molecules. Preferably the at least one additional peptide has the amino acid
sequence set forth
in SEQ ID NO: 4 to 24.
The polynucleotide may be substantially pure, or contained in a suitable
vector or delivery
system. The nucleic acid may be DNA, cDNA, PNA, CNA, RNA or a combination
thereof.
Methods for designing and introducing such a nucleic acid are well known in
the art. An
overview is provided by e.g. Pascolo S. 2006; Stan R. 2006, or A Mahdavi 2006.
Polynucleotide vaccines are easy to prepare, but the mode of action of these
vectors in
inducing an immune response is not fully understood. Suitable vectors and
delivery systems
include viral DNA and/or RNA, such as systems based on adenovirus, vaccinia
virus,
retroviruses, herpes virus, adeno-associated virus or hybrids containing
elements of more than
one virus. Non-viral delivery systems include cationic lipids and cationic
polymers and are
well known in the art of DNA delivery. Physical delivery, such as via a "gene-
gun," may also
be used. The peptide or peptides encoded by the nucleic acid may be a fusion
protein, for
example with an epitope that stimulates T cells for the respective opposite
CDR as noted
above.
The medicament of the invention may also include one or more adjuvants.
Adjuvants are
substances that non-specifically enhance or potentiate the immune response
(e.g., immune
responses mediated by CTLs and helper-T (TH) cells to an antigen, and would
thus be
considered useful in the medicament of the present invention. Suitable
adjuvants include, but
are not limited to, 1018 ISS, aluminium salts, Amplivax, AS15, BCG, CP-
870,893, CpG7909,
CyaA, dSLIM, flagellin or TLR5 ligands derived from flagellin, FLT3 ligand, GM-
CSF,
IC30, IC31, Imiquimod (ALDARA), ImuFact IMP321, Interleukins as IL-2, IL-13,
IL-21,
Interferon-alpha or -beta, or pegylated derivatives thereof, IS Patch, ISS,
ISCOMATRIX,
ISCOMs, JuvImmune, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS
1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, water-in-oil and
oil-in-
water emulsions, OK-432, 0M-174, 0M-197-MP-EC, ONTAK, OspA, PepTele vector
system, PLG and dextran microparticles, resiquimod, SRL172, Virosomes and
other Virus-
CA 02724198 2013-12-23
WO 2009/138236- 58 - PCT/EP2009/003447
like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21
stimulon,
which is derived from saponin, mycobacterial extracts and synthetic bacterial
cell wall
mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or
Superfos. Adjuvants
such as Freund's or GM-CSF are preferred. Several immunological adjuvants
(e.g., MF59)
specific for dendritic cells and their preparation have been described
previously (Dupuis M et
al 1998; Allison 1998). Also cytokines may be used. Several cytokines have
been directly
linked to influencing dendritic cell migration to lymphoid tissues (e.g., TNF-
cc), accelerating
the maturation of dendritic cells into efficient antigen-presenting cells for
T-lymphocytes
(e.g., GM-CSF, IL-1 and IL-4) (U.S. Pat. No. 5,849,589, specifically
incorporated herein by
reference in its entirety) and acting as immunoadjuvants (e.g., IL-12, IL-15,
IL-23, IL-7, IFN-
alpha. IFN-beta) (Gabrilovich et al 1996).
CpG immunostimulatory oligonucleotides have also been reported to enhance the
effects of
adjuvants in a vaccine setting. Without being bound by theory, CpG
oligonucleotides act by
activating the innate (non-adaptive) immune system via Toll-like receptors
(TLR), mainly
TLR9. CpG triggered TLR9 activation enhances antigen-specific humoral and
cellular
responses to a wide variety of antigens, including peptide or protein
antigens, live or killed
viruses, dendritic cell vaccines, autologous cellular vaccines and
polysaccharide conjugates in
both prophylactic and therapeutic vaccines. More importantly it enhances
dendritic cell
maturation and differentiation, resulting in enhanced activation of TH1 cells
and strong
cytotoxic T-lymphocyte (CTL) generation, even in the absence of CD4 T cell
help. The TH1
bias induced by TLR9 stimulation is maintained even in the presence of vaccine
adjuvants
such as alum or incomplete Freund's adjuvant (IFA) that normally promote a TH2
bias. CpG
oligonucleotides show even greater adjuvant activity when formulated or co-
administered
with other adjuvants or in formulations such as microparticles, nanoparticles,
lipid emulsions
or similar formulations, which are especially necessary for inducing a strong
response when
the antigen is relatively weak. They also accelerate the immune response and
enable the
antigen doses to be reduced by approximately two orders of magnitude, with
comparable
antibody responses to the full-dose vaccine without CpG in some experiments
(Krieg et al
2006). US Pat. No. 6,406,705 B1 describes the combined use of CpG
oligonucleotides, non-
nucleic acid adjuvants and an antigen to induce an antigen-specific immune
response. A CpG
TLR9 antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen
(Berlin,
Germany) which is a preferred component of the pharmaceutical composition of
the present
CA 02724198 2010-11-12
WO 2009/138236- 59 - PCT/EP2009/003447
invention. Other TLR binding molecules such as RNA binding TLR 7, TLR 8 and/or
TLR 9
may also be used.
Other examples for useful adjuvants include, but are not limited to chemically
modified CpGs
(e.g. CpR, Idera), dsRNA analogues such as Poly(I:C) and AmpliGen, non-CpG
bacterial
DNA or RNA as well as immunoactive small molecules and antibodies such as
cyclophosphamide, sunitinib, Bevacizumab, celebrex, NCX-4016, sildenafil,
tadalafil,
vardenafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632,
pazopanib, VEGF
Trap, ZD2171, AZD2171, anti-CTLA4 and SC58175, which may act therapeutically
and/or
as an adjuvant. The amounts and concentrations of adjuvants and additives
useful in the
context of the present invention can readily be determined by the skilled
artisan without
undue experimentation. Preferred adjuvants are dSLIM, Interferon-alpha, -beta,
CpG7909,
131, ALDARA (Imiquimod), PeviTer, RNA, tadalafil, temozolomide, and JuvImmune.
The present invention provides a medicament that useful in treating cancer, in
particular
glioma and brain cancer, breast cancer, prostate cancer, esophagus cancer,
colorectal cancer,
renal cancer, pancreatic cancer, squamous cell carcinomas and keratinocytic
neoplasms of the
skin, leukemia, lung cancer, ovarian cancer, and melanoma.
The present invention includes a kit comprising: (a) a container that contains
a pharmaceutical
composition as described above, in solution or in lyophilized form; (b)
optionally a second
container containing a diluent or reconstituting solution for the lyophilized
formulation; and
(c) optionally, instructions for (i) use of the solution or (ii)
reconstitution and/or use of the
lyophilized formulation.
The kit may further comprise one or more of (iii) a buffer, (iv) a diluent,
(v) a filter, (vi) a
needle, or (v) a syringe. The container is preferably a bottle, a vial, a
syringe or test tube; and
it may be a multi-use container. The pharmaceutical composition is preferably
lyophilized.
Kits of the present invention preferably comprise a lyophilized formulation of
the present
invention in a suitable container and instructions for its reconstitution
and/or use. Suitable
containers include, for example, bottles, vials (e.g. dual chamber vials),
syringes (such as dual
chamber syringes) and test tubes. The container may be formed from a variety
of materials
such as glass or plastic. Preferably the kit and/or container contains
instructions on or
CA 02724198 2010-11-12
WO 2009/138236- 60 - PCT/EP2009/003447
associated with the container that indicates directions for reconstitution
and/or use. For
example, the label may indicate that the lyophilized formulation is to
reconstituted to peptide
concentrations as described above. The label may further indicate that the
formulation is
useful or intended for subcutaneous administration.
The container holding the formulation may be a multi-use vial, which allows
for repeat
administrations (e.g., from 2 to 6 administrations) of the reconstituted
formulation. The kit
may further comprise a second container comprising a suitable diluent (e.g.,
sodium
bicarbonate solution).
Upon mixing of the diluent and the lyophilized formulation, the final peptide
concentration in
the reconstituted formulation is preferably at least 0.15 mg/mL/peptide (=75
g) and
preferably not more than 3 mg/mL/peptide (=1500 g). The kit may further
include other
materials desirable from a commercial and user standpoint, including other
buffers, diluents,
filters, needles, syringes, and package inserts with instructions for use.
Kits of the present invention may have a single container that contains the
formulation of the
pharmaceutical compositions according to the present invention with or without
other
components (e.g., other compounds or pharmaceutical compositions of these
other
compounds) or may have distinct container for each component.
Preferably, kits of the invention include a formulation of the invention
packaged for use in
combination with the co-administration of a second compound (such as adjuvants
(e.g. GM-
CSF), a chemotherapeutic agent, a natural product, a hormone or antagonist, a
anti-
angiogenesis agent or inhibitor, a apoptosis-inducing agent or a chelator) or
a pharmaceutical
composition thereof. The components of the kit may be pre-complexed or each
component
may be in a separate distinct container prior to administration to a patient.
The components of
the kit may be provided in one or more liquid solutions, preferably, an
aqueous solution, more
preferably, a sterile aqueous solution. The components of the kit may also be
provided as
solids, which may be converted into liquids by addition of suitable solvents,
which are
preferably provided in another distinct container.
The container of a therapeutic kit may be a vial, test tube, flask, bottle,
syringe, or any other
means of enclosing a solid or liquid. Usually, when there is more than one
component, the kit
CA 02724198 2013-12-23
WO 2009/138236- 61 - PCT/EP2009/003447
will contain a second vial or other container, which allows for separate
dosing. The kit may
also contain another container for a pharmaceutically acceptable liquid.
Preferably, a
therapeutic kit will contain an apparatus (e.g., one or more needles,
syringes, eye droppers,
pipette, etc.), which enables administration of the agents of the invention
that are components
of the present kit.
The present formulation is one that is suitable for administration of the
peptides by any
acceptable route such as oral (enteral), nasal, ophthalmic, subcutaneous,
intradermal,
intramuscular, intravenous or transdermal. Preferably the administration is
s.c., and most
preferably, i.d. Administration may be by infusion pump.
The present invention will now be described in the following examples that
describe preferred
embodiments thereof, nevertheless, without being limited thereto. For the
purposes of the
present invention, all references as cited herein are incorporated by
reference in their
entireties. In the Figures and in the Sequence Listing
Brief description of the drawings
Fig. 1 shows the ESI-liquid chromatography mass spectrum identifying the tumor
associated
peptide NCAN-001 from the glioblastoma sample GB1006.
Fig. 2 depicts the mRNA expression profile of the gene NCAN encoding the
glioblastoma
associated peptide NCAN-001. Expression of this gene is absent or very low in
normal tissues
while it is strongly increased in glioblastoma samples (GB! 006T to GB1011T;
NCH359T and
NCH361T).
Fig. 3 depicts the relative mRNA expression profile of the gene BIRC.5
Expression of this
gene is absent or very low in normal tissues while it is strongly increased in
tumor samples
Figs. 4a and 4b depict the presence of PSMA and Survivin-specific IFNy-
secreting CD4+ T-
= cells in peripheral blood mononuclear cells (PBMC) from different time
points of a
vaccinated patient which were determined using an IFNy-EliSpot. Time points:
pre-
vaccination (a) and after 3.(b), 6.(c), 7.(d), 8.(e), 9.(f), 10.(g), 11.(h)
vaccination.
CA 02724198 2010-11-12
WO 2009/138236- 62 - PCT/EP2009/003447
Fig. 5 shows the presence of Survivin-specific IFN7-, IL-5, IL-10, TNFa-
secreting CD4+ T-
cells in PBMC from three different time points of a vaccinated patient which
were determined
via ICS-Assay. Time points: after 1.(a), 3.(b), 7.(c), vaccination.
Fig. 6 shows the biochemical response in patients 8 and 10, showing PSA
stability with no
rise greater than 10% from baseline PSA.
Fig. 7 shows the biochemical response in patients 11 and 16, showing PSA DT
increase
without PSA stability.
Fig. 8 shows the biochemical response in patient 5, showing PSA DT increase
without PSA
stability.
Fig. 9 shows the biochemical response in patients 1, 4, 10, 12 and 13 showing
no change of
PSA DT during vaccination.
Fig. 10 shows the biochemical response in patients 2, 6, 9, 14, 18 and 19
showing no change
of PSA DT during vaccination.
Fig. 11 shows the biochemical response in patients 7, 15 and 17 showing
interim PSA decline
or DT increase followed by DT decrease.
Fig. 12 shows that from the prostate cancer vaccination study, BIR-002-peptide-
specific
CD4+ T-cell clones could be established from several vaccinated cancer
patients that are
functional with respect to IFN-gamma production in response to BIR-002. Wang
et al., 2008
describe T-cell clones obtained from healthy donors only after several rounds
of in vitro
priming and stimulation, while the present T-cells can be induced in patients
by vaccinations.
PMA/ionomycin = antigen-independent unspecific activation; Survivin (II): BIR-
002
stimulation; PSMA (II): stimulation with irrelevant peptide. All reactive
cells are CD4
positive.
Fig. 13 shows that BIR-002 is naturally presented by dendritic cells. Immature
dendritic cells
incubated with recombinant survivin protein are recognized by BIR-002 specific
T-cells from
vaccinated patients as shown by intracellular cytokine staining. These results
suggest that
CA 02724198 2010-11-12
WO 2009/138236- 63 - PCT/EP2009/003447
BIR-002 is naturally processed by proteinases within dendritic cells and that
the BIR-002
epitope is not destroyed by processing. In addition, these CD4+ 1-cells are
multifunctional as
they secrete cytokines IFN-gamma, TNF-alpha and IL-2, have surface expression
of CD40
ligand (CD154) and degranulate indicated by surface expression of CD107a. The
indicated T-
cell response is antigen-specific, as the T-cells are not activated by
dendritic cells incubated
with the irrelevant protein RAP80, or HIV-001 peptide.
Fig. 14 shows that a high fraction of BIR-002-specific CD4+ T cells derived
from BIR-002
vaccinated prostate cancer patients express beneficial cytokines IFN-gamma,
TNF-alpha, IL-2
while the immunoregulatory cytokines IL-10 and IL-17 are not expressed to that
extent.
Shown are primary data and summarized data from intracellular cytokine
staining of 1-cells
speicifc for BIR-002 or two control class II restricted peptides.
Fig. 15 shows that several tumor cell lines expressing different HLA-DR
alleles are
recognized by patient-derived PBMCs (shown for the patients Pro26 and Pro15).
Thus: 1.
patients develop multi-clonal 1-cell responses after vaccination with BIR-002;
2. BIR-002
shows promiscuous binding to several HLA class II alleles: DR1 (see also Wang
et al), DQ5
(not tested by Wang et al), DR11 (see also Wang et al) or DRB3 (in contrast to
Wang et al.,
2008, Table 1); 3. Functional presentation of BIR-002 is possible in the
context of several
HLA class II molecules (TNF-alpha production). As for HLA class I (HLA-A, -B,
C) in
principle also three different gene loci can be found for HLA class II that
express functional
class II molecules on the cell surface, namely HLA-DQ, HLA-DP and HLA-DR.
Class I
molecules are composed of a heavy chain (-A, -B, -C) and a beta-2-
microglobulin that is
constant in all three genes. Nevertheless, class II molecules are composed of
each of two
variable chains (alpha und beta). Thus, sophisticated genetically typing is
always complicated
with class II. In the table so-called serologic types are given, which are
based on antibody
binding. Thus, "DQ3" for example comprises different alleles of HLA-DQ alpha
and beta
chains that are commonly found together and react with a particular antibody.
The cells in the
table are:
Name cell line Reference
AL E418 EBV transformed B-cell Human Immunology Volume 51, Issue 1,
line November 1996, Pages 13-22
LAM B lymphoma cell line Oncogenomics 19 September 2002, Volume
21,
Number 42, Pages 6549-6556
CA 02724198 2010-11-12
WO 2009/138236- 64 - PCT/EP2009/003447
H0301 EBV transformed B cell line The Journal of Immunology, 1998, 160:
3363-
3373.
BM15 Drl 1 + APC cell line The Journal of Immunology, 2004, 173:
1876-
1886
MGAR homozygous B-LCL Gene Therapy (2004) 11, 1408-1415
LG2-EBV autologous B cell line Cancer Immunity, Vol. 2, p. 9 (19 July
2002)
EMJ B Lymphoblastoid Cell Line ECACC No. 8602103 IHW Number 9097: and
Hum Immunol. 1980 Dec;1(4):363-8.
SEQ ID No 1 to SEQ ID No 3 show the sequences of the tumor associated peptide
of the
present invention derived from survivin.
SEQ ID No 4 to SEQ ID No 13 and SEQ ID No 24 show the sequences of other tumor
associated peptides used in the present invention.
SEQ ID No 14 shows the sequences of the peptide of HBV.
SEQ ID No 15 to SEQ ID No 23 show the sequences of other tumor associated
peptides used
in the present invention.
SEQ ID No 25 to SEQ ID No 27 show the sequences of the associated peptides of
Wang et al.
(WO 2007/036638).
SEQ ID No 28 to SEQ ID No 33 show the sequences of tumor associated peptides
of Piesche.
SEQ ID No 34 to SEQ ID No 63 show the sequences of the Peptides as designed in
Example
3.
SEQ ID No 64 and SEQ ID No 65 show the sequences of the Peptides as used in
Example 4.
SEQ ID No 66 and SEQ ID No 72 show the sequences of the Peptides as used in
Example 5.
EXAMPLES
EXAMPLE 1:
CA 02724198 2010-11-12
WO 2009/138236- 65 - PCT/EP2009/003447
Identification of tumor associated peptides presented on cell surface
Tissue samples
Patients' tumor and healthy tissues were provided by Hopital Cantonal
Universitaire de
Geneve (Medical Oncology Laboratory of Tumor Immunology) and Neurochirurgische
Universitats-Klinik Heidelberg (Molekularbiologisches Labor). Written informed
consents of
all patients had been given before surgery. Tissues were shock-frozen in
liquid nitrogen
immediately after surgery and stored until isolation of peptides at -80 C.
Isolation of HLA peptides from tissue samples
HLA peptide pools from shock-frozen tissue samples were obtained by immune
precipitation
from solid tissues according to a slightly modified protocol (Falk, K. et al
1991; Seeger, F.H.
et al. T 1999) using the HLA-A*02-specific antibody BB7.2 or the HLA-A, -B, -C-
specific
antibody W6/32, CNBr-activated sepharose, acid treatment, and ultrafiltration.
Method two:
The HLA peptide pools as obtained were separated according to their
hydrophobicity by
reversed-phase chromatography (Acquity UPLC system, Waters) and the eluting
peptides
were analyzed in an LTQ- Orbitrap hybrid mass spectrometer (ThermoElectron)
equipped
with an ESI source. Peptide pools were loaded directly onto the analytical
fused-silica micro-
capillary column (75 pm i.d. x 250 mm) packed with 1.7 tm C18 reversed-phase
material
(Waters) applying a flow rate of 400 nL per minute. Subsequently, the peptides
were
separated using an two-step 180 minute-binary gradient from 10% to 33% B at
flow rates of
300 nL per minute. The gradient was composed of Solvent A (0.1% formic acid in
water) and
solvent B (0.1% formic acid in acetonitrile). A gold coated glass capillary
(PicoTip, New
Objective) was used for introduction into the micro-ES! source. The LTQ-
Orbitrap mass
spectrometer was operated in the data-dependent mode using a TOPS strategy. In
brief, a scan
cycle was initiated with a full scan of high mass accuracy in the orbitrap (R
= 30 000), which
was followed by MS/MS scans also in the orbitrap (R = 7500) on the 5 most
abundant
precursor ions with dynamic exclusion of previously selected ions. Tandem mass
spectra were
interpreted by SEQUEST and additional manual control. The identified peptide
sequence was
assured by comparison of the generated natural peptide fragmentation pattern
with the
fragmentation pattern of a synthetic sequence-identical reference peptide. Fig
1 shows an
exemplary spectrum obtained from tumor tissue for the MHC class I associated
peptide
NCAN-001.
CA 02724198 2010-11-12
WO 2009/138236- 66 - PCT/EP2009/003447
EXAMPLE 2
Expression profiling of genes encoding the peptides of the invention
Not all peptides identified as being presented on the surface of tumor cells
by MHC
molecules are suitable for irnmunotherapy, because the majority of these
peptides are derived
from normal cellular proteins expressed by many cell types. Only few of these
peptides are
tumor-associated and likely able to induce T cells with a high specificity of
recognition for
the tumor from which they were derived. In order to identify such peptides and
minimize the
risk for autoimmunity induced by vaccination the inventors focused on those
peptides that are
derived from proteins that are over-expressed on tumor cells compared to the
majority of
normal tissues.
The ideal peptide will be derived from a protein that is unique to the tumor
and not present in
any other tissue. To identify peptides that are derived from genes with an
expression profile
similar to the ideal one the identified peptides were assigned to the proteins
and genes,
respectively, from which they were derived and expression profiles of these
genes were
generated.
RNA sources and preparation
Surgically removed tissue specimens were provided by two different clinical
sites (see
Example 1) after written informed consent had been obtained from each patient.
Tumor tissue
specimens were snap-frozen in liquid nitrogen immediately after surgery and
later
homogenized with mortar and pestle under liquid nitrogen. Total RNA was
prepared from
these samples using TRIzol (Invitrogen, Karlsruhe, Germany) followed by a
cleanup with
RNeasy (QIAGEN, Hilden, Germany); both methods were performed according to the
manufacturer's protocol.
Total RNA from healthy human tissues was obtained commercially (Ambion,
Huntingdon,
UK; Clontech, Heidelberg, Germany; Stratagene, Amsterdam, Netherlands;
BioChain,
Hayward, CA, USA). The RNA from several individuals (between 2 and 123
individuals) was
mixed such that RNA from each individual was equally weighted. Leukocytes were
isolated
from blood samples of 4 healthy volunteers.
CA 02724198 2010-11-12
WO 2009/138236- 67 - PCT/EP2009/003447
Quality and quantity of all RNA samples were assessed on an Agilent 2100
Bioanalyzer
(Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).
Microarray experiments
Gene expression analysis of all tumor and normal tissue RNA samples was
performed by
Affymetrix Human Genome (HG) U133A or HG-U133 Plus 2.0 oligonucleotide
microarrays
(Affymetrix, Santa Clara, CA, USA). All steps were carried out according to
the Affymetrix
manual. Briefly, double-stranded cDNA was synthesized from 5-8 j.tg of total
RNA, using
SuperScript RTII (Invitrogen) and the oligo-dT-T7 primer (MWG Biotech,
Ebersberg,
Germany) as described in the manual. In vitro transcription was performed with
the BioArray
High Yield RNA Transcript Labelling Kit (ENZO Diagnostics, Inc., Farmingdale,
NY, USA)
for the U133A arrays or with the GeneChip IVT Labelling Kit (Affymetrix) for
the U133 Plus
2.0 arrays, followed by cRNA fragmentation, hybridization, and staining with
streptavidin-
phycoerythrin and biotinylated anti-streptavidin antibody (Molecular Probes,
Leiden,
Netherlands). Images were scanned with the Agilent 2500A GeneArray Scanner
(U133A) or
the Affymetrix Gene-Chip Scanner 3000 (U133 Plus 2.0), and data were analyzed
with the
GCOS software (Affymetrix), using default settings for all parameters. For
normalization, 100
housekeeping genes provided by Affymetrix were used. Relative expression
values were
calculated from the signal log ratios given by the software and the normal
sample was
arbitrarily set to 1Ø
The expression profile of the source gene NCAN of the peptide NCAN-001 of the
present
invention shows a high expression in glioblastoma tumor tissue whereas the
gene is not
expressed or expressed at very low levels in normal tissues (Fig. 2).
EXAMPLE 3
HLA-DR Motif Peptides from Survivin (swissprot: 015392)
Epitope Prediction: Prediction of potential HLA-DR ligands was carried out
using the www
database SYFPEITHI. Briefly, the sequence of survivin was screened against a
matrix pattern
which evaluates every amino acid within the nonamer core sequence of 15mer
peptides fitting
the respective HLA-DR motif Anchor residues are given values of up to 10;
other residues
values up to 3, reflecting amino acid preferences for certain positions within
the peptide. The
theoretical maximum score for a candidate peptide varies from 28 to 43; scores
for abundant
natural ligands are typically above 20.
CA 02724198 2010-11-12
WO 2009/138236- 68 - PCT/EP2009/003447
TLGEFLKLDRERAICN (SEQ ID No. 1) (or truncated versions) appears among the top
scoring peptides in 5 of 6 predictions.
DRB1*01 (maximal theoretical score 43)
58 FFCFKELEGWEPDDD (SEQ ID No. 34) 36
98 LGEFLICLDRERAKNK (SEQ ID No. 35) 28
22 FICNWPFLEGCACTPE (SEQ ID No. 36) 28
DRB1*03 (maximal theoretical score 40)
99 GEFLICLDRERAICNKI (SEQ ID No. 37) 29
WQPFLICDHRISTFKN (SEQ ID No. 38) 26
3 APTLPPAWQPFLKDH (SEQ ID No. 39) 25
DRB1*04 (maximal theoretical score 28)
98 LGEFLICLDRERAICNK (SEQ ID No. 40) 28
10 WQPFLKDHRISTFKN (SEQ ID No. 41) 28
3 APTLPPAWQPFLKDH (SEQ ID No. 42) 26
DRB1*07 (maximal theoretical score 34)
121 ICKEFEETAEKVRRAI (SEQ ID No. 43) 24
128 AEKVRRAIEQLAAMD (SEQ ID No. 44) 24
3 APTLPPAWQPFLKDH (SEQ ID No. 45) 22
16 DHRISTFKNWPFLEG (SEQ ID No. 46) 20
28 LEGCACTPERMAEAG (SEQ ID No. 47) 18
40 EAGFIHCPTENEPDL (SEQ ID No. 48) 18
93 FEELTLGEFLKLDRE (SEQ ID No. 49) 16
103 KLDRERAICNKIAKET (SEQ ID No. 50) 16
DRB1*11 (maximal theoretical score 38)
98 LGEFLICLDRERAKNK (SEQ ID No. 51) 32
83 GCAFLSVKKQFEELT (SEQ ID No. 52) 24
58 FFCFICELEGWEPDDD (SEQ ID No. 53) 22
CA 02724198 2010-11-12
WO 2009/138236- 69 - PCT/EP2009/003447
DRB1*15 (maximal theoretical score 34)
95 ELTLGEFLICLDRERA (SEQ ID No. 54) 30
19 ISTFKNWPFLEGCAC (SEQ ID No. 55) 28
55 AQCFFCFKELEGWEP (SEQ ID No. 56) 28
Steps leading to the decision about the sequence
1. For each peptide, a 9mer core sequence is necessary for HLA-DR binding.
Predicted core
sequences:
DRB1*01 FLKLDRERA (SEQ ID No. 57)
DRB1*03 LKLDRERAK (SEQ ID No. 58)
DRB1*04 FLKLDRERA (SEQ ID No. 59)
DRB1*11 FLKLDRERA (SEQ ID No. 60)
DRB1*15 LGEFLKLDR (SEQ ID No. 61)
2. Combine core sequences to obtain one promiscuitive core sequence:
Combined: LGEFLKLDRERAK (SEQ ID No. 62)
3. Add flanking sequences to a final length of 15 amino acids:
Final: TLGEFLKLDRERAK (SEQ ID No. 63)
EXAMPLE 4
A clinical study was conducted in order to confirm the immunogenicity of the
peptide with
the SEQ ID NO: 1. The primary study objective was the investigation of the PSA
(prostate-
specific antigen)-based response (PSA-R) to the subcutaneous administration of
a prostate-
specific peptide panel (vaccination therapy) in patients with biochemical
relapse after radical
prostatectomy without detection of manifest metastatic lesions.
The secondary study objective was the investigation of the tolerability and
feasibility of
administering vaccination therapy in patients with prostate carcinoma with
special
consideration of immunological phenomena in terms of a T cell response.
The study was designed as a prospective, randomized Phase I/II study for the
indication of
"biochemical relapse after radical prostatectomy without detection of manifest
metastatic
lesions."
CA 02724198 2010-11-12
WO 2009/138236- 70 - PCT/EP2009/003447
Study population
As part of this Phase I/II study, an attempt was made to induce PSA regression
as an
indicator of cessation of tumor growth by means of vaccination with a prostate-
specific
peptide panel in HLA-A*02+ patients with biochemical relapse after radical
prostatectomy. A
combination of prostate-specific peptides was administered subcutaneously with
evaluation
of the extent of the respective immune response in the context of various
administration
forms of the antigenic structures.
In contrast to previous vaccination studies, the planned study targeted the
treatment of
patients with a small tumor burden not yet detectable by imaging procedures.
The patients
were all immunized in the same way using known prostate-specific antigenic
structures to
enhance the immune response to the malignantly transformed cells.-Nineteen
patients were
treated.
Table 7: Study population
Total % Median Range
Age 19 63 55 - 77
Prior neo- / adjuvant treatment
None 11 58
Radiation 3 16
Intermittent Hormonal Therapy 2 11
Rad. + Int. Horm. Therapy 2 11
Rad. + Chemotherapy 1 5
TNM at RPX
T2a-c RO 6 32
T3a-c RO 6 32
T2a-c R1 3 16
T3a-c R1 3 16
T3aN2 RO 1 5
Gleason score
- 7 10 53
8-10 3 16
unknown 6 32
RPX prior to vaccination in months 41 9 - 124
First relapse post OP in months 14 1 - 90
CA 02724198 2010-11-12
WO 2009/138236 PCT/EP2009/003447
PSA at vaccination start 0.76 0.14 ¨ 10.8
Treatment schedule
After rule-out of manifest metastatic lesions using computed tomography and
skeletal
scintigraphy, the prostate-specific peptide vaccine was subcutaneously
administered
according to the different administration forms to patients with detected PSA
relapse after
prior radical prostatectomy (PSA increase in terms of a 50% elevated value
during two
measurements at least 14 days apart). The vaccine was administered 8 x on days
0, 7, 14, 28,
42, and 56 (approximately 100 micrograms per peptide and injection each time).
After each
vaccination treatment and again on day 70, PSA was measured to evaluate the
therapeutic
response.
If a tumor response (complete remission [PSA-CR], partial remission [PSA-PR],
or stable
clinical course [no change, PSA-NC]) is detected, the patient received the
vaccine once a
month as maintenance therapy according to the selected administration form.
The patient's
response to vaccination therapy was evaluated in detail as follows:
Complete remission (PSA-CR): Normalization of an initially elevated PSA level,
confirmed
by measurement after an interval of at least 4 weeks. Normalization is defined
as a PSA nadir
of <0.2 ng/ml, which would be expected after radical prostatectomy with
complete tumor or
prostate extirpation.
Partial remission: a) PSA-PR < 80% (Reduction in an initially elevated PSA
level by 80%,
confirmed by measurement after an interval of at least 4 weeks); and b) PSA-PR
< 50%
(Reduction in an initially elevated PSA level by 50%, confirmed by measurement
after an
interval of at least 4 weeks.)
Stable disease (PSA-SD): No significant change over a period of at least four
weeks. This
includes stabilization and a reduction of less than 50% and an increase of
less than 10%,
confirmed by measurement after an interval of at least 4 weeks.
Progression (PSA-PD): Increase in the PSA level by more than 10%. In the event
of PSA
progression, the study was terminated.
CA 02724198 2010-11-12
WO 2009/138236- 72 - PCT/EP2009/003447
After enrollment of the patients in the study, the epitope-specific vaccine
was used; the
proteins specifically expressed in prostatic epithelial cells (e.g., PSMA /
PSCA) were taken
into account. In addition to investigating the general efficacy of the
administered vaccine with
respect to monitoring the growth of residual tumor fractions as evaluated by
PSA monitoring,
this study investigated the effects of various vaccination methods with
respect to efficient
modulation of the immune system. In addition to simple subcutaneous
administration of the
peptides according to the invention alone various combinations with adjuvants
were also
used. The vaccine included a combination of at least 6 peptides derived from
PSA, PSCA,
PSMA, Survivin, TRP-P8 and Prostein, respectively. A peptide derived from
influenza MP
was used as a positive control. Peptides derived from PSMA and Survivin were
used at T
helper epitopes. In particular, depot and adjuvant activity for peptide
vaccines of Montanide
(a formulation of the classical incomplete Freund's adjuvant suitable for use
in humans),
which has recently been described very favorably, was used. For this purpose,
500 Ill of the
peptide solution was mixed with 500 pi of Montanide and administered. Thereby,
a water-in-
oil emulsion is built that slowly releases the antigen contained in the
aqueous phase over
weeks. The physical stability of the emulsion is very high, as at 4 C it can
be stored for more
than 3 months without significant phase separation. The depot function of
Montanide has
been exploited in several vaccination trials with good results (Oka et al.,
2004).
One study arm investigated the efficacy of vaccination during concomitant
stimulation of the
immune system by growth factors, GM-CSF, Leukine solution for injection. GM-
CSF is a
very commonly used adjuvant in peptide vaccination trials with several thereof
reporting
enhanced clinical and T-cell responses. Initially, GM-CSF is a dendritic cell
recruitment and
differentiation factor that is thought to enhance the number of dendritic cell
at the vaccines'
injection site. Although GM-CSF does not by itself activate antigen presenting
cells as
dendritic cells and macrophages an indirect activation in vivo has been
reported (Molenkamp
et al., 2005).
Another study arm investigated the efficacy of vaccination during concomitant
activation of
dendritic cells by epicutaneous use of imiquimod. Imiquimod was administered
as an 5%
ointment (Aldara). It has a strong immunostimulatory via its effect on TLR7
positive cells
(e.g. plasmacytoid DCs, Langerhans cells, dermal DCs), activates the MyD88-
dependent
pathway. Activated APCs release T-cell stimulating and inflammatory cytokines,
upregulate
costimulation and migrate to draining lymph nodes. The potential of iniquimod
to enhance
CA 02724198 2010-11-12
WO 2009/138236- 73 - PCT/EP2009/003447
peptide-induced CTL response by mixing the antigens into the ointment or by
application of
Aldara over the s.c. or i.d. injection site for the antigens has been
demonstrated in animal
models.
Another study arm investigated the efficacy of vaccination during concomitant
activation of
dendritic cells by mixing them with protamine-stabilized mRNA encoding mucin-1
to activate
TLR 7/8. mRNA shows a broad activation of mouse and human immune cell
populations. The
presence of the poly-basic protein protamine in the formulation increases the
half-life of the
mRNA and induces the formation of potentially depot-forming particles. This
adjuvant may
therefore combine depot-forming and APC-activating properties.
In summary, the administration forms of the vaccine included the following
approaches:
a) Subcutaneous administration of the peptide vaccine emulsified in Montanide;
b) Subcutaneous administration of the peptide vaccine emulsified in 500 I of
Montanide in
combination with topical administration of 225 I of GM-CSF with the objective
of achieving
a stronger immune response triggered by concomitant administration of growth
factors;
c) Subcutaneous administration of the peptide vaccine emulsified in 500 I of
Montanide in
combination with local hyperthermia, the latter given with the objective of
achieving a
thermally induced stronger immune response;
d)Subcutaneous administration of the peptide vaccine emulsified in 500 I of
Montanide in
combination with epicutaneous imiquimod in order to activate dendritic cells
via TLR 7;
e) Subcutaneous administration of the peptide vaccine emulsified in 500 1 of
Montanide
together with 55 I of mucin-1 mRNA/protamine in order to activate dendritic
cells via TLR
7/8.
Schedule
The entire duration of the study was 3 years. Prostate-specific peptide
vaccines were
administered to patients on days 0, 7, 14, 28, 42, and 56. In patients with
stable disease or an
objective tumor response (PSA-CR or PSA-PR), the vaccinations was received
once a month
i.d. until detectable progression occurs. On the basis of the experience
available thus far,
peptide injections are tolerated without significant adverse reactions.
Because the response to
vaccination therapy was evaluated solely serologically on the basis of the PSA
measurement,
a test was performed at the start of the study to determine whether the
administered vaccine
interferes with PSA measurement in vitro, which could simulate a clinical
response. On days
CA 02724198 2010-11-12
WO 2009/138236 PCT/EP2009/003447
0, 7, 14, 28, 42, 56, and 70, blood samples was taken for laboratory tests,
PSA levels,
differential blood count, FACS analysis, and cytokines. If treatment is
continued past Day 70,
6-week PSA monitoring was performed in order to detect treatment failure in a
timely
manner.
Treatment was ended if documented progression of the disease occurred in terms
of a
continuous PSA elevation.
Beginning on day 84, immunization therapy was continued at 4-week intervals
until
documented progression or up to day 420 (15 months). Decisions regarding
continuation of
therapy (in successful cases) outside of this study were made on a case-by-
case basis.
Unexpected adverse reactions did not occur in this study.
The laboratory tests included coagulation, electrolytes, LDH, 132-M, CK,
hepatic enzymes,
bilirubin, creatinine, uric acid, total protein, coagulation, CRP,
differential blood count with
smear, PSA level, cytokines, FACS, Elispot.
Analysis of the cutaneous reaction to defined bacterial and fungal antigens
(48-72 hours after
administration, delayed type hypersensitivity (DTH), T cell-mediated, will
serve as an
analysis of the patient's cellular immune system before the start of the
study)
The peptides required for the study (nona-peptides) was manufactured in the
laboratory of PD
Dr. Stefan Stevanovic in the department of Prof. H.-G. Rammensee. These
peptides was
purified by HPLC and analyzed by mass spectrometry. The purity of the peptides
can also be
checked by HPLC, mass spectrometry, and Edman sequencing. Using these methods,
purity
of up to 98% can be documented (which must be regarded as the maximum
according to the
current state of the methods). The synthesized peptides was dissolved in DMSO
(CryoSure,
WAK Chemie Medical GmbH; 10 mg/ml), diluted to 1:10 in Ampuwa (Fresenius
Kabi), and
aliquoted under sterile conditions.
Clinical response
In two patients PET-CT scan could reveal local recurrence after local tumor
was detected by
continuous digital rectal examination. In the remaining 17 patients the
location of disease
activity could not be verified at study termination.
CA 02724198 2010-11-12
WO 2009/138236- 75 - PCT/EP2009/003447
Repeated laboratory evaluation of differential blood count or extensive
clinical chemistry did
not reveal any abnormalities nor changes during the study.
Of the 19 patients, 16 patients reacted to the Survivin II peptide (IFN-g
ELISPOT, +/- ICS)
according to SEQ ID NO: 1. Among them were 12 patients with induction of an
anti-survivin
T-cell response upon vaccination, 2 with pre existing anti-Survivin T cells
and 2 patients of
whom it was not determined, whether pre existing anti-Survivin T cells were
abundant.
Biochemical response
Complete response was considered as a non-detectable PSA value according to
the lowest
value detectable of the laboratory collaborating after initially elevated PSA.
The measurement
had to be confirmed after an interval of at least four weeks. A PR > 80% and >
50% had to be
reevaluated after four weeks accordingly. A PSA within the range of less than
50% decrease
or less than 10% increase reflected stable disease if at least confirmed after
four weeks.
Progressive disease was considered any increase of more than 10% of PSA at
treatment start.
Biochemical response in patients who terminated the study was followed until
they received
further treatment with local radiation or antihormonal therapy. 19 patients
consented to
participate and the data was analyzed with the longest follow-up lasting about
3.75 years.
PSA stability and DT increase
PSA values of two patients (10.2%) exhibited stability according to the above
mentioned
criteria of biochemical response which state that no rise of the PSA value
greater than 10 % at
treatment start had occurred at study end (Fig. 6, Tables 8, 9, and 10).
Follow up in those two
cases was conducted 14 and 16 months after the last vaccine application.
Average duration of
stability was 24 months (28 and 31) at data cut-off with an average of 18
vaccinations (14 and
20) applied.
Out of these two patients, one patient showed partial response > 50% for a
period of 9
months, followed by a period of slow PSA rise with a doubling time of 20.5
compared to 9.8
months prior vaccination. Initial PSA relapse started 18 months post surgery
for a pT2pN0
Gleason 5 tumor.
CA 02724198 2010-11-12
WO 2009/138236- 76 - PCT/EP2009/003447
At data analysis Patient 8 exhibited stable disease since the beginning of the
vaccination
program 28 months ago. He had stopped treatment due to an allergic reaction
after 10 months
and the 14th vaccination. He had an unfavorable pT3b Gleason 3+4 situation
with a PSA nadir
after radical prostatectomy not below 0.6 ng/ml and PSA progression without
timely delay
after initial decline postoperatively. Doubling time slowed from 6.6 months to
148 months.
These two patients received dermal Imiquimod at the application site at each
peptide
vaccination (Figure 9, 10, and 11, Table 13).
PSA DT increase without PSA stability
PSA DT of Patient 11 was increased from 1.5 to 10.1 months during six month on
study.
Since he started with a PSA of 10.8 ng/ml and progressed to 17.8 ng/ml he
terminated study
procedures to receive antiandrogen monotherapy without any malignant lesions
visualized in
PET-CT. He received Aldara as adjuvant.
Patient 16 started into vaccine treatment plus Mucin-1 -mRNA/protamine with a
doubling
time of 6.1 months. PSA velocity declined into a half life time of 2.7 months
for five months
followed by a statistically calculated rise of PSA DT of 14.4 months which is
continuing 16
months after treatment start. With an initial PSA of 0.29 ng/ml, he dropped to
0.19 ng/ml
during the first 5 months on study treatment, rose to 0.4 ng/ml within the
following 8 months
and terminated the study per protocol with 0.41 ng/ml 19 months after
treatment start (Fig. 7
Table 8 and 10).
PSA progression
Patient 5 progressed during the study according to the estimated PSA doubling
time before
vaccination. However, he experienced a PSA decline with a half-time life of
20.2 months
after treatment end for a continuing period of 10 months at data cut-off. He
still was not
receiving any secondary treatment after vaccination end. He was vaccinated
with montanide
as the only adjuvant (Figure 8, Table 13).
Table 8: PSA Doubling Time in months
Total % Geometric Range of
Mean DT
PSA DT prior vaccination in months 19 8.3 1.5 ¨ 44.8
CA 02724198 2010-11-12
WO 2009/138236- 77 - PCT/EP2009/003447
PSA DT at study end or at end of follow-up 18* 11.2 2.2 -148
No change of PSA DT during vaccination 11 58 2.2 ¨44.8
Increased PSA DT continuing at end of study 4 21
No change of PSA DT during vacc but decline after 1 5
Interim PSA decline or DT increase followed by DT 3 16
decrease
* PSA DT at study end or end of follow-up was not included for Pat. 5 due to
PSA decline
Table 9: PSA stability with no rise greater than 10% from baseline PSA
PSA baseline PSA end of study PSA end of follow Months since
ng/ml ng/ml up baseline
ng/ml
pat 3 0.7 0.51 0.73 31
pat 8 1.76 1.84 1.85 28
Table 10: Permanent increase of PSA DT in months during vaccination
ith DT prior 2th DT during 3th DT during
vaccine months vaccine months vaccine
months
pat 3 9.8 - 2.3 20.5
pat 8 6.6 148
pat 11 1.5 10.1
pat 16 6.1 -2.7 14.4
geometric mean 4.9 25.8
3
DT
Table 11: No change of PSA DT in months during vacc but decline after
DT prior vaccine 2th DT during vaccine months
months
pat 5 3.2 -20.2
Table 12: Interim PSA DT decline/stability in months followed by accelerated
rise
CA 02724198 2010-11-12
WO 2009/138236- 78 - PCT/EP2009/003447
lth DT prior 2th DT during 3th DT during 4th DT during
vaccine vaccine vaccine vaccine
months months months months
pat 7 3.7 21.5 2.8
pat 15 1.3 25.8 -9.9 7.4
pat 17 10.2 -1.9 4.8
Table 13: Adjuvants and patient response. No PSA response (-), interim PSA
fall and
accelerated rise after (+0, PSA DT increase (+)
No Aldara Hyper- GmCSF RNA
adjuvants Response Response thermia Response Response
Response
pat 1 - pat 3 + pat 13 - pat 4 - pat 16 +
pat 2 - pat 7 +/- pat 10 - pat 6 - pat 17 +/-
pat 5 - pat 8 + pat 12 - pat 18
pat 9 - pat 11 + pat 14 - pat 19 -
pat 15 +1-
Synthesis
The peptides were synthesized using a fully automatically in the EPS 221
peptide synthesizer
manufactured by Abimed. The synthesis program follows the manufacturer's
standard
protocols. To the extent possible, the batch numbers of the reagent batches
are registered for
each peptide.
Processing to the raw peptide
The processing of the raw peptide was done by splitting off of the synthesis
resin and release
of the side-chain protective groups by TFA / phenol / ethane dithiol /
thioanisole / water
(90/3.75/1.25/2.5/2.5, volume percent, respectively) 1 h or 3 h (peptides with
arginine).
Precipitation of the raw peptide in methyl-tert-butylether, washing with
methyl-tert-butylether
and twice with diethylether, drying and dissolution of the peptide pellet in
acetic acid.
Another precipitation in diethylether, drying, resuspension in water, and
freeze-drying.
Preparative HPLC
HPLC system Varian "Star," chromatography column 250 x 10 mm C18 5 1.im
(Manufacturer
Ziemer). Mobile solvent A: water with 0.1% TFA, mobile solvent B: acetonitrile
with 0.08%
CA 02724198 2010-11-12
WO 2009/138236- 79 - PCT/EP2009/003447
TFA. The gradient used for separation is oriented to the hydrophobicity of the
peptide. The
separated peptide fractions are freeze-dried.
Analysis
For each peptide, an HPLC chromatogram and a MALDI mass spectrum were recorded
in
order to prove the identity (via the molar mass in the mass spectrum) and
purity (via the peak
areas in the HPLC chromatogram).
Synthetic peptides and stimuli
Synthetic peptides used for the stimulation and for functional tests were the
HIV-derived
epitope (HIV gag 164181: YVDRFYKTLRAEQASQEV (SEQ ID No: 65), negative
control), PSMA 459-473: NYTLRVDCTPLMYSL (SEQ ID No: 64) and Survivin 97-111:
TLGEFLKLDRERAKN (SEQ ID No: 1). Staphylococcus enterotoxin B (SEB, Sigma-
Aldrich, Taufkirchen, Germany) was used as a positive control stimulation for
CD4+ T-cells
in the Interferon-y ELISPOT.
In vitro amplification of specific T-cells
Peripheral blood mononuclear cells from prostate carcinoma patients were
obtained at
different time-points during vaccination and cryopreserved in 90% fetal calf
serum and 10%
DMSO in liquid nitrogen. After thawing, approximately 5 x 106 cells were
cultivated (24-well
cell culture plate, Greiner Bio-One, Frickenhausen, Germany) in IMDM medium
supplemented with 50U/m1 Penicillin, 50 g/m1 Streptomycin (all Biowhittaker,
Verviers,
Belgium), 10% heat-inactivated human serum (c.c. pro, Neustadt, Germany) and
50 M beta-
mercaptoethanol at 37 C and 7.5% CO2. Pooled synthetic HLA-class II binding
peptides were
added at day 1, each at 5 g/m1 and the culture was supplemented with
recombinant human
IL-2 (r-hIL2, R&D Systems GmbH, Wiesbaden, Germany) at days 2, 5, 7 and 9 of
the T-cell
stimulation.
Enzyme-linked immunosorbent spot (ELISPOT) assay
The functionality of expanded T-cells was tested in a standard Interferon-y
ELISPOT assay
according to the recommendations of the CIMT Monitoring Panel (www.c-imt.org).
Briefly,
cells were harvested after the 12 day culture, washed, counted and seeded in
culture medium
on an ELISPOT plate (Millipore, Schwalbach, Germany). Between 0.15 and 0.25 x
106 cells
were tested in duplicates or triplicates, in the presence of the synthetic
peptides at 2.5 g/m1
CA 02724198 2010-11-12
WO 2009/138236- 80 - PCT/EP2009/003447
or SEB at 1 g/ml. Production of IFN-y was detected with a pair of specific
monoclonal
antibodies (1D1-k and 7-B6-1, both Mabtech, Nacka Strand, Sweden) after 26
hour
incubation at 37 C and 5% CO2. ExtraAvidin-Alkaline Phosphatase and BCIP/NBT
substrate
(both Sigma-Aldrich) were added for 1 hour and 10 min respectively. ELISPOT
analysis was
performed using ImmunoSpot readers (Series 3A and 5, Cellular Technology Ltd,
Aalen,
Germany).
Intracellular cytokine staining
Cells recovered from the ELISPOT were further cultivated in the presence of 2
ng/ml r-hIL2
for nine additional days. After this re-stimulation period, effectors were
harvested, washed
and stimulated in a standard assay with the peptides at 5 g/m1 or PMA and
Ionomycin
(50ng/m1 and 1 M, respectively) in the presence of Golgi-STOP (BD Biosciences,
Heidelberg, Germany) following the manufacturers instructions. Following an
incubation
period of 6 hours, cells were washed in PBS 1%FCS 0.02% NaN3 and stained with
monoclonal antibodies (MoAb) CD4-APC-Cy7 (BD Biosciences) and CD8-PE-Cy7
(Beckman Coulter) for 20 mm at 4 C in the dark. After a washing step, cells
were
permeabilized 20 mm with Cytofix/Cytoperm reagent (BD Biosciences) then
stained for
intracellular cytokines for 30 min. MoAb used were IFN-y-FITC, IL-10-PE (both
BD
Biosciences), IL-5-APC (Miltenyi Biotec, Bergisch Gladbach, Germany) and TNF-a-
Pacific
Blue (Biolegend, San Diego, CA). Cell acquisition was performed on a Cytometer
Canto II
using the software Diva and analysis with FlowJo (BD Biosciences).
EXAMPLE 5
Binding of BIR-11, BIR-12, and BIR-13 to HLA-A*0211
The objective of this analysis was to evaluate the affinity of BIR-004
(ELTLGEFLKLDRERAKN (SEQ ID No: 2)) C-terminal peptides to the MHC molecule
coded by the HLA-A*0211 allele as this an allele with reported capacity to
bind peptides with
C-terminal asparagine residues. MHC ligands with c-terminal N are not very
frequent and we
have only tested 66 peptides with N in the C-terminus. The vast majority is
non-binders,
however, there are a few exceptions: RLYNFSFLN (SEQ ID No: 66) binds strongly
to
A*0211 and also YADGGQWYN (SEQ ID No: 67) binds to A*0211...").
The tests clearly indicated that binding to HLA-A*0211 has been found for BIR-
11 (C-
terminal nonamer: KLDRERAKN (SEQ ID No: 68)) and BIR-13 (C-terminal decamer:
CA 02724198 2010-11-12
WO 2009/138236- 81 - PCT/EP2009/003447
LKLDRERAKN (SEQ ID No: 69)) at higher concentrations but not for BIR-12 (C-
terminal
octamer: LDRERAKN (SEQ ID No: 70)). The positive control peptide (Sequence:
FLPSDYFPSV (SEQ ID No: 71)) showed clear binding properties.
Principle of test
An assay was set up as follows: Stable HLA/peptide complexes consist of three
molecules:
HLA heavy chain, beta-2 microglobulin (b2m) and the peptidic ligand. The
activity of
denatured recombinant HLA-A*0211 heavy chain molecules alone can be preserved
making
them functional equivalents of "empty HLA-A*0211 molecules". When diluted into
aqueous
buffer containing b2m and an appropriate peptide, these molecules fold rapidly
and efficiently
in an entirely peptide-dependent manner. The availability of these molecules
is used in an
ELISA-based assay to measure the affinity of interaction between peptide and
HLA class I
molecule {Sylvester-Hvid, 2002 SYLVESTER}{VID2002 /id).
Purified recombinant HLA-A*0211 molecules were incubated together with b2m and
graded
doses of the peptide of interest. The amount of de novo-folded HLA/peptide
complexes was
determined by a quantitative ELISA. Dissociation constants (KD values) were
calculated
using a standard curve recorded from dilutions of a calibrant HLA/peptide
complex. The
deviance in the measurements was too big to give reliable KD values, although
it can be said
that the KD value for BIR13 is in the range of the positive control whereas
the KD value for
BIR-11 is higher. A lower KD value reflects higher affinity to HLA-A*0211.
Binding-Scores of the nonamer BIR-11 and the nomamer BIR-1 la against several
alleles
using SYFPEITHI
KLDRERAKD
(SEQ ID No: 72) Allele-id Allele name Rel score score
KLDRERAKD 74 A*0301 0.45 20
KLDRERAKD 65 A*0201 0.42 15
KLDRERAKD 99 B*1501 (B62) 0.36 10
KLDRERAKD 334 A*0101 0.28 14
KLDRERAKN
(SEQ ID No: 68) Allele-id Allele name Rel score score
CA 02724198 2010-11-12
WO 2009/138236- 82 - PCT/EP2009/003447
KLDRERAKN 74 A*0301 0.45 20
KLDRERAKN 65 A*0201 0.42 15
KLDRERAKN 99 B*1501 (B62) 0.36 10
KLDRERAKN 334 A*0101 0.28 14
Reference List
Al-Joudi FS, Iskandar ZA, Imran AK (2007). Survivin expression correlates with
unfavourable prognoses in invasive ductal carcinoma of the breast. Med J
Malaysia 62, 6-8.
al-Sheneber IF, Shibata HR, Sampalis J, Jothy S (1993). Prognostic
significance of
proliferating cell nuclear antigen expression in colorectal cancer. Cancer 71,
1954-1959.
Angileri FF, Aguennouz M, Conti A, La TD, Cardali S, Crupi R, Tomasello C,
Germano A,
Vita G, Tomasello F (2008). Nuclear factor-kappaB activation and differential
expression of
survivin and Bc1-2 in human grade 2-4 astrocytomas. Cancer.
Apostolopoulos V, McKenzie IF (1994). Cellular mucins: targets for
immunotherapy. Crit
Rev. Immunol. 14, 293-309.
Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S,
Pinilla C,
Romero P (2006). Decreased specific CD8+ T cell cross-reactivity of antigen
recognition
following vaccination with Melan-A peptide. Eur. J Immunol. 36, 1805-1814.
Asher RA, Morgenstern DA, Fidler PS, Adcock KH, Oohira A, Braistead JE, Levine
JM,
Margolis RU, Rogers JH, Fawcett JW (2000). Neurocan is upregulated in injured
brain and in
cytokine-treated astrocytes. J Neurosci. 20, 2427-2438.
Bamias A, Chorti M, Deliveliotis C, Trakas N, Skolarikos A, Protogerou B,
Legaki S,
Tsakalou G, Tamvakis N, Dimopoulos MA (2003). Prognostic significance of CA
125, CD44,
and epithelial membrane antigen in renal cell carcinoma. Urology 62, 368-373.
Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989). Specific, Major
Histocompatibility
Complex-Unrestricted Recognition of Tumor-Associated Mucins by Human Cytotoxic
T
Cells. PNAS 86, 7159-7163.
Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, Peters G (1994).
CDK6
(PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent
kinases that
associate with cyclin Dl. Oncogene 9, 71-79.
Beilmann M, Vande Woude GF, Dienes HP, Schirmacher P (2000). Hepatocyte growth
factor-stimulated invasiveness of monocytes. Blood 95, 3964-3969.
Berger M, Bergers G, Arnold B, Hammerling GJ, Ganss R (2005). Regulator of G-
protein
signaling-5 induction in pericytes coincides with active vessel remodeling
during
neovascularization. Blood 105, 1094-1101.
Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, Fowler P,
Schlicht HJ,
Vitiello A, Chesnut RC, . (1993). Definition of a minimal optimal cytotoxic T-
cell epitope
within the hepatitis B virus nucleocapsid protein. J. Virol. 67, 2376-2380.
Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C (1995). Essential
role for the c-
met receptor in the migration of myogenic precursor cells into the limb bud.
Nature 376, 768-
771.
Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y (2006). Suppression of survivin
expression in
glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes
caspase-dependent
apoptosis. Mol. Cancer Ther. 5, 2337-2347.
Borset M, Seidel C, Hjorth-Hansen H, Waage A, Sundan A (1999). The role of
hepatocyte
growth factor and its receptor c-Met in multiple myeloma and other blood
malignancies.
Leuk. Lymphoma 32, 249-256.
CA 02724198 2010-11-12
WO 2009/138236- 83 - PCT/EP2009/003447
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF,
Aaronson SA
(1991). Identification of the hepatocyte growth factor receptor as the c-met
proto-oncogene
product. Science 251, 802-804.
Bowen AR, Hanks AN, Murphy KJ, Florell SR, Grossman D (2004). Proliferation,
apoptosis,
and survivin expression in keratinocytic neoplasms and hyperplasias. Am J
Dermatopathol.
26, 177-181.
Boyton RJ, Lohmann T, Londei M, Kalbacher H, Halder T, Frater AJ, Douek DC,
Leslie DG,
Flavell RA, Altmann DM (1998). Glutamic acid decarboxylase T lymphocyte
responses
associated with susceptibility or resistance to type I diabetes: analysis in
disease discordant
human twins, non-obese diabetic mice and HLA-DQ transgenic mice. Int. Immunol.
10,
1765-1776.
Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR (1997). Imbalance of
expression of
matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix
metalloproteinases
(TIMPs) in human pancreatic carcinoma. J Pathol. 182, 347-355.
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm
A,
Rammensee HG, Kanz L, Brugger W (1999a). Identification of HLA-A2-restricted T-
cell
epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine
therapies.
Blood 93, 4309-4317.
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm
A,
Rammensee HG, Kanz L, Brugger W (1999b). Identification of HLA-A2-restricted T-
cell
epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine
therapies.
Blood 93, 4309-4317.
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000).
Induction of
cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-
pulsed dendritic
cells. Blood 96,3102-3108.
Browner MF, Smith WW, Castelhano AL (1995). Matrilysin-inhibitor complexes:
common
themes among metalloproteases. Biochemistry 34, 6602-6610.
Burton EC, Prados MD (2000). Malignant gliomas. Curr. Treat. Options. Oncol 1,
459-468.
Cao Y, Karsten U, Zerban H, Bannasch P (2000). Expression of MUC1, Thomsen-
Friedenreich-related antigens, and cytokeratin 19 in human renal cell
carcinomas and tubular
clear cell lesions. Virchows Arch. 436, 119-126.
Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, Belli F,
Mezzanzanica D, Costa
A, Andreola S, Leo E, Parmiani G, Castelli C (2003). The apoptosis inhibitor
protein survivin
induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
Cancer Res. 63,
4507-4515.
Castellino F, Huang AY, tan-Bonnet G, Stoll S, Scheinecker C, Germain RN
(2006).
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T
cell-
dendritic cell interaction. Nature 440, 890-895.
CBTRUS. Primary Brain Tumors in the United States, Statistical Report. 2006.
Ref Type: Internet Communication
Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ,
Loeffler JS
(2002). Quantitatively determined survivin expression levels are of prognostic
value in human
gliomas. J Clin Oncol 20, 1063-1068.
Chanock SJ, Foster CB, Miller FW, O'Hanlon TP (2004). HLA-A, -B, -Cw, -DQA1
and -
DRB1 Alleles in a Caucasian Population from Bethesda, USA. Hum. Immunol. 65,
1211-
1223.
Cheever MA, Chen W, Disis ML, Takahashi M, Peace DJ (1993). T-cell immunity to
oncogenic proteins including mutated ras and chimeric bcr-abl. Ann N. Y. Acad.
Sci. 690,
101-112.
CA 02724198 2010-11-12
WO 2009/138236- 84 - PCT/EP2009/003447
Chen X, Higgins J, Cheung ST, Li R, Mason V, Montgomery K, Fan ST, van de RM,
So S
(2004). Novel endothelial cell markers in hepatocellular carcinoma. Mod.
Pathol. 17, 1198-
1210.
Colombetti S, Basso V, Mueller DL, Mondino A (2006). Prolonged TCR/CD28
engagement
drives IL-2-independent T cell clonal expansion through signaling mediated by
the
mammalian target of rapamycin. J Immunol. 176, 2730-2738.
Cresswell P (1994). Assembly, transport, and function of MHC class II
molecules. Annu.
Rev. Immunol. 12, 259-293.
Dazzi C, Cariello A, Giannini M, Del DM, Giovanis P, Fiorentini G, Leoni M,
Rosti G, Turci
D, Tienghi A, Vertogen B, Zumaglini F, De GU, Marangolo M (2000). A sequential
chemo-
radiotherapeutic treatment for patients with malignant gliomas: a phase II
pilot study.
Anticancer Res. 20, 515-518.
De VL, Zheng B, Fischer T, Elenko E, Farquhar MG (2000). The regulator of G
protein
signaling family. Annu. Rev. Pharmacol. Toxicol. 40, 235-271.
Delsol G, Al ST, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, Rigal-
Huguet F, Robert
A, Stein H, Mason DY (1988). Coexpression of epithelial membrane antigen
(EMA), Ki-1,
and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic
value in so-called
malignant histiocytosis. Am. J. Pathol. 130, 59-70.
Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor 0, Altenberend F,
Muller M,
Kramer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee
HG,
Klingel K, Stevanovic S (2006). Unexpected Abundance of HLA Class II Presented
Peptides
in Primary Renal Cell Carcinomas. Clin Cancer Res. 12, 4163-4170.
Denys H, De WO, Nusgens B, Kong Y, Sciot R, Le AT, Van DK, Jadidizadeh A,
Tejpar S,
Mareel M, Alman B, Cassiman JJ (2004). Invasion and MMP expression profile in
desmoid
tumours. Br. J Cancer 90, 1443-1449.
Deshpande A, Sicinski P, Hinds PW (2005). Cyclins and cdks in development and
cancer: a
perspective. Oncogene 24, 2909-2915.
Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L,
Nordlinger B, Bretti
S, Bottardi S, Giordano S, . (1995). Overexpression and amplification of the
met/HGF
receptor gene during the progression of colorectal cancer. Clin. Cancer Res.
1, 147-154.
Dix AR, Brooks WH, Roszman TL, Morford LA (1999). Immune defects observed in
patients
with primary malignant brain tumors. J Neuroimmunol. 100, 216-232:
Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van WC (2001). Hepatocyte growth
factor/scatter factor-induced activation of MEK and PI3K signal pathways
contributes to
expression of proangiogenic cytokines interleukin-8 and vascular endothelial
growth factor in
head and neck squamous cell carcinoma. Cancer Res. 61, 5911-5918.
Duchateau PN, Pullinger CR, Cho MH, Eng C, Kane JP (2001). Apolipoprotein L
gene
family: tissue-specific expression, splicing, promoter regions; discovery of a
new gene. J.
Lipid Res. 42, 620-630.
Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor
PM,
Malloy MJ, Kane JP (1997). Apolipoprotein L, a new human high density
lipoprotein
apolipoprotein expressed by the pancreas. Identification, cloning,
characterization, and plasma
distribution of apolipoprotein L. J. Biol. Chem. 272, 25576-25582.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ,
Topalian
SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp
CA,
Rogers-Freezer L, Morton KB, Mavroukakis SA, White DE, Rosenberg SA (2002).
Cancer
regression and autoimmunity in patients after clonal repopulation with
antitumor
lymphocytes. Science 298, 850-854.
Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal
RE,
Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA,
Mangiameli DP,
Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A,
Rosenberg
CA 02724198 2010-11-12
WO 2009/138236- 85 - PCT/EP2009/003447
SA (2005). Adoptive cell transfer therapy following non-myeloablative but
lymphodepleting
chemotherapy for the treatment of patients with refractory metastatic
melanoma. J. Clin.
Oncol. 23, 2346-2357.
Duperray C, Klein B, Dune BG, Zhang X, Jourdan M, Poncelet P, Favier F,
Vincent C,
Brochier J, Lenoir G, . (1989). Phenotypic analysis of human myeloma cell
lines. Blood 73,
566-572.
Engel M, Maurel P, Margolis RU, Margolis RK (1996). Chondroitin sulfate
proteoglycans in
the developing central nervous system. I. cellular sites of synthesis of
neurocan and
phosphacan. J Comp Neurol. 366, 34-43.
Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P,
Cremona 0,
Campanacci M, Comoglio PM (1995). The Met/HGF receptor is over-expressed in
human
osteosarcomas and is activated by either a paracrine or an autocrine circuit.
Oncogene 10,
739-749.
Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J,
Barratt-
Boyes SM (1995). MUC-1 epithelial tumor mucin-based immunity and cancer
vaccines.
Immunol. Rev. 145, 61-89.
Fischer J, Palmedo G, von KR, Bugert P, Prayer-Galetti T, Pagano F, Kovacs G
(1998).
Duplication and overexpression of the mutant allele of the MET proto-oncogene
in multiple
hereditary papillary renal cell tumours. Oncogene 17, 733-739.
Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG
(2001).
Altered peptide ligand vaccination with F1t3 ligand expanded dendritic cells
for tumor
immunotherapy. Proc. Natl. Acad. Sci. U. S. A 98, 8809-8814.
Friedlander DR, Miley P, Karthikeyan L, Margolis RK, Margolis RU, Grumet M
(1994). The
neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell
adhesion
molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite
outgrowth. J Cell Biol. 125, 669-680.
Fujita K, Denda K, Yamamoto M, Matsumoto T, Fujime M, Irimura T (1999).
Expression of
MUC1 mucins inversely correlated with post-surgical survival of renal cell
carcinoma
patients. Br. J. Cancer 80, 301-308.
Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Woude GF,
Webb
CP (2001). Suppression of Ras-mediated tumorigenicity and metastasis through
inhibition of
the Met receptor tyrosine kinase. Proc. Natl. Acad. Sci. U. S. A 98, 10722-
10727.
Furge KA, Zhang YW, Vande Woude GF (2000). Met receptor tyrosine kinase:
enhanced
signaling through adapter proteins. Oncogene 19, 5582-5589.
Furuya M, Nishiyama M, Kimura S, Suyama T, Naya Y, Ito H, Nikaido T, Ishikura
H (2004).
Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour
vasculature of
human renal cell carcinoma. J. Pathol. 203, 551-558.
Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH, Matrisian LM (1994).
Structure
and expression of the human gene for the matrix metalloproteinase matrilysin.
J Biol Chem.
269, 2032-2040.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
Tosolini M,
Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski
Z,
Fridman WH, Pages F (2006). Type, density, and location of immune cells within
human
colorectal tumors predict clinical outcome. Science 313, 1960-1964.
Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP (2006). Adoptive
immunotherapy for
cancer: building on success. Nat. Rev. Immunol. 6, 383-393.
Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988). A
highly
immunogenic region of a human polymorphic epithelial mucin expressed by
carcinomas is
made up of tandem repeats. J. Biol. Chem. 263, 12820-12823.
Gemer EW, Meyskens FL, Jr. (2004). Polyamines and cancer: old molecules, new
understanding. Nat. Rev. Cancer 4, 781-792.
CA 02724198 2010-11-12
WO 2009/138236- 86 - PCT/EP2009/003447
Gherardi E, Stoker M (1991). Hepatocyte growth factor--scatter factor:
mitogen, motogen,
and met. Cancer Cells 3, 227-232.
Ghosh JC, Dohi T, Kang BH, Altieri DC (2008). Hsp60 regulation of tumor cell
apoptosis. J
Biol. Chem. 283, 5188-5194.
Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou
J (1989). A core
protein epitope of the polymorphic epithelial mucin detected by the monoclonal
antibody SM-
3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer 43,
1072-1076.
Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki
RG, Dupont
B, Ritter G, Chen YT, Knuth A, Old LJ (2003). Survey of naturally occurring
CD4+ T cell
responses against NY-ESO-1 in cancer patients: correlation with antibody
responses. Proc
Natl. Acad. Sci. U. S. A 100, 8862-8867.
Gong L, Jiang C, Zhang B, Hu H, Wang W, Liu X (2006). Adenovirus-mediated
Expression
of Both Antisense Ornithine Decarboxylase and S-adenosylmethionine
Decarboxylase
Induces G(1) Arrest in HT-29 Cells. J Biochem. Mol. Biol 39, 730-736.
Grumet M, Friedlander DR, Sakurai T (1996). Functions of brain chondroitin
sulfate
proteoglycans during developments: interactions with adhesion molecules.
Perspect. Dev.
Neurobiol. 3, 319-330.
Grumet M, Miley P, Sakurai T, Karthikeyan L, Bourdon M, Margolis Ric Margolis
RU
(1994). Interactions with tenascin and differential effects on cell adhesion
of neurocan and
phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. J
Biol. Chem.
269,12142-12146.
Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB,
Zhang K,
Allison D, Grizzle WE, Wang W, Gillespie GY, Johnson MR (2006). Increased
expression of
thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and
survivin is
associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol.
80, 261-274.
Gursky S, Olopade CH, Rowley JD (2001). Identification of a 1.2 Kb cDNA
fragment from a
region on 9p21 commonly deleted in multiple tumor types. Cancer Genet.
Cytogenet. 129, 93-
101.
Halaban R (1999). Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer
Metastasis Rev. 18, 333-343.
Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P. Nagy ZA,
Sinigaglia F
(1995). Peptide binding specificity of HLA-DR4 molecules: correlation with
rheumatoid
arthritis association. J Exp. Med 181, 1847-1855.
Hanada K, Yewdell JW, Yang JC (2004). Immune recognition of a human renal
cancer
antigen through post-translational protein splicing. Nature 427, 252-256.
Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G (1999). Cyclin-D1
expression in
human renal-cell carcinoma. Int. J. Cancer 84, 268-272.
Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW (1998). Adipophilin is a
specific
marker of lipid accumulation in diverse cell types and diseases. Cell Tissue
Res. 294, 309-
321.
Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon
D,
Friedman A, Bigner DD, Sampson JH. Tumor-specific peptide vaccination in newly-
diagnosed patients with GBM. Journal of Clinical Oncology, 2006 ASCO Annual
Meeting
Proceedings Part I Vol 24, No. 18S (June 20 Supplement), 2006: 2529. 20-6-
2006.
Herz C, Aumailley M, Schulte C, Schlotzer-Schrehardt U, Bruckner-Tuderman L,
Has C
(2006). Kindlin-1 is a phosphoprotein involved in regulation of polarity,
proliferation, and
motility of epidermal keratinocytes. J Biol Chem. 281, 36082-36090.
Hwang ML, Lukens JR, Bullock TN (2007). Cognate memory CD4+ T cells generated
with
dendritic cell priming influence the expansion, trafficking, and
differentiation of secondary
CD8+ T cells and enhance tumor control. J Immunol. 179, 5829-5838.
CA 02724198 2010-11-12
WO 2009/138236- 87 - PCT/EP2009/003447
Jadeski LC, Chakraborty C, Lala PK (2003). Nitric oxide-mediated promotion of
mammary
tumour cell migration requires sequential activation of nitric oxide synthase,
guanylate
cyclase and mitogen-activated protein kinase. Int. J. Cancer 106, 496-504.
Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP
(2003).
CD4+ T cells are required for secondary expansion and memory in CD8+ T
lymphocytes.
Nature 421, 852-856.
Jarvinen TA, Liu ET (2006). Simultaneous amplification of HER-2 (ERBB2) and
topoisomerase IIalpha (TOP2A) genes--molecular basis for combination
chemotherapy in
cancer. Curr. Cancer Drug Targets. 6, 579-602.
Jones LL, Margolis RU, Tuszynski MH (2003). The chondroitin sulfate
proteoglycans
neurocan, brevican, phosphacan, and versican are differentially regulated
following spinal
cord injury. Exp. Neurol. 182, 399-411.
Jucker M, Gunther A, Gradl G, Fonatsch C, Krueger G, Diehl V, Tesch H (1994).
The
Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some
cases of
human leukemia and lymphoma. Leuk. Res. 18, 7-16.
Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K,
Kurisu K
(2003). Expression of survivin in astrocytic tumors: correlation with
malignant grade and
prognosis. Cancer 97, 1077-1083.
Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P (2002). Culprit and
victim -- DNA
topoisomerase II. Lancet Oncol. 3, 235-243.
Kennedy RC, Shearer MH, Watts AM, Bright R.K. (2003). CD4+ T lymphocytes play
a critical
role in antibody production and tumor immunity against simian virus 40 large
tumor antigen.
Cancer Res. 63, 1040-1045.
Kloeker S, Major MB, Calderwood DA, Ginsberg MH, Jones DA, Beckerle MC (2004).
The
Kindler syndrome protein is regulated by transforming growth factor-beta and
involved in
integrin-mediated adhesion. J. Biol. Chem. 279, 6824-6833.
Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Herraiz M,
Sangro B, Prieto
J, Borras-Cuesta F, Celis E (2002). Identification of an antigenic epitope for
helper T
lymphocytes from carcinoembryonic antigen. Clin Cancer Res. 8, 3219-3225.
Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau
JH, Vande
Woude GF (1997). Met and hepatocyte growth factor/scatter factor expression in
human
gliomas. Cancer Res. 57, 5391-5398.
Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC,
Vasmatzis G (2005). Clear cell renal cell carcinoma: gene expression analyses
identify a
potential signature for tumor aggressiveness. Clin Cancer Res. 11, 5128-5139.
Kraus S, Abel PD, Nachtmann C, Linsenmann HJ, Weidner W, Stamp GW, Chaudhary
KS,
Mitchell SE, Franke FE, Lalani e (2002). MUC1 mucin and trefoil factor 1
protein expression
in renal cell carcinoma: correlation with prognosis. Hum. Pathol. 33, 60-67.
Kurokawa Y, Matoba R, Nakamori S, Takemasa I, Nagano H, Dono K, Umeshita K,
Sakon
M, Monden M, Kato K (2004). PCR-array gene expression profiling of
hepatocellular
carcinoma. J. Exp. Clin. Cancer Res. 23, 135-141.
Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, Becker HD, Rammensee HG,
Stevanovic S
(2004). Differential quantitative analysis of MHC ligands by mass spectrometry
using stable
isotope labeling. Nat. Biotechnol. 22, 450-454.
Leontiou C, Lightowlers R, Lakey JH, Austin CA (2003). Kinetic analysis of
human
topoisomerase IIalpha and beta DNA binding by surface plasmon resonance. FEBS
Lett. 554,
206-210.
Leroy X, Copin MC, Devisme L, Buisine MP, Aubert JP, Gosselin B, Porchet N
(2002).
Expression of human mucin genes in normal kidney and renal cell carcinoma.
Histopathology
40, 450-457.
CA 02724198 2010-11-12
WO 2009/138236- 88 - PCT/EP2009/003447
Lew DJ, Dulic V, Reed SI (1991). Isolation of three novel human cyclins by
rescue of G1
cyclin (Cln) function in yeast. Cell 66, 1197-1206.
Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M (2001).
Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth
factor
during melanoma development. Oncogene 20, 8125-8135.
Li H, Leung TC, Hoffman S, Balsamo J, Lilien J (2000). Coordinate regulation
of cadherin
and integrin function by the chondroitin sulfate proteoglycan neurocan. J Cell
Biol. 149,
1275-1288.
Lin TS, Chiou SH, Wang LS, Huang HH, Chiang SF, Shih AY, Chen YL, Chen CY, Hsu
CP,
Hsu NY, Chou MC, Kuo SJ, Chow KC (2004). Expression spectra of matrix
metalloproteinases in metastatic non-small cell lung cancer. Oncol. Rep. 12,
717-723.
Littaua RA, Takeda A, Cruz J, Ennis FA (1992). Vaccinia virus-specific human
CD4+
cytotoxic T-lymphocyte clones. J Virol. 66, 2274-2280.
Liu X, Chen N, Wang X, He Y, Chen X, Huang Y, Yin W, Zhou Q (2006). Apoptosis
and
proliferation markers in diffusely infiltrating astrocytomas: profiling of 17
molecules. J
Neuropathol. Exp. Neurol. 65, 905-913.
Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H,
Chesnut RW, Sette
A (1997). The hepatitis B virus-specific CTL responses induced in humans by
lipopeptide
vaccination are comparable to those elicited by acute viral infection. J.
Immunol. 159, 1383-
1392.
Lo ML, Staibano S, Pannone G, Mignogna MD, Mariggio A, Salvatore G, Chieffi P,
Tramontano D, De RG, Altieri DC (2001). Expression of the apoptosis inhibitor
survivin in
aggressive squamous cell carcinoma. Exp. Mol. Pathol. 70, 249-254.
Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, Landberg G
(2002). The
cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways
in
tumorogenesis based on pattern of genetic aberrations and inactivation of the
pRb node.
Oncogene 21, 4680-4690.
Louhelainen J, Wijkstrom H, Hemminki K (2000). Initiation-development
modelling of
allelic losses on chromosome 9 in multifocal bladder cancer. Eur. J. Cancer
36, 1441-1451.
Macdonald DR (2001). Temozolomide for recurrent high-grade glioma. Semin.
Oncol 28, 3-
12.
Mach B, Steimle V, Martinez-Soria E, Reith W(1996). Regulation of MHC class II
genes:
lessons from a disease. Annu. Rev. Immunol. 14, 301-331.
Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, Karhu R, Kallioniemi
A
(2002). Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in
pancreatic
cancer. Genes Chromosomes. Cancer 35, 353-358.
Malcherek G, Gnau V, Stevanovic S, Rammensee HG, Jung G, Melms A (1994).
Analysis of
allele-specific contact sites of natural HLA-DR17 ligands. J Immunol. 153,
1141-1149.
Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G,
Mazzi B,
Bellone M, Dellabona P, Protti MP (1999). Melanoma cells present a MAGE-3
epitope to
CD4(+) cytotoxic T cells in association with histocompatibility leukocyte
antigen DR11. J
Exp. Med 189, 871-876.
Margolis RK, Rauch U, Maurel P, Margolis RU (1996). Neurocan and phosphacan:
two
major nervous tissue-specific chondroitin sulfate proteoglycans. Perspect.
Dev. Neurobiol. 3,
273-290.
Mark AS, Mangkomkanok M (1989). B-cell lymphoma marking only with anti-
epithelial
membrane antigen. Cancer 63, 2152-2155.
Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B
(2000).
Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated
anti-tumor
immunity. J Immunol. 165, 6047-6055.
CA 02724198 2010-11-12
WO 2009/138236- 89 - PCT/EP2009/003447
Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E,
Johnson
BE, Salgia R (2002). Modulation of the c-Met/hepatocyte growth factor pathway
in small cell
lung cancer. Clin. Cancer Res. 8, 620-627.
Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H (1993). The
prognostic
significance of proliferating cell nuclear antigen, epidermal growth factor
receptor, and mdr
gene expression in colorectal cancer. Cancer 71, 2454-2460.
McKeon RJ, Jurynec MJ, Buck CR (1999). The chondroitin sulfate proteoglycans
neurocan
and phosphacan are expressed by reactive astrocytes in the chronic CNS glial
scar. J
Neurosci. 19, 10778-10788.
Mellai M, Caldera V, Patrucco A, Annovazzi L, Schiffer D (2008). Survivin
expression in
glioblastomas correlates with proliferation, but not with apoptosis.
Anticancer Res. 28, 109-
118.
Meyer-Puttlitz B, Junker E, Margolis RU, Margolis RK (1996). Chondroitin
sulfate
proteoglycans in the developing central nervous system. II. Immunocytochemical
localization
of neurocan and phosphacan. J Comp Neurol. 366, 44-54.
Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H, Umeda M (1990). Purification
and
characterization of extracellular matrix-degrading metalloproteinase, matrin
(pump-1),
secreted from human rectal carcinoma cell line. Cancer Res. 50, 7758-7764.
Mizuno K, Higuchi 0, Ihle JN, Nakamura T (1993). Hepatocyte growth factor
stimulates
growth of hematopoietic progenitor cells. Biochem. Biophys. Res. Commun. 194,
178-186.
Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos W, Wijnands PG,
Scheper
RJ, de Gruijl TD (2005). Matched skin and sentinel lymph node samples of
melanoma
patients reveal exclusive migration of mature dendritic cells. Am. J Pathol.
167, 1301-1307.
Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJ (2002). The apolipoprotein
L gene
cluster has emerged recently in evolution and is expressed in human vascular
tissue.
Genomics 79, 539-546.
Montesano R, Soriano JV, Malinda KM, Ponce ML, Bafico A, Kleinman HK, Bottaro
DP,
Aaronson SA (1998). Differential effects of hepatocyte growth factor isoforms
on epithelial
and endothelial tubulogenesis. Cell Growth Differ. 9, 355-365.
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE,
Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-
Freezer LJ,
-Mavroukakis SA, Rosenberg SA (2006). Cancer Regression in Patients After
Transfer of
Genetically Engineered Lymphocytes. Science.
Morgenstern DA, Asher RA, Fawcett JW (2002). Chondroitin sulphate
proteoglycans in the
CNS injury response. Prog. Brain Res. 137, 313-332.
Mon M, Barnard GF, Mimori K, Ueo H, Akiyoshi T, Sugimachi K (1995).
Overexpression of
matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer 75, 1516-
1519.
Mortara L, Castellani P, Meazza R, Tosi G, De Lerma BA, Procopio FA, Comes A,
Zardi L,
Ferrini S, Accolla RS (2006). CIITA-induced MHC class II expression in mammary
adenocarcinoma leads to a Thl polarization of the tumor microenvironment,
tumor rejection,
and specific antitumor memory. Clin Cancer Res. 12, 3435-3443.
Mott JD, Werb Z (2004). Regulation of matrix biology by matrix
metalloproteinases. Curr.
Opin. Cell Biol 16, 558-564.
Nakamura T, Tabuchi Y, Nakae S, Ohno M, Saitoh Y (1996). Serum
carcinoembryonic
antigen levels and proliferating cell nuclear antigen labeling index for
patients with colorectal
carcinoma. Correlation with tumor progression and survival. Cancer 77, 1741-
1746.
Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK,
Comoglio
PM (1991). Hepatocyte growth factor (HGF) stimulates the tyrosine kinase
activity of the
receptor encoded by the proto-oncogene c-MET. Oncogene 6, 501-504.
CA 02724198 2010-11-12
WO 2009/138236 - 90 - PCT/EP2009/003447
Napolitano M, Keime-Guibert F, Monj our A, Lafitte C, Amen i A, Cornu P, Broet
P, Delattre
JY (1999). Treatment of supratentorial glioblastoma multiforme with
radiotherapy and a
combination of BCNU and tamoxifen: a phase II study. J Neurooncol. 45, 229-
235.
Nieder C, Grosu AL, Molls M (2000). A comparison of treatment results for
recurrent
malignant gliomas. Cancer Treat. Rev. 26, 397-409.
Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K (1997).
Cytotoxic T
lymphocytes derived from bone marrow mononuclear cells of multiple myeloma
patients
recognize an underglycosylated form of MUC1 mucin. Int. Immunol. 9, 791-798.
Novellino L, Castelli C, Parmiani G (2005). A listing of human tumor antigens
recognized by
T cells: March 2004 update. Cancer Immunol. Immunother. 54, 187-207.
O'Driscoll L, Linehan R, Clynes M (2003). Survivin: role in normal cells and
in pathological
conditions. Curr. Cancer Drug Targets. 3, 131-152.
Ohara 0, Nagase T, Ishikawa K, Nalcajima D, Ohira M, Seki N, Nomura N (1997).
Construction and characterization of human brain cDNA libraries suitable for
analysis of
cDNA clones encoding relatively large proteins. DNA Res. 4, 53-59.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y,
Kawakami
M, Ikegame K, Hosen N, Yoshihara S. Wu F, Fujiki F, Murakami M, Masuda T,
Nishida S,
Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S.
Kawase I,
Sugiyama H (2004). Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T
lymphocytes
by WT1 peptide vaccine and the resultant cancer regression. Proc Natl. Acad.
Sci. U. S. A
101,13885-13890.
Penna A, Fowler P, Bertoletti A, Guilhot S, Moss B, Margolskee RF, Cavalli A,
Valli A,
Fiaccadori F, Chisari FV, . (1992). Hepatitis B virus (HBV)-specific cytotoxic
T-cell (CTL)
response in humans: characterization of HLA class II-restricted CTLs that
recognize
endogenously synthesized HBV envelope antigens. J Virol. 66, 1193-1198.
Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trumper L,
Schroers R
(2007). Identification of a promiscuous HLA DR-restricted T-cell epitope
derived from the
inhibitor of apoptosis protein survivin. Hum. Immunol. 68, 572-576.
Pons E, Uphoff CC, Drexler HG (1998). Expression of hepatocyte growth factor
and its
receptor c-met in human leukemia-lymphoma cell lines. Leuk. Res. 22, 797-804.
Ponzetto C, Bardelli A, Maina F, Longati P, Panayotou G, Dhand R, Waterfield
MD,
Comoglio PM (1993). A novel-recognition motif for phosphatidylinositol 3-
kinase binding
mediates its association with the hepatocyte growth factor/scatter factor
receptor. Mol. Cell
Biol. 13, 4600-4608.
Prados MD, Levin V (2000). Biology and treatment of malignant glioma. Semin.
Oncol 27, 1-
10.
Previsani N, Lavanchy D (2002). Hepatitis B. World Health Organization
Department of
Communicable Diseases Surveillance and Response. 2002 WHO/CDS/CSR/LY0/2002.
2:Hepatitis B.
Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong
MH,
Vande Woude GF, Resau JH, Teh BT (2002). Met protein expression level
correlates with
survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 62,
589-596.
Qin Z, Blankenstein T (2000). CD4+ T cell--mediated tumor rejection involves
inhibition of
angiogenesis that is dependent on IFN gamma receptor expression by
nonhematopoietic cells.
Immunity. 12, 677-686.
Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H,
Blankenstein T
(2003). A critical requirement of interferon gamma-mediated angiostasis for
tumor rejection
by CD8+ T cells. Cancer Res. 63, 4095-4100.
Quantin B, Murphy G, Breathnach R (1989). Pump-1 cDNA codes for a protein with
characteristics similar to those of classical collagenase family members.
Biochemistry 28,
5327-5334.
CA 02724198 2010-11-12
WO 2009/138236- 91 - PCT/EP2009/003447
Rae FK, Stephenson SA, Nicol DL, Clements JA (2000). Novel association of a
diverse range
of genes with renal cell carcinoma as identified by differential display. Int.
J. Cancer 88, 726-
732.
Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis GL (2000).
Over-
expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF
receptor
(cMET) are associated with a high risk of metastasis and recurrence for
children and young
adults with papillary thyroid carcinoma. Clin Endocrinol. (Oxf) 53, 635-644.
Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999).
SYFPEITHI:
database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219.
Ranunensee,H.G., Bachmann,J., and Stevanovic,S. (1997). MHC Ligands and
Peptide Motifs.
Springer-Verlag, Heidelberg, Germany).
Rammensee HG, Friede T, Stevanoviic S (1995). MHC ligands and peptide motifs:
first
listing. Immunogenetics 41, 178-228.
Rauch U, Feng K, Zhou XH (2001). Neurocan: a brain chondroitin sulfate
proteoglycan. Cell
Mol. Life Sci. 58, 1842-1856.
Rehermann B, Nascimbeni M (2005). Immunology of hepatitis B virus and
hepatitis C virus
infection. Nat. Rev. Immunol. 5, 215-229.
Retzler C, Gohring W, Rauch U (1996). Analysis of neurocan structures
interacting with the
neural cell adhesion molecule N-CAM. J Biol. Chem. 271, 27304-27310.
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM,
Robertson CN, Lee RE, Rubin JT, . (1987). A progress report on the treatment
of 157 patients
with advanced cancer using lymphokine-activated killer cells and interleukin-2
or high-dose
interleukin-2 alone. N. Engl. J. Med. 316, 889-897.
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon
P,
Lotze MT, Yang JC, Seipp CA, . (1988). Use of tumor-infiltrating lymphocytes
and
interleukin-2 in the immunotherapy of patients with metastatic melanoma. A
preliminary
report. N. Engl. J Med 319, 1676-1680.
Roth W, Weller M (1999). Chemotherapy and immunotherapy of malignant glioma:
molecular mechanisms and clinical perspectives. Cell Mol. Life Sci. 56, 481-
506.
Rubin JS, Bottaro DP, Aaronson SA (1993). Hepatocyte growth factor/scatter
factor and its
receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta 1155, 357-
371.
Ruiz M, -Kobayashi H, Lasarte JJ, Prieto J, Borras-Cuesta F, Celis E, Sarobe P
(2004).
Identification and characterization of a T-helper peptide from
carcinoembryonic antigen. Clin
Cancer Res. 10, 2860-2867.
Sablotzki A, Ebel H, Muhling J, Dehne MG, Nopens H, Giesselmann H, Hempelmann
G
(2000). Dysregulation of immune response following neurosurgical operations.
Acta
Anaesthesiol. Scand. 44, 82-87.
Sadler E, Klausegger A, Muss W, Deinsberger U, Pohla-Gubo G, Laimer M,
Lanschuetzer C,
Bauer JW, Hintner H (2006). Novel KIND1 gene mutation in Kindler syndrome with
severe
gastrointestinal tract involvement. Arch. Dermatol. 142, 1619-1624.
Saha S, Bardelli A, Bucichaults P, Velculescu VE, Rago C, St CB, Romans KE,
Choti MA,
Lengauer C, Kinzler KW, Vogelstein B (2001). A phosphatase associated with
metastasis of
colorectal cancer. Science 294, 1343-1346.
Saino M, Maruyama T, Sekiya T, Kayama T, Murakami Y (2004). Inhibition of
angiogenesis
in human glioma cell lines by antisense RNA from the soluble guanylate cyclase
genes,
GUCY1A3 and GUCY1B3. Oncol. Rep. 12, 47-52.
Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T,
Arita K,
Kurisu K (2007). Survivin subcellular localization in high-grade astrocytomas:
simultaneous
expression in both nucleus and cytoplasm is negative prognostic marker. J
Neurooncol. 82,
193-198.
CA 02724198 2010-11-12
WO 2009/138236- 92 - PCT/EP2009/003447
Sakaguchi A, Kikuchi A (2004). Functional compatibility between isoform alpha
and beta of
type II DNA topoisomerase. J Cell Sci. 117, 1047-1054.
Sasaki T, Lopes MB, Hankins GR, Helm GA (2002). Expression of survivin, an
inhibitor of
apoptosis protein, in tumors of the nervous system. Acta Neuropathol. 104, 105-
109.
Sato F, Abraham JM, Yin J, Kan T, Ito T, Mori Y, Hamilton JP, Jin Z, Cheng Y,
Paun B,
Berki AT, Wang S, Shimada Y, Meltzer SJ (2006). Polo-like kinase and survivin
are
esophageal tumor-specific promoters. Biochem. Biophys. Res. Commun. 342, 465-
471.
Schmidt C, Bladt F, Goedecke S, Brinlcmann V, Zschiesche W, Sharpe M, Gherardi
E,
Birchmeier C (1995). Scatter factor/hepatocyte growth factor is essential for
liver
development. Nature 373, 699-702.
Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert
D,
Ratnmensee HG, Rieber EP (2000). Generation of survivin-specific CD8+ T
effector cells by
dendritic cells pulsed with protein or selected peptides. Cancer Res. 60, 4845-
4849.
Schoenberger SP, Toes RE, van d, V, Offringa R, Melief CJ (1998). T-cell help
for cytotoxic
T lymphocytes is mediated by CD4O-CD4OL interactions. Nature 393, 480-483.
Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR (2000).
Rapid
degradation of a large fraction of newly synthesized proteins by proteasomes.
Nature 404,
770-774.
Shedlock DJ, Shen H (2003). Requirement for CD4 T cell help in generating
functional CD8
T cell memory. Science 300, 337-339.
Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D (1988). Isolation and
Sequencing of a
cDNA Coding for the Human DF3 Breast Carcinoma-Associated Antigen. PNAS 85,
2320-
2323.
Singh-Jasuja H, Emmerich NP, Rammensee HG (2004). The Tubingen approach:
identification, selection, and validation of tumor-associated HLA peptides for
cancer therapy.
Cancer Immunol. Immunother. 53, 187-195.
Smith GM, Strunz C (2005). Growth factor and cytokine regulation of
chondroitin sulfate
proteoglycans by astrocytes. Glia 52, 209-218.
Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, de Kok
JB
(2004). Survivin is an independent prognostic marker for risk stratification
of breast cancer
patients. Clin Chem. 50, 1986-1993.
Sun JC, Bevan MJ (2003). Defective CD8 T cell memory following acute infection
without
CD4 T cell help. Science 300, 339-342.
Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A
(1994).
Expression of MUCI on myeloma cells and induction of HLA-unrestricted CTL
against
MUC1 from a multiple myeloma patient. J. Immunol. 153, 2102-2109.
Takayama H, Larochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA,
Merlino
G (1997). Diverse tumorigenesis associated with aberrant development in mice
overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci.
U. S. A 94,
701-706.
Takayama H, LaRochelle WJ, Anver M, Bocicman DE, Merlino G (1996). Scatter
factor/hepatocyte growth factor as a regulator of skeletal muscle and neural
crest
development. PNAS 93, 5866-5871.
Tan HY, Liu J, Wu SM, Luo HS (2005). Expression of a novel apoptosis inhibitor-
survivin in
colorectal carcinoma. World J Gastroenterol. 11, 4689-4692.
Ten KM, van der Wal JB, Sluiter W, Hofland LJ, Jeekel J, Sonneveld P, van
Eijck CH (2006).
The role of superoxide anions in the development of distant tumour recurrence.
Br. J Cancer.
Teofili L, Di Febo AL, Pierconti F, Maggiano N, Bendandi M, Rutella S,
Cingolani A, Di
RN, Musto P, Pileri S, Leone G, Larocca LM (2001). Expression of the c-met
proto-oncogene
and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 97, 1063-
1069.
CA 02724198 2010-11-12
WO 2009/138236- 93 - PCT/EP2009/003447
Tompkins SM, Rota PA, Moore JC, Jensen PE (1993). A europium fluoroimmunoassay
for
measuring binding of antigen to class II MHC glycoproteins. J Immunol. Methods
163, 209-
216.
Tripathi A, Dasgupta S, Roy A, Sengupta A, Roy B, Roychowdhury S, Panda CK
(2003).
Sequential deletions in both arms of chromosome 9 are associated with the
development of
head and neck squamous cell carcinoma in Indian patients. J. Exp. Clin. Cancer
Res. 22, 289-
297.
Troussard X, vet-Loiseau H, Macro M, Mellerin MP, Malet M, Roussel M, Sola B
(2000).
Cyclin D1 expression in patients with multiple myeloma. Hematol. J. 1, 181-
185.
Tuck AB, Park M, Sterns EE, Boag A, Elliott BE (1996). Coexpression of
hepatocyte growth
factor and receptor (Met) in human breast carcinoma. Am. J. Pathol. 148, 225-
232.
Uehara Y, Minowa 0, Mori C, Shiota K, Kuno J, Noda T, Kitamura N (1995).
Placental
defect and embryonic lethality in mice lacking hepatocyte growth
factor/scatter factor. Nature
373, 702-705.
Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H, Asoh S,
Teramoto A, Ohta S (2005). Prognostic significance of the immunohistochemical
index of
survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol.
72, 231-238.
van der Bruggen P. Traversari C, Chomez P, Lurquin C, De PE, Van den EB, Knuth
A, Boon
T (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on
a human
melanoma. Science 254, 1643-1647.
van d, V, Taher TE, Keehnen RM, Smit L, Groenink M, Pals ST (1997). Paracrine
regulation
of germinal center B cell adhesion through the c-met-hepatocyte growth
factor/scatter factor
pathway. J. Exp. Med. 185, 2121-2131.
Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA (1999). Expression of
cyclin D1
in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin
immunohistochemical
study. Mod. Pathol. 12, 412-416.
Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der BP,
Boon T,
Van Den Eynde BJ (2004). An antigenic peptide produced by peptide splicing in
the
proteasome. Science 304, 587-590.
Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee HG, Coligan JE, Martin
R
(1994). Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from
self-
peptides. J Immunol. 153, 1665-1673. -
Walter S, Herrgen L, Schoor 0, Jung G, Wemet D, Buhring HJ, Rammensee HG,
Stevanovic
S (2003). Cutting edge: predetermined avidity of human CD8 T cells expanded on
calibrated
MHC/anti-CD28-coated microspheres. J. Immunol. 17/, 4974-4978.
Wang FQ, So J, Reierstad S, Fishman DA (2005). Matrilysin (MMP-7) promotes
invasion of
ovarian cancer cells by activation of progelatinase. Int. J Cancer 114, 19-31.
Wang JC, Livingstone AM (2003). Cutting edge: CD4+ T cell help can be
essential for
primary CD8+ T cell responses in vivo. J Immunol. 171, 6339-6343.
Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM (2001). Activation of the
Met receptor
by cell attachment induces and sustains hepatocellular carcinomas in
transgenic mice. J. Cell
Biol. 153, 1023-1034.
Weber RG, Rieger J, Naumann U, Lichter P, Weller M (2001). Chromosomal
imbalances
associated with response to chemotherapy and cytotoxic cytokines in human
malignant
glioma cell lines. Int. J. Cancer 91, 213-218.
Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor 0,
Kurek R,
Loeser W, Bichler KH, Wemet D, Stevanovic S, Rammensee HG (2002). Integrated
functional genomics approach for the design of patient-individual antitumor
vaccines. Cancer
Res. 62, 5818-5827.
Weinstein EJ, Boumer M, Head R, Zakeri H, Bauer C, Mazzarella R (2003). URP1:
a
member of a novel family of PH and FERM domain-containing membrane-associated
CA 02724198 2010-11-12
WO 2009/138236- 94 - PCT/EP2009/003447
proteins is significantly over-expressed in lung and colon carcinomas.
Biochim. Biophys.
Acta 1637, 207-216.
Wierecky J, Muller MR, Horger MS, Brugger W, Kanz L, Brossart P (2005).
Induction of
clinical and immunological responses in patients with metastatic renal cell
carcinoma after
vaccinations with peptide pulsed dendritic cells. J Clin Oncol (Meeting
Abstracts) 23, 2507.
Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS, Guan XY (2006). Expression of
cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma.
Br. J Cancer
94, 108-114.
Xiong Y, Connolly T, Futcher B, Beach D (1991). Human D-type cyclin. Cell 65,
691-699.
Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, Kamei M, Takeno
S,
Kawahara K (2007). Survivin expression predicts early recurrence in early-
stage breast
cancer. Anticancer Res. 27, 2803-2808.
Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002).
Adoptive
T cell therapy using antigen-specific CD8+ T cell clones for the treatment of
patients with
metastatic melanoma: in vivo persistence, migration, and antitumor effect of
transferred T
cells. Proc. Natl. Acad. Sci. U. S. A 99, 16168-16173.
Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish
AS
(2001). Expression profiling of renal epithelial neoplasms: a method for tumor
classification
and discovery of diagnostic molecular markers. Am. J. Pathol. 158, 1639-1651.
Zacharias U, Rauch U (2006). Competition and cooperation between tenascin-R,
lecticans and
contactin 1 regulate neurite growth and morphology. J Cell Sci. 119, 3456-
3466.
Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997).
Identification of an
enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic
antigen.
Cancer Res. 57, 4570-4577.
Zamegar R, Michalopoulos GK (1995). The many faces of hepatocyte growth
factor: from
hepatopoiesis to hematopoiesis. J. Cell Biol. 129, 1177-1180.
Zeh HJ, III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC (1999). High
avidity CTLs
for two self-antigens demonstrate superior in vitro and in vivo antitumor
efficacy. J Immunol.
162, 989-994.
Zhang B, Liu XX, Zhang Y, Jiang CY, Hu HY, Gong L, Liu M, Teng QS (2006).
Polyamine
depletion by ODC-AdoMetDC antisense adenovirus impairs human colorectal cancer
growth
and invasion in vitro and in vivo. J Gene Med 8, 980-989.
Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, Fu LA, He XS, Ma FC, Wang
XL
(2005). Survivin expression and its relation with proliferation, apoptosis,
and angiogenesis in
brain gliomas. Cancer 104, 2775-2783.
Zhou YT, Guy GR, Low BC (2005). BNIP-2 induces cell elongation and membrane
protrusions by interacting with Cdc42 via a unique Cdc42-binding motif within
its BNIP-2
and Cdc42GAP homology domain. Exp. Cell Res. 303, 263-274.
